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Abstract 
  The number of individuals affected by a central nervous system disorder 
continues to steadily increase. Unfortunately, in many cases the available therapeutic 
options leaves these diseases undertreated and additional molecular probes are needed to 
fully understand these conditions. Historically, natural products have served as a rich 
source of new molecular scaffolds for developing these probes due to their complex 
structures and unique ability to perturb biological pathways through diverse mechanisms.  
With this in mind, the kappa opioid receptor (KOR) agonist salvinorin A, the mu 
opioid receptor (MOR) agonist herkinorin, and the anti-tau diarylheptanoid myricanol 
were identified as potential probes for investigating substance abuse, pain, and 
Alzheimer’s Disease, respectively. To determine how the unique neoclerodane structure 
of salvinorin A interacts with the KOR, methods to chemical modify the steric and 
electronic properties of the furan ring were developed. The resulting structure-activity 
relationships (SAR) identified three compounds that successfully attenuated drug seeking 
behavior in an animal model of drug relapse.  In a separate study, a simple modification 
to the A-ring of herkinorin was found to drastically increase the potency and selectivity 
for the MOR, thus increasing the potential in vivo utility of the probe. Additional SAR 
studies also resulted in the first sub-nanomolar diterpene MOR agonist. Finally, an 
enantioselective route to both enantiomers of myricanol was developed to provide the 
necessary material for more extensive biological investigations into the compound’s tau 
degradation mechanism. The three studies described herein, highlight the importance of 
using chemical synthesis to modify and build complex natural products scaffolds in order 
to probe biological systems.   
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I. Introduction 
 
Challenges in Treating Central Nervous System Disorders 
The central nervous system (CNS), made up of the brain and spinal cord, is 
arguable the most complex system in the human body. Signals initiated in the brain’s 100 
billion neurons are transduced through 1014 synapses to the rest of the central and 
peripheral nervous systems and control nearly every aspect of life from cognition to the 
biological events necessary for survival.1 However, due to the high complexity present in 
the CNS, diseases causing even small perturbations from normal function often result in 
severe, life-altering symptoms. Currently, it is estimated that as many as 1.5 billion 
people suffer from a CNS-related disorder, representing approximately a third of all 
diagnosed diseases.2,3 Furthermore, the debilitating nature of many of these diseases 
creates a significant burden to provide care for those affected, resulting in annual cost 
totaling more than $317 billion from health care expenditures, loss of earnings, and 
disability benefits.4 This amount can only be expected to grow as the average population 
age continues to rise since the incidence of many CNS diseases increases exponentially 
after the age of 65.5 Clearly diseases affecting the CNS represent a serious health care 
concern and novel therapies are needed to treat this growing problem. 
Traditionally the pharmaceutical industry has fulfilled the need for new CNS 
therapeutics, resulting in several very successful drugs including 21 of the 100 top selling 
prescription pharmaceutics of 2013 (Table 1.1). Despite this historic success, many 
pharmaceutical companies have begun reducing and eliminating their CNS discovery 
 2 
programs.6 This defunding can largely be attributed to the challenges in bringing a CNS 
drug to market. Among these challenges are the difficulties in attaining proper brain 
 
Table 1.1. List of CNS Pharmaceuticals Found in the 100 Top Selling Pharmaceutical 
Product List of 2013. 
Rank Drug Medical Use Sales 
($, in millions) 
1 Abilify Psychosis, depression 1,600 
7 Cymbalta Depression, anxiety 1,000 
10 Copaxone Multiple sclerosis 851 
18 Lyrica Neuropathic pain 624 
19 OxyContin Pain 585 
26 Lucentis Macular degeneration 460 
27 Vyvanse Attention deficit 
hyperactivity disorder 
447 
29 Namenda Alzheimer’s Disease 434 
38 Methylphenidate Attention deficit 
hyperactivity disorder 
327 
39 Suboxone Pain, opioid addiction 321 
46 Seroquel XR Psychosis, depression 291 
48 Avonex Multiple sclerosis 281 
50 Rebif Multiple sclerosis 280 
52 Gilenya Multiple sclerosis 272 
57 Acetaminophen/ 
hydrocodone 
Pain 264 
66 Amphetamine/ 
dextroamphetamine 
Attention deficit 
hyperactivity disorder; 
narcolepsy 
240 
71 Lidocaine Pain 225 
72 Lunesta Insomnia 225 
74 Zytiga Shift work sleep disorder, 
narcolepsy 
222 
97 Afinitor Attention deficit 
hyperactivity disorder 
180 
99 Adderall XR Attention deficit 
hyperactivity disorder 
177 
Based upon data from Q 2013 found at http://www.drugs.com/stats/top100/sales. 
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penetration, the increased risk of side effects, and poor target identification and 
validation. Taken together, these challenges result in a decreased approval rate for 
clinical candidates and increased development times compared to other therapeutic 
areas.7,8 
For a compound to exert a biological effect in the brain, it must first transverse the 
blood brain barrier (BBB). The BBB is a series of capillary endothelial cells connected 
by tight junctions that form a barrier between the circulating blood and the intracellular 
fluid of the CNS. This protective barrier allows for the passage of nutrients and hormones 
into the brain and limits the access of xenobiotics.9 The majority of CNS drugs gain 
access to the brain via intercellular passive diffusion (Figure 1.1).10 Furthermore, 
transmembrane transporters, such as p-glycoprotein, act as a second layer of defense and 
actively efflux compounds out of the CNS.11 Conversely, some molecules, such as 
glucose and amino acids, are actively shuttled across the BBB via influx transporters. An 
effort has been made to design drugs that achieve proper brain penetration via active 
transport,12 however these design principles are still under development. 
The existence of the BBB requires that in addition to classical pharmacokinetic 
values, such as bioavailability and plasma concentration, other parameters must be used 
to measure brain penetration. Historically, the total brain concentration (Cb) and the 
brain-to-plasma ratio (Cb/Cp) have been used for this purpose due to the relative
!  
Passive diffusion Active uptake
Influx
transporters
Active efflux
Figure 1.1. Schematic representation of mechanisms controlling BBB penetration.
Tight junctions Blood
Efflux
pumps
Brain
 4 
simplicity in their measurements.13 However, when used alone, these measurements can 
be misleading as they do not accurately describe the amount of free drug available to 
interact with the target. Receptor occupancy, which measure the percent of total receptors 
being occupied by the drug, is a more useful parameter, however these tests are time 
consuming and costly.14 Therefore, they are typically reserved only for compounds late in 
the drug development process. 
Several studies have sought to use these and other parameters to correlate brain 
penetration with certain physicochemical properties. A retrospective analysis performed 
at Pfizer revealed that CNS-active drugs are typically smaller (median MW=305.3), less 
lipophilic (median clogP=2.8), have fewer hydrogen bond donors (median=1), and 
smaller polar surface areas (median TPSA=44.8 Å2) than non-CNS drugs.15 Although this 
and other related studies have provided optimal ranges for these physiochemical 
parameters,15-17 much like Lipinski’s Rule of Five, these are only guidelines for 
developing a successful CNS drug. 
 In addition to the difficulties faced through brain penetration, the complexity of 
the CNS also creates significant problems in identifying and validating reliable biological 
targets. In many CNS disorders, especially those involving psychosis and 
neurodegeneration, this is the direct result of a poor understanding of the underlying 
cause of the disease. Historically target identification was a somewhat serendipitous 
process and the mechanisms of action for many drugs were only determined after a 
favorable phenotype had been discovered.18 The sequencing of the human genome has 
recently resulted in a shift to a more genetic-based approach, however this has been met 
with only limited success.19 
 5 
Even when potential targets have been proposed, the complexity of CNS disorders 
also results in poor preclinical animal models.8 The models that do exist typically are the 
result of one of two approaches.7 When the pathophysiology cause is well understood, 
genetically modified animals are created to emulate these effects and allow for the 
investigation of novel therapeutics. The second approach relies on the use of already 
approved drugs to build a behavioral or pharmacodynamics model. This model can then 
be used to identify novel compounds that produce similar results. Unfortunately, in 
several CNS disorders—particularly for those diseases where there are no approved drugs 
and the underlying cause is not well defined—these approaches have yet to produce a 
reliable animal model. Furthermore, useful predictive and prognostic biomarkers for 
many CNS diseases are virtually non-existent.18 This ultimately results in poor translation 
of preclinical successes into clinical results leading to increased pessimism for the 
pharmaceutical industry. 
 The combination of increasing incidences of CNS diagnoses and decreased 
interest of the pharmaceutical industry toward the development of novel therapies has the 
potential to lead to a very bleak future. It is therefore necessary to continue research 
efforts that will validate proposed targets, improve upon existing treatments, and to 
provide probe molecules that assist in the understanding the basic pathophysiological 
causes of diseases. This is particularly true in the areas of: (1) drug abuse therapies where 
several biological targets have been proposed but current treatment is limited; (2) pain 
management where all approved therapies possess undesirable side effects; and (3) 
Alzheimer’s Disease where the underlying cause of the disease remains unknown.  
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Substance Abuse and Dependence 
 Illicit drug use and addiction represents a serious and growing problem in the 
United States and much of the developed world. The National Survey on Drug Use and 
Health (NSDUH) conducted by the Substance Abuse and Mental Health Services 
Administration indicates approximately 23.9 million Americans aged 12 or older have 
used an illicit substance within the last year.20 This number represents 9.3% of the 
population, which has increased nearly an entire percent over the last decade. Because of 
the addicting and rewarding nature of many illicit drugs, this increased level of drug use 
has also resulted in increased levels of those suffering from substance abuse or 
dependency. According to the NSDUH, in 2012 an estimated 22.2 million individuals 
were classified as abusing or dependent upon an illicit drug or alcohol. However, of these 
affected individuals only 4 million received treatment, clearly demonstrating a severe 
treatment gap. While the majority of these treatments consist of psychotherapy, either in 
a group or individual setting, pharmacological interventions also exist for opiate and 
alcohol abuse.21 These therapies assist in preventing relapse and easing withdrawal 
symptoms by correcting the biochemical changes that take place in the brain during 
addiction.22  
There are currently four FDA-approved drugs used for the treatment of opioid 
dependence, all of which act at the mu-opioid receptor (MOR)—the site of action for 
abused opiates such as heroin (Figure 1.2). Methadone and buprenorphine are used in 
replacement therapy in which a prescription drug is used to take the place of the drug of 
abuse. This prescription eases the withdrawal symptoms and reduces intense drug 
cravings by providing low levels of receptor activation.23 The prescribed dose is then 
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typically reduced over a period of 4 weeks in specialized methadone clinics or longer 
periods of time during outpatient care.21 Although methadone replacement therapy has 
been used successfully for several decades, it has been criticized as simply replacing 
illicit opiate addicts with methadone addicts and methadone detoxification is an arduous 
process in itself. Furthermore, as a MOR full agonist, the possibility of methadone 
overdose still exists, a problem that is exacerbated by methadone’s long duration of 
action. As a partial agonist at the MOR, buprenorphine is less prone to overdose, 
however evidence exists that buprenorphine may not be as effective as methadone.24 
The other two medications approved to treat opioid dependence are the MOR 
antagonists naltrexone and naloxone. As antagonists, these drugs block the action of 
abused opiates, however they also induce acute opiate withdrawal. For this reason, 
naltrexone or naloxone is sometimes used to induce rapid opioid detoxification while the 
patient is under general anesthesia. However, this process introduces inherit risk and 
numerous deaths have been reported from this procedure.25 Furthermore, antagonist-
based therapies require continued patient compliance as even a single skipped dose 
allows for illicit opiates to have an effect if the patient relapses. So while these MOR 
agonist- and antagonist-based treatments have found some clinical utility, they are far 
from ideal and additional research into novel therapies is well warranted. 
HO
O
N
H3CO
HO MetBu
H
buprenorphine
MOR partial agonist
O NMe2
methadone
MOR full agonist
HO
O
N
O
OH
naltrexone
MOR antagonist
Figure 1.2. FDA-approved drugs used in the treatment of opiate addiction and their action at the MOR.
HO
O
N
O
OH
naloxone
MOR antagonist
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Although not illicit, nicotine found in tobacco products is extremely addicting. 
Nicotine derives its rewarding effects by activating nicotinic acetylcholine receptors 
(nAChR), leading to a increase in dopamine in the nucleus accumbens26—a portion of the 
brain heavily involved in motivation, reward, and reinforcement learning.27 The cessation 
of nicotine use, therefore, results in a decrease in dopamine and the onset of withdrawal 
symptoms. Nicotine replacement therapy in the form of patches, sprays, gums, and 
lozenges are used mitigate these symptoms by providing enough nicotine to reduce 
cravings.  
As an alternative to nicotine replacement therapy, varenicline and bupropion can 
be prescribed to aid in overcoming nicotine addictions (Figure 1.3). Varenicline is a 
partial nAChR agonist developed by Pfizer based upon the naturally occurring partial 
agonist cytisine28—which is also used to aid in smoking cessation in parts of Europe and 
Russia.29 As partial agonists, varenicline and cytisine provide consistent, low levels of 
dopamine to reduce withdrawal symptoms and occupy the nAChR binding sites thus 
preventing nicotine from producing a rewarding effect. 
The other medication prescribed for smoking cessation is the antidepressant 
bupropion, which is a nAChR antagonist and norepinephrine/dopamine reuptake 
inhibitor.30 Much like the partial agonists, bupropion blocks the effects of nicotine by 
antagonizing the nAChR. However, rather than increasing dopamine by activating 
!
Me
N
N
nicotine
nAChR full agonist
N
N
NH
varenicline
nAChR partial agonist
Cl
O H
N
bupropion
nAChR antagonist
catecholamine reuptake inhibitor
N
O
NH
cytisine
nAChR partial agonist
Figure 1.3. Drugs prescribed to assist in smoking cessation and their relevant pharmacology.
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nAChR, bupropion raises levels of dopamine by inhibiting the uptake of norepinephrine 
and dopamine. These clinically approved medications for nicotine addiction highlight an 
important feature for drug abuse therapies: to properly treat addiction and abuse an 
effective treatment must not only limit the rewarding action of the drug, but also mitigate 
the negative symptoms associated with its discontinuation. 
 In comparison to opiates and nicotine, the effects of ethanol on the CNS are 
considerably more complex, affecting both lipid membrane composition as well as 
several excitatory and inhibitory neurotransmitter receptors.31 Additionally, the MOR is 
at least partially responsible for the rewarding affects of alcohol32 and the MOR 
antagonist naltrexone is prescribed for the management of alcohol dependence (Figure 
1.4). The rewarding affects of alcohol and the potential for relapse are also successfully 
mitigated with acamprosate, although its mechanism of action is still debated.33,34 
The oldest!
medication used to 
treat alcohol abuse, 
disulfiram, has a less 
direct effect on the CNS but instead inhibits acetaldehyde dehydrogenase. In the liver, 
ethanol is first converted to acetaldehyde, which is in turn converted to acetic acid by 
acetaldehyde dehydrogenase. While on disulfiram, the consumption of alcohol leads to a 
buildup of acetaldehyde resulting in a number of negative effects including nausea, 
vomiting, and headaches. Although largely effective in preventing alcohol use when in a 
controlled setting, disulfiram does not control cravings and patient compliance is often an 
issue.35  
HO
O
N
O
OH
naltrexone
MOR antagonist
N
S
S S
S
N Me
Me
Me
Me
disulfiram
acetaldehyde dehydrogenase inhibitor
S N
H
O
MeO
O
OH
acamprosate
Figure 1.4. Treatment options for alcohol abuse and their known mechanisms of action.
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 With the exception of alcohol abuse therapies, all approved treatments for 
substance abuse act at the same receptor as the drug of abuse. However, for many abused 
substances, including alcohol and CNS stimulants like cocaine and methamphetamine, 
the cause of the rewarding properties is either too complex or is not amenable to targeting 
for a drug abuse therapy. In these cases, if a viable therapeutic option is to be developed 
alternative strategies to mitigating the rewarding effects must be explored. The dopamine 
hypothesis of drug addiction states that the rewarding properties of drugs of abuse are 
produced by increased levels of dopamine in the brain, especially in the nucleus 
accumbens and ventral tegmental area.36 Therefore the reduction of dopamine in these 
areas may reduce drug-seeking behavior. 
Of the many targets that have been explored to develop a novel drug abuse 
therapy, the kappa opioid receptor (KOR) shows particular promise. Unlike the MOR, 
activation of the KOR results in decreased levels of dopamine.37 Although initially 
developed by the Upjohn Company as potentially non-addictive analgesics, the 
arylacetamide class of KOR agonist represented by U69,693, U50,488h, and enadoline 
(Figure 1.5), has shown considerable efficacy in in various animal models of addiction.38-
45 Unfortunately these traditional KOR agonists suffer from several side effects including 
dysphoria, depression, and sedation thus preventing their utility as drug abuse 
treatments.46,47 More recently, several other KOR agonists, including those based on the 
naturally occurring neoclerodane diterpene salvinorin A, have renewed interest in 
targeting the KOR, largely due to their ability to decrease cocaine-induced drug-seeking 
behavior with an improved side-effect profile.44,48-50 Ongoing research in this field is 
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focused on elucidting the reason for these differences, which could potentially validate 
the KOR as a therapeutic target for treating drug addiction and abuse. 
! 
 
Chronic and Severe Pain 
Approximately 100 million Americans suffer from chronic or reoccurring pain, 
representing nearly half of the adult population and more than all cancer, heart disease, 
and diabetes patients combined.51 This can largely be attributed to the comorbidity of 
chronic pain with several major disease states including cancer, arthritis, and diabetes.52 
For example, approximately 50-70% cancer patients suffer from some degree pain.53 As a 
result of this prevalence, pain is the leading reason for seeking medical care and 
approximately $635 billion annually are lost to health care costs and decreases in 
productivity.52 The analgesics used today can be divided in two general classes: non-
steroid anti-inflammatory drugs (NSAIDs) and opiates. 
 NSAID analgesics, such as ibuprofen and aspirin (Figure 1.6), are amongst the 
most commonly used drugs for the treatment of pain and as their name implies are 
particularly effective in controlling pain associated with inflammation. In 1971, Vane 
determined the anti-inflammatory affects of aspirin and other NSAIDs arise from the 
disruption of prostaglandin synthesis via the inhibition of the cyclooxygenase (COX) 
enzyme.54 The COX enzyme exists in at least two separate isoforms: COX-1 and COX-
O
N
Me N
O
U69,593
O
N
Me N
U50,488h
Cl
Cl
O
N
Me N
O
enadoline
O
OH H
O
O
O
AcO
CO2Me
Me
Me
salvinorin A
Figure 1.5. Representative arylacetamide KOR agonists and the naturally occurring KOR agonist salvinorin A.
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2.55,56 COX-1 is constitutively expressed and serves a protective role by synthesizing the 
prostaglandins found in the gastric mucosa. Under normal conditions, COX-2 is found in 
only low levels, 
however its 
expression is rapidly 
induced by pro-
inflammatory 
stimuli.57 Because 
aspirin and other 
traditional NSAIDs non-selectively inhibit COX-1/2, their chronic use can result in ulcers 
do to decreased production of protective prostaglandins found in the stomach lining.58 In 
response to the discovery of the inducible isoform COX-2, several COX-2 selective 
NSAIDs, including celecoxib, rofecoxib, and valdecoxib, were developed that possess 
minimal gastrointestinal side effects.58 Despite this improvement, the use of COX-2 
inhibitors does increase the risk of cardiovascular complications,59 which has ultimately 
resulted in the costly removal of rofecoxib and valdecoxib from the market.60  
The more powerful opioid class of analgesics is often used to treat severe and 
chronic pain, sometimes in combination with NSAIDs. Opioids provide pain relief by 
activating the opioid receptors, a group of three related G-protein coupled receptors 
(GPCRs) found throughout the body. The activation of the opioid receptors by their 
endogenous peptide ligands or exogenous agonists initiates numerous downstream effects 
including the inhibition adenylate cyclase, the opening of potassium channels, and the 
inhibition of N-type Ca2+ channels.61  These effects ultimately inhibit neurotransmitter 
Me
Me
Me
O
OH
ibuprofen
non-selective COX inhibitor
O O
Me
HO O
celecoxib
COX-2 selective inhibitor
SH2N
O O
N
Me
N
CF3
rofecoxib
COX-2 selective inhibitor
SMe
O O
O
O
valdecoxib
COX-2 selective inhibitor
SH2N
O O
O
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release thereby preventing the neurons from transmitting the signals of pain to the brain. 
Through this mechanism, all three opioid receptors have analgesic potential, however 
most clinically used opioids, such as morphine, oxycodone, pentazocine, and meperidine 
(Figure 1.7) are either synthetic or semi-synthetic derivatives of morphine and therefore 
act at the MOR.62 
Despite being the “gold standard” for pain management, all opioid analgesics 
suffer from a similar side effect profile that includes sedation, respiratory depression, 
constipation, tolerance, and depression.63 These “on target” side effects are the direct 
result of the opioids action at the MOR. The exact mechanism by which opioids induce 
sedation is not fully understood, however it is believed to be related to a decrease in 
sensory input.64 Similarly, respiratory depression is caused by a reduction in the brain’s 
responsiveness to CO2.65 Respiratory depression is especially dangerous as it is the 
leading cause of death from opioid overdose.66 Sedation and respiratory depression are 
primarily related to the opioids effect on the nervous system, however the presence of 
MOR in the gastrointestinal tract results in decreased intestinal motility following opioid 
treatment.67 In some instances, this constipation can be overcome by co-administering 
peripherally restricted MOR antagonist such as melthylnaltrexone, however this side 
effect often remains a dose limiting consideration.  
In addition to these side effects that can be observed after acute opioid treatment,
morphine oxycodone meperidinepentazocine
Figure 1.7. Structures of opioid analgesics highlighting their shared phenylpiperidine structure.
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the chronic use of opioids results in significant biochemical adaptations within the 
nervous system. This leads to increased levels of drug being required to produce 
analgesia (tolerance) and normal function (dependence). Tolerance is particularly 
concerning as the increased doses are more likely to cause other side effects. Due to the 
widespread use of opioid analgesics and the frequency of their side effects, a significant 
effort has been made to separate the analgesic properties of opioids from their negative 
effects. 
 Although several theories have been proposed to account for these observed side 
effects increasing evidence indicates that β-arrestin-2 plays a critical role in their 
development.68 Most importantly, genetically modified mice lacking β-arrestin-2 show 
increased and prolonged morphine analgesia and decreased tolerance, constipation and 
respiratory suppression.69 β-Arrestins are a small family of proteins involved in GPCR 
regulation and desensitization. Upon activation, a GPCR can be phosphorylated by one of 
several GPCR kinases, which leads to β-arrestin recruitment and eventual internalization 
and desensitization of the receptor.70 In addition to this desensitization mechanism, it is 
now apparent that the GPCR/β-arrestin complex is also capable of initiating unique signal 
transduction pathways.71 For many receptors, including the MOR, it is possible for a 
ligand to activate the receptor without recruiting β-arrestins, a phenomenon known as 
functional selectivity. Therefore, MOR agonists that are able to activate the receptor 
without causing β-arrestin-2 recruitment may produce analgesia without the 
accompanying β-arrestin-dependent side effects. The identification of functionally 
selective agonists will likely require that novel ligands not based upon the traditional 
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morphine scaffold be identified and their interactions with the MOR thoroughly 
investigated.  
 
Alzheimer’s Disease 
According to the World Health Organization (WHO), dementia represents a major 
health care problem affecting the entire global population.72 Defined by a general decline 
in cognitive ability that interferes with daily life, dementia was estimated to effect 35.6 
million individuals worldwide in 2010. However, as healthcare advances continue to 
raise the average life expectancy, this number is expected to nearly double every 20 years 
with an estimated 66 million suffers by 2030 and 115 million by 2050.73 In addition to 
those personally diagnosed with dementia, a significant burden is also placed on 
caregivers. This burden is both social and financial, with estimated annual healthcare cost 
reaching $604 billion in 2012.74 Clearly the WHO is correct in stating that developing a 
cure must become a global priority. Since Alzheimer’s Disease (AD) represents 
approximately 60-80% of all dementia cases, understanding and developing a treatment 
for AD is a logical, albeit difficult, first step.75 
The first reported case of AD, was described by Alois Alzheimer in 1906.76 In his 
study, Alzheimer correlated the now stereotypical dementia of a patient, Auguste Deter, 
with two abnormal deposits discovered during his posthumous histological examination 
of her brain. These deposits were later identified as extracellular senile plaques composed 
of the peptide beta-amyloid (Aβ)77,78 and intracellular neurofibrillary tangles (NFT) made 
up of the microtubule-associated protein tau.79-81 The presence of these deposits in the 
brains of all AD patients suggests that either one or both of them are responsible for the 
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neuronal degeneration associated with AD. However, the exact role that Aβ plaques and 
NFT play is still debated and several theories have been proposed. 
The oldest hypothesis, the cholinergic hypothesis, proposes that AD is caused by 
decreased levels of the neurotransmitter acetylcholine (ACh) in the brain.82 This is 
primarily based upon reports that detailed decreased levels of choline acetyltransferase—
an enzyme responsible for the biosynthesis of acetylcholine—in the AD patients’ 
brains.83-85 ACh has also been shown to be involved in learning and memory,86 further 
supporting the hypothesis that a decrease in ACh would lead to the observed dementia. 
Research into the cholinergic hypothesis ultimately produced four of the approved 
treatment options for AD (Figure 1.8). Tacrine, donepezil, rivastigmine, and galantamine 
are inhibitors of acetylcholine esterase—an enzyme responsible for the breakdown of 
ACh.87 Unfortunately, these treatment options are only marginally effective at treating the 
symptoms of AD and do not halt its progress. This has led a decline in the support of the 
cholinergic hypothesis.88  
The other approved treatment option for AD is the N-methyl-D-aspartate 
(NMDA) receptor antagonist memantine (Figure 1.8). Activation of NMDA receptors 
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with endogenous glutamate results in an influx of calcium into the neuron, which is 
necessary for proper neuronal function and plasticity.89 However, over activation of 
NMDA receptors leads to calcium overload and cell death. Memantine is thought to 
operate by partially blocking the influx of calcium and prevent this excitotoxicity. Once 
again, memantine only appears to treat the symptoms of AD and does not provide an 
answer to the underlying cause.90  
! In 1991, the amyloid cascade hypothesis was proposed to attempt to account for!
the formation of plaques and NFT and establish how they lead to dementia in AD (Figure 
1.9).91 This theory postulates that dysregulation of the machinery that processes the 
amyloid precursor protein (APP) into Aβ leads to the 
formation of plaques. These plaques are toxic themselves but 
also lead to the hyperphosphorylation of tau protein. This 
hyperphosphorylation causes tau to aggregate leading to 
neuronal degeneration and ultimately dementia. It is 
important to note that the amyloid cascade hypothesis 
accounts for both Aβ plaques and NFT however, the exact 
mechanism through which plaques induce the formation of 
NFT is not established.92 This theory is supported by the fact 
that genetic mutations that lead to early onset familial AD (EOFAD) have been identified 
in the genes that encode APP93-95 and two proteins responsible for APP’s cleavage to 
Aβ.96-98 This evidence has led researchers to develop inhibitors of the enzymes 
responsible for Aβ production as a potential cure for AD. 
Dysregulation of APP Processing
Formation of Aβ Plaques
Hyperphosphorylation of
Tau Protein
Tau Aggregation and
NFT Formation
Neuronal Degernation
Clincal Dementia
Figure 1.9. Amyloid cascade 
hypothesis, adapted from Ref 91.
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APP is an integral membrane protein found largely in the synapses of neurons. 
APP is first cleaved by one of two proteases: α-secretase or β-secretase. Processing of 
APP by α-secretase produces soluble N-terminal APP (APPSα) that is not amyloidogenic 
and thus does not produce AD.99 Cleavage of APP by β-secretase produces a membrane 
bound fragment referred to as C99,100 which is further processed by γ-secretase to give 
Aβ.101 However, both β-secretase and γ-secretase are involved in other physiological 
functions. Most notably, β-secretase is involved in the nerve myelination through the 
processing of neuregulin 1102 and γ-secretase processes Notch receptors—an important 
receptor in multiple cell signaling systems.103 Several “Notch sparing” γ-secretase 
inhibitors have and are currently being developed to avoid potential side effects. 
However the NSAID (R)-flurbiprofen, a γ-secretase inhibitor that does not effect Notch 
processing, was shown to be ineffective in Phase 3 clinical trials.104 Similarly, several β-
secretase inhibitors are also being investigated105 including the Merck compound MK-
8931, which is currently in Phase 2/3 clinical trials for the treatment of mild to moderate 
AD.106 
The other major lesion found in the brains of AD patients are composed of the 
protein tau.107 Tau normally binds to and stabilizes microtubules and promotes their 
assembly and polymerization, thereby promoting axonal function and viability.108-110 
However, in AD—and at least 20 other neurodegenerative disease known collectively as 
tauopathies—tau is hyperphosphorylated leading to its dissociation from microtubules 
and aggregation into paired helical filaments (PHF) or straight filaments (SF). These 
PHFs and SF make up the NFT lesions. Thus it appears as though tau-induced 
neurodegeneration arises from a combination of a toxic gain of function through the 
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formation of NFT and a toxic loss of function through the destabilization of microtubules.  
Proponents of this tau-hypothesis are supported by the fact that the location and 
formation of NFT correlates more strongly with disease progression than Aβ plaque 
formation.111 Furthermore, transgenic mice lacking tau protein are protected from Aβ-
induced toxicity112,113 and tau dysfunction alone is sufficient to produce dementia.114 This 
mounting evidence clearly establishes tau’s central role in AD pathology. 
Accordingly, a significant effort has been made toward developing a tau-targeting 
therapy for AD.115 Since tau protein is phosphorylated by members of several kinase 
families including GSK-3,116 MARK117, PKA118, and Cdk5119, inhibitors of these proteins 
have been thoroughly investigated. Although several have shown promise in animal 
models, the GSK-3 inhibitor tideglusib showed no clinical benefit in patients with AD or 
progressive paranuclear palsy, another tauopathy.120 
Other studies have sought not to inhibit phosphorylation but to prevent tau 
aggregation. A high-throughput screen of over 200,000 compounds revealed several 
rhodanines, anthraquinones, N-phenylamines, and phenylthiazolylhydrazides are 
effective tau aggregation inhibitors (TAI).121 The oldest known TAI, methylene blue, has 
recently completed a successful phase 2 clinical trial and will be advancing into phase 3 
studies with a more stable reduced analogue.122 Although these results with TAI appear 
promising, pre-aggregation forms of tau have also been shown to be neurotoxic and affect 
memory.123 Thus the decrease in the overall concentration of tau protein may be more 
beneficial. On the other hand, completely eliminating tau protein may have negative 
effects due to a loss of microtubule stabilization. Transgenic mice deficient in tau, 
however, are not only viable but also do not show obvious signs of neurodegeneration.124 
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Several studies have investigated the potential of decreasing tau concentrations by 
activating the proteasome125 or autophagosome.126 Nevertheless, there remains a desperate 
need for the discovery and pharmacological characterization of additional small 
molecules that are able to affect tau concentrations in order to validate this therapeutic 
option. 
 
Natural Products 
Prior to written history, humans have been using plants and other natural 
substances in the treatment of a variety of human ailments, including several CNS 
disorders. For instance, the oldest medical text from ancient Mesopotamia dated to about 
2600 BC describes the use of opium poppy (Papaver somniferum) to treat pain.127 
Historically these medicines consisted of the complex mixtures of compounds that were 
isolated from the natural source. However the isolation of pure morphine from the poppy 
plant in 1804 marked a new era of natural product chemistry in which the beneficial 
effects could be attributed to a single chemical component.128 Several decades later 
another monumental step was taken when Felix Hoffmann prepared acetyl salicylic acid 
(aspirin) from salicylic acid, providing the first example of a chemical modification used 
to improve the biological properties of a natural product.129 Natural products have 
continued to play a major role in drug development and up until relatively recently, these 
compounds represented the largest source of lead compounds. However, in the 1980s the 
advent of combinatorial chemistry allowed access to large libraries of completely 
synthetic compounds. Nevertheless, natural products still remain incredibly influential in 
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drug development and 34% of currently approved small molecules are natural products or 
derivatives derived from them.130 
 The influence of natural products on drug design can be attributed to the many 
advantages natural products have over other small molecules. Principal among these is 
the structural diversity and complexity of natural products that often provides high 
degrees of specificity and potency. Several millennia of evolutionary pressures have 
forced the producing organisms to develop secondary metabolites finely tuned to perform 
a specific biological function. In many cases, these functions are defensive in nature, 
which explains why a particularly high percentage of anti-cancer and anti-infective drugs 
are natural product based.130 By comparison, combinatorial libraries are oftentimes driven 
by the ease in which compounds can be synthesized rather than being driven by a specific 
biological need. This has resulted in libraries filled with molecules with less than ideal 
drug-like properties and multiple violations of drug design principles such as Lipinski’s 
Rule of Five. On the other hand, natural products are often cited as exceptions to 
Lipinski’s rules, partially due to their ability to take advantage of active uptake 
mechanisms.131 The recent efforts to develop “natural product-like” libraries made up of 
more structurally complex scaffolds will, hopefully, produce more promising lead 
compounds.132-136  
 In addition to the complex structure found in many natural products, their 
identification through ethnobotanical studies provides another unique benefit. 
Ethnobotany can be described as the study of the relationship between plants and people. 
Due to the long history of utilizing plants for a medicinal purpose, countless traditional 
remedies have been developed to treat a variety of ailments. Over the last several 
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decades, natural product chemists have begun searching for the individual chemical 
components found in these remedies that may be exerting the beneficial effects. This 
approach often narrows the potential biological targets to those that could produce the 
observed biological effect or conversely, narrow the plants to investigate to identify a 
desired biological response. Alternatively, natural products discovered in this manner 
may lead to the identification of novel biological pathways or molecular targets. Perhaps 
the best example of this is the identification of the opioid receptors, whose discover was 
highly dependent upon radioligands derived from naturally occurring opiates. 
Additionally, ethnobotanical studies can provide preliminary toxicity and 
pharmacokinetic information. This is particularly useful in CNS disorders where brain 
penetration can be a significant hurdle (vide supra). Thus if a plant is used to produce an 
altered mental state (ex: hallucination, sedation, etc.) it is likely doing so by acting 
directly in the brain. These advantages clearly indicate that the use of ethnobotany to 
guide isolation studies is a powerful tool to the natural products chemist. 
 Despite the many advantages provided by natural products in early drug discovery 
there are several challenges associated with their use. Among these are the difficulties in 
isolation and reisolation of the active component. Since many secondary metabolites are 
produced in only minute quantities, isolation of significant amounts for biological studies 
is often problematic. This can be particularly true since secondary metabolites synthesis 
can vary depending upon environmental cues. Although efforts to provide this material 
through total synthesis or molecular biology have proven successful in some cases, these 
studies are often time consuming and laborious. Furthermore, natural products often need 
significant structure optimization to modulate their pharmacokinetic properties for use as 
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drugs. The complex structure and high functional group density found in many natural 
products necessitate the use of mild or carefully optimized reaction conditions to achieve 
selective transformations. 
Finally, the enactment of the Convention on Biological Diversity in 1993 and the 
Nagoya Protocol in 2010 has introduced considerable legal complications in natural 
product field. These treaties outline specific guidelines for the conservation of biological 
diversity including “the fair and equitable sharing of the benefits arising out of the 
utilization of genetic resources.”137,138 While these measures are morally and ethically 
valuable, the added regulations has deterred or slowed some pharmaceutical and 
academic research interests.139 Nevertheless difficulties arising from accessibility, 
intellectual property and structure modification are common to many drug discovery 
efforts, regardless of the source of the initial lead. 
 Natural products clearly represent an important starting point for investigating 
complex biological systems. In particular, the numerous benefits of natural products are 
often well suited to overcome the many challenges faced in CNS drug discovery. For 
instance, the neoclerodane diterpene salvinorin A (Figure 1.10) is a naturally occurring 
KOR agonist that appears to have unique pharmacological properties when compared to 
traditional, synthetic KOR agonists. Therefore salvinorin A has promising potential as a 
probe of the KOR’s role in drug addiction. Similarly, a semi-synthetic derivative of 
salvinorin A, herkinorin, is a MOR agonist structurally unlike all other MOR agonist, 
which suggests it may not possess the same side-effect profile as the opioid analgesics. 
Finally, the diarylheptanoid myricanol has recently been shown to decrease cellular 
concentrations of tau protein making it an attractive scaffold for investigating 
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Alzheimer’s Disease. While these three compounds are useful leads for developing CNS 
probe molecules, a detailed understanding of their interactions with their biological
targets is still needed. Such an understanding will only be possible through the synthesis 
or chemical manipulation of the structures of these natural products.  
!  
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II. Modifications to the Furan Ring of Salvinorin A 
 
Introduction 
The psychoactive plant Salvia divinorum found in Oaxaca, Mexico has been used 
by Mazatec shamans for centuries in traditional divination rituals due to the vivid 
hallucinations experienced following ingestion of the plant’s leaves.1 In addition to its use 
to induce divination, S. divinorum was also used in the treatment for constipation, 
diarrhea, headache, and rheumatism.1 The hallucinatory effects of S. divinorum, have 
more recently attracted the attention of recreational drug users seeking a “legal high.”2,3 
However, several state and national legislatures have responded by outlawing the sale of 
the plant.4 In 1982, the neoclerodane diterpene salvinorin A (Figure 2.1, 1) was isolated 
from S. divinorum5 and was later determined to be responsible for the plant’s 
hallucinatory actions.6 
Following the identification and structure elucidation of 1, its pharmacological 
target was identified through the NIH Psychoactive Drug Screening Program.7 In a screen 
of 50 targets consisting of 
receptors, transporters, and 
ion channels, 1 was found to 
bind selectively and potently 
activate the kappa opioid 
receptor (KOR). These 
actions are particularly 
noteworthy for several 
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Figure 2.1. Structures of salvinorin A (1) and structurally dissimilar hallucinogens 
LSD and psilocin and opioid ligands U50,488H and morphine.
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reasons. First, 1 does not derive its psychoactive effects from the 5-HT2a receptor, the 
target of traditional hallucinogens such as psilocin and LSD (Figure 2.1). This 
involvement of the KOR in perception provides support for the notion that the KOR 
could serve as a potential target for a number of diseases where perception is altered, for 
example schizophrenia or dementia.8 Secondly, the terpenoid structure of 1 makes it 
structurally distinct from other known opioid ligands such as the arylacetamide 
U50,488H and opiates like morphine (Figure 2.1). A basic nitrogen was previously 
believed to be a structural requirement for binding to a highly conserved aspartate residue 
within the binding site of the opioid receptors.9,10 However, the isolation of 1 as the first 
non-nitrogenous opioid has led to a crucial rethinking of this hypothesis and the 
development of novel non-nitrogenous ligands.11  
Due to the structural distinctiveness of 1, several models have been developed in 
an attempt to understand how it interacts with the KOR (Figure 2.2). Historically, most 
opioid receptor models begin with the creation of an in silico salt-bridge between a basic 
nitrogen and the conserved aspartate residue in TMIII.12 However, the lack of basic 
nitrogen in 1 requires alternative approaches to be taken. Using a molecular model 
original built for the KOR agonist U69,598, Roth et. al. proposed a model with key 
hydrogen bonding interactions taking place at the furan ring (Q115), lactone carbonyl 
oxygen (Y139), carbomethoxy carbonyl oxygen (Y312) and the acetate carbonyl oxygen 
(Y313) (Figure 2.2A).7 Based upon subsequent site-directed mutagenesis, covalent 
labeling, and substituted-cysteine accessibility method (SCAM) studies this model was 
later adjusted to revise the H-bonding interactions at the furan ring (Y119 and Y320) and 
! 44 
to include hydrophobic iterations with the methyl ester (I294 and E297) and C2 acetate 
(Y313) (Figure 2.2B).13,14 
Using chimeric opioid receptors and site-directed mutagenesis, an additional 
model was proposed by Kane.12 Here the key interactions consisted of hydrophobic 
interaction with the C2 acetate (Y312 and Y313), H-bonding interactions with the lactone 
carbonyl oxygen (Q115), and pi-stacking interactions with the furan (Y320) (Figure
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2.2C). In an alternative approach to incorporate data from structure-activity relationship 
studies, this group also utilized a training set of 15 derivatives of 1 to develop a virtual 
model. This model was shown to be reasonable accurate at predicting the activity of other 
analogues of 1. Similar pi-stacking with the furan ring (Y320) was proposed however the 
role of the amino acid residues Q115, Y119, and Y313 were adjusted to interact with the 
C2 ester, diterpene backbone, and carbomethoxy carbonyl, respectively (Figure 2.2D).15  
Although the four models discussed above are slightly different, all the residues invoked 
are in close proximity within the three-dimensional structure of the receptor. This is 
particularly impressive considering that the antagonist-bound structure of the KOR was 
not solved until 2012,16 several years after these models were developed. 
The advent of the crystal structure of the KOR is likely to have a profound impact 
upon future ligand development. It is, however, important to note that because the KOR 
antagonist JD-Tic was bound in the active site, the receptor is in the inactive state. 
Nevertheless, virtual library screening using this inactive state has produced novel 
agonist leads17 suggesting that binding models for 1 based upon this structure may be 
useful. Following the solving of the structure, a model was developed for the endogenous 
peptide dynorphin A, the arylacetamide U69,593, the octahydroisoquinolinone 
carboxamide 1xx, and 1.18,19 The model for 1 proposes a very detailed list of the amino 
acid residues that are in close proximity to the ligand (Figure 2.2E). Among these are the 
pocket created by Glu209, Cys210, and Trp124 to accommodate the furan ring without 
any clear H-bond or pi-stacking interactions. The C4 methyl ester is proposed to interact 
through both H-bonding interactions (Thr111 and Tyr320) and potentially through a pi-
stacking interaction (Tyr320). Finally, the acetoxy moeity is suggested to interact through 
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both a hydrophobic interaction via the acetyl methyl (Tyr139) and an H-bond interaction 
via the carbonyl oxygen (Arg138). Although this latest model differs the most from the 
other four, because it is based upon the KOR crystal structure rather than that of 
rhodopsin, it likely provides the clearest picture of the true interactions. However this 
cannot be definitively known until a crystal structure of the 1-KOR complex is solved. 
Until this time, further elucidation of how 1 binds with the KOR will require the 
continued use of structure-activity relationship (SAR) studies through the development of 
semi-synthetic probe 
molecules. Historically 
these studies have been 
important in determining 
the functionality in 1 
required for proper binding 
and activation. This topic has been eloquently reviewed,20 and some general trends are 
highlighted in Figure 2.3. However two positions have attracted the majority of the 
attention and deserve additional comment. Removal of the C2 acetyl moiety results in the 
alcohol salvinorin B, a diterpene also found in the leaves of S. divinorum, that is devoid 
of KOR activity.21 Largely due to the ease and reproducibility of this hydrolysis, 
numerous studies have explored this position ultimately leading to several important 
findings. These include the discovery of methanesulfonyl (Ms), ethoxymethyl (EOM), 
and methoxymethyl (MOM) substituted salvinorin B which all show equal or increased 
affinity at the KOR (Figure 2.4). Because of their increased metabolic stability these 
compounds have served as excellent probe molecules for examining the KOR in vivo.22-25 
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Figure 2.3. Established structure activity relationships for 1 at the KOR.
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An equally important finding was that C2 aromatic esters possess significantly less 
activity at KOR but increased activity at the mu opioid receptor (MOR), making these 
probes attractive leads for novel treatments for pain. 
The other well-studied position is the furan moiety appended at C12. Primarily 
due to the metabolic toxicity associated with furan rings,26 most of these investigations 
have focused on its replacement. Heterocycles such as oxazolines, oxazoles, pyrroles, 
triazoles, benzothiophenes, and benzofurans have been explored however these analogues 
ultimately result in poor affinity. A ligand bearing a 2-methyl-1,3,5-oxazdiazole (3) did 
however result in only a modest 30-fold reduction in binding relative to 1 (Figure 2.4). 
Therefore the preparation of additional heterocyclic isosteres may be worthwhile to 
improve the metabolic stability of 1. 
Prior to 2013, significantly less work had been done to investigate the effects of 
substitutions on the furan ring itself. The lone examples in the literature, 16-
bromosalvinorin A (4) and 16-vinylsalvinorin A (5), showed only small differences in 
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binding at the KOR in comparison to 1,27 indicating other substitutions may also be 
tolerated. Because the furan ring is implicated in every proposed binding model (Figure 
2.2) substitutions that effect the steric or electronic character of the furan ring may be 
useful in determining how 1 interacts with its molecular target.  
 
Synthesis of Analogues 
Replacement of Furan with Isoxazoles 
 Based upon the limited success of previous studies utilizing heterocycles that 
differed significantly from furan, it was envisioned that isoxazoles appended to the 
neoclerodane core at the 3-position would serve as better probes. These heterocycles 
differ from furan by the replacement of the C16 methine with a nitrogen and allow for 
substitutions at C15. This additional nitrogen is expected to cause increased in vivo 
stability due to differences in metabolism. The toxicity associated with furans is the result 
of their CYP450-mediated oxidation, which eventually results in enonals that can 
undergo bioconjugation either via a Michael addition or through attack of the aldehyde 
(Scheme 2.1). The pi system of the isoxazole is less electron rich due to the additional 
heteroatom, therefore isoxazoles undergo reductive ring openings. Hydrolysis of the 
resulting imine results in a diketone that is more metabolically stable.26 The ability to 
include substitutions at C15 will allow for additional probing of the KOR binding pocket. 
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The synthesis of the isoxazole probes begins with the known three step protocol 
to convert the furan ring of 1 to an aldehyde (Scheme 2.2).28 Briefly, ruthenium-catalyzed 
oxidative degradation of the furan produces the carboxcylic acid that is then converted to 
an ethyl thioester. Selective reduction of the thioester in the presence of four other 
carbonyls is accomplished using a mild Fukuyama reduction. Through this process gram 
quantities of the aldehyde 7 can be synthesized with only a single chromatographic 
purification step. Condensation of 7 with hydroxylamine in refluxing methanol and 
pyridine produces the oxime 8 as separable mixture of cis and trans isomers. This 
mixture is then oxidized to the nitrile oxide with (bis(trifluoracetoxy)iodo)benzene 
(PIFA)  which undergoes a [3+2] dipolar cycloaddition with a number of terminal 
alkynes.29 The resulting isoxazoles were isolated in moderate yields and as a single 
regioisomer. In this initial study, both aromatic and aliphatic alkynes were used to 
investigate potential effects on activity at the KOR. 
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To access the unsubstituted isoxazole, ethynyltrimethylsilane was employed in the 
cycloaddition reaction to produce 13. Unfortunately attempts to remove the silyl 
protecting group using either CsF30 or TBAF resulted in a formal loss of ketene to 
produce the nitrile 14 (Scheme 2.3). This structural assignment was confirmed by 
comparison to a sample of 14 prepared via the tosylchloride-mediated dehydration of 8. 
A careful examination of the literature reveals that this fluoride-promoted fragmentation 
of the isoxazole ring is known and thought to occur via the corresponding anion.31 
Recently, similar fragmentations have been used for the installation of acetonitriles 
moieties to aromatic systems.32,33 
 
 
 Substitutions to the Furan Ring 
 In order to probe the steric and electronic effects in the furan ring binding pocket 
of the KOR, a series of probe molecules with modifications to the furan ring was needed. 
The methods that were developed to provide these substitutions drew heavily upon the 
selective bromination of the C16 position and subsequent palladium-catalyzed Stille 
coupling that had been previously reported. However both of these processes would 
require significant improvement in order to expand the number of substitutions that could 
be accessed.  
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 The bromination of 1 with NBS has been reported several times in the 
literature,27,34,35 however under these conditions the reaction requires extended reaction 
times leading to decomposition of 1 and yields that vary between 10-61%. A brief screen 
of several additives found that the addition of a catalytic amount of Br2 led to complete 
conversion after only 30 minutes and consistent yields of 
49% (Scheme 2.4).36 The arylbromide product (4) was 
spectroscopically identical to that isolated from the 
uncatalyzed reaction and for the first time the regiochemistry 
was confirmed by single-crystal X-ray diffraction (Figure 
2.5). The mechanism by which Br2 affects the reaction 
remains to be elucidated however Br2 may simply be serving 
as a source of catalytic HBr. Interestingly, the use of 
stoichiometric amount of Br2 results in the dibromide 15.  
 With rapid and reliable access to 4, investigations into using this arylbromide as a 
functional handle to introduce other substitutions to the furan ring were now possible. 
This has previously be demonstrated with a Stille coupling in the synthesis of 5, however 
the significant toxicity associated with organotin reagents makes this process less than 
ideal. The limited toxicity of boronic acids makes Suzuki-Miyaura couplings an attractive 
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alternative. Furthermore, the number of commercially available boronic acids now 
greatly outnumbers that of stannanes (14,601 and 1,097, respectively).37 
To determine whether a Suzuki-Miyaura coupling could be applied to introduce 
substitution to the furan ring of 1 the cross-coupling of 4 and phenylboronic acid was first 
explored. The biaryl phosphine ligand SPhos developed by Buchwald has been shown to 
be quite successful in challenging Suzuki-Miyaura reactions and was therefore selected 
for the first attempt.38,39 Employing the literature precedented reaction conditions led to 
full conversion of 4, however two isomeric products were isolated from the reaction 
mixture. Detailed analysis of the 1H and 13C NMR spectra revealed these two compounds 
to be the C8 epimers 16 and 17 (Table 2.1). Epimerization at this alpha center is well 
documented in both semi-synthetic and total synthesis efforts and occurs under both basic 
and acid conditions.40,41 Additionally, C8-epi-1 is found in the smoke of pyrolysed S. 
divinorum leaves.42,43 Unfortunately this epimerization results in a loss of nearly all 
activity at the KOR and evaluation of the 16 and 17 using a calcium mobilization assay 
indicated that 17 was nearly 50 times less potent that 16. Therefore careful optimization 
of these reaction conditions was necessary to avoid this deleterious side reaction. 
Noting that the epimerization is likely due to either the basic or thermal 
conditions used during the reaction, optimization studies focused primarily around these 
two variables (Table 2.1). Reducing the amount of base present did successfully reduce 
the amount of epimerization (Entry 1-3), however this also significantly reduced the 
conversion rate for the reaction. This proved to be particularly negative because 4 could 
not be easily removed from 16 by simple silica gel chromatography. Fortunately reducing 
the temperature from 100 °C to 60 °C with 3.0 equivalents of base resulted in full 
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conversion of 4 without any observable epimerization. Interestingly, decreasing the 
amount of base at this temperature resulted in lower conversion and increased levels of 
epimerization. Cooling the reaction to room temperature was unsuccessful and produced 
less than <10% conversion. Full conversion of 4 was observed in both THF and 1,4-
dioxane but with increased levels of epimerization indicating toluene was the optimal 
solvent. 
With these optimized conditions in hand, the full scope of potential substitutions 
was explored using a variety of commercially available boronic acids (Scheme 2.5). 
Substitutions were well-tolerated at all three positions to the phenyl ring producing 
 
Table 2.1. Optimization of Suzuki-Miyaura Reaction Conditions.a 
 
Entry Equiv Base Temp (°C) Solvent % Conversion b Ratio 16/17 c 
1 3.0 100 PhMe 100 12:1 
2 2.5 100 PhMe 92 80:1 
3 2.0 100 PhMe 17 >99:1 
4 3.0 60 PhMe 100 >99:1 
5 2.5 60 PhMe 96 25:1 
6 3.0 RT PhMe <10 --d 
7 2.5 RT PhMe <10 --d 
8 2.5 60 1,4-Diox 100 19:1 
9 2.5 60 THF 100 5:1 
a General reaction conditions: PhB(OH)2 (2 equiv), Pd2(dba)3 (0.04 equiv), SPhos (0.16 
equiv). b Conversion based on the consumption of 4 as measured by GC–MS. c Ratio of 
15/16 measure by HPLC. d Not measured due to lack of product formation. 
OH H
O
O
O
AcO
CO2Me
Me
Me
Br
4
OH H
O
O
O
AcO
CO2Me
Me
Me
16
PhB(OH)2
Pd2(dba)3
SPhos
K3PO4
Solvent
Temp
16 h
OH H
O
O
O
AcO
CO2Me
Me
Me
17
Ph Ph
8
! 54 
products in moderate to excellent yield. As expected, boronic acids bearing electron-
donating groups generally produced higher yields than electron-deficient boronic acids. 
Furans substituted at either the 2- or 3-position and the 3-thiophene were successfully 
appended to C16, however the 2-thiophene boronic acid was unsuccessful. These 
heterocyclic boronic acids are prone to protodeborylation.44 This was somewhat 
overcome through the use of the MIDA-boronate technology developed by Burke 
however low reaction yields were still observed after 24 hours.45 The incorporation of 
alkyl or alkenyl moieties was somewhat more challenging and the only successful 
products isolated were 39-42. With all other alkyl boronic acids (such as cyclohexyl or 
isopropyl) and partially with phenethylboronic acid, the major product was 1, from 
!
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protodebromination of 4. 
General access to alkyl 
substitutions was, however, 
made possible via the selective 
reduction of an olefin 
precursor. For example, the 
vinyl group in 5, was easily 
reduced with Pd/C to an ethyl 
moiety (44) without the over 
reduction of the furan ring that had been previously reported (Scheme 2.6).35,46 Under 
these conditions the nitro-substituted analogues 21-23 were also reduced to the 
corresponding anilines 45-47, which were also unobtainable with Suzuki-Miyaura 
couplings.  
 To complement the sp2- and sp3-hybridzed substitutions made possible by the 
Suzuki-Miyaura couplings, terminal alkynes were introduced through a Sonogashira 
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reaction (Scheme 2.7). In this case standard conditions proved successful without the 
need for optimization and no epimerization was observed despite the use of excess 
triethylamine at elevated temperatures. Using these conditions a more focused series was 
synthesized to access the effects of alkyl and aromatic groups at the end of the alkyne. 
The gaseous nature of propyne did prevent the use of a Sonogashira coupling however 
performing a Suzuki-Miyaura reaction with a trifluoroborate salt produced 43 in 
acceptable yields (Scheme 2.5). Similar conditions also allowed for the synthesis of the 
vinyl-substituted 5.  
  The dibromide 16 was also a compatible partner in cross-coupling reactions, 
albeit a less efficient one. At first, the reaction was performed with a single equivalent of 
phenyl boronic acid to determine if there was any preference in regioselectivity, which 
could potentially allow access to C15-substituted analogues (Scheme 2.8). Interestingly 
the reaction resulted in a mixture of recovered starting material and the diarylated product 
54. The lack of a monoarylated product suggests that the second coupling reaction occurs 
faster than the first. Dimethylation of 16 with excess methylboronic acid resulted in 55 in 
 
Scheme 2.8. Disubstitutions to the furan ring via Suzuki-Miyaura reactions.a
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only 46%, which corresponds to less than 68% yield for each methylation. By 
comparison, the methylation of 5 was achieved in 76% yield, indicating that 16 is either 
less reactive or less stable in the cross-coupling reactions. The diarylation with 5-formyl- 
2-furanboronic acid and 5-formyl-2-thiopheneboronic acid was also briefly explored as a 
potential opportunity to convert the furan ring into heterocyclic triads. These motifs have 
recently attracted attention due to their ability to induce apoptosis.47 Although an 
interesting notion, the low yields of these transformations limited the exploration of 
converting 1 into an apoptosis-inducing chemical probe.  
 As an alternative method to alter the steric and electronic parameters of the furan 
ring, trifluoromethyl groups were introduced as shown in Scheme 2.9. Using recently 
developed conditions developed for the trifluormethylation of various arenes and 
heteroarenes,48 1 was efficiently converted into a easily separable mixture of 58 and 59. 
The position of each substitution was assigned through a combination of 2D NMR and C-
F coupling constants. The HMBC spectra of 58 and 59 show strong correlations between 
the C12 proton and carbons C13, C14, and C16. This allowed for the assignment of the 
remaining aromatic carbon signal to C15. This C15 signal in the 13C spectrum of 58 
appeared as a quartet (2JCF = 43 Hz) indicating it was directly appended to a 
trifluoromethyl group. COSY experiments were used to confirm this assignment however 
were less conclusive due to weak coupling of the C14 and C15 protons of 59. Of these 
two probes, 58 is particularly useful because only one other report has illustrated the 
monosubstitution of this position.49  
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This other report also details the synthesis of 60 and 61 by heating 1 with 
paraformaldehyde in acetic acid (Scheme 2.10). An attempt to reproduce this result 
yielded a complex mixture of the mono- and bis-acetoxymethylated products (62 and 63, 
respectively) in addition to 60 and 61. All efforts to improve the selectivity or yield of 
this reaction using Lewis acids (such as BF3·OEt2 and LiCl), increasing the reaction times 
and temperatures, or through slow addition of the paraformaldehyde were unsuccessful. 
The primary alcohol of 61 was, however, successful oxidized to the aldehyde 64 under 
Swern conditions. Condensation of 64 with hydroxylamine led to the intermediate oxime, 
which was converted directly to 65 without further purification. This three compound 
series (60, 64, and 65) was expected to complement the corresponding all carbon series 
(44, 5, and 53) and provide useful insight into how electron density in the furan ring 
affects interactions with the KOR. 
Scheme 2.9. Trifluoromethylation of 1 using photoredox catalysis.a
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In Vitro Studies  
 To assess how the modifications that had been made to the furan ring of 1 would 
affect activity at the KOR, compounds 4-65 were screened using a DiscoveRx 
HitHunter® cAMP Assay Platform. This in vitro measure of receptor activation utilizes 
CHO cells overexpressing the KOR on the cell surface. Activation of the receptors with 
KOR agonists leads to a release of the Gαi that inhibits the forskolin-induced formation 
of cAMP by adenylate cyclase. These levels of cAMP are then quantified using a 
competitive immunosassay.50 Using this assay the EC50 and Emax values of 4-64 were 
obtained to measure their potencies and efficacies, respectively. Although most of these 
compounds retained full efficacy at the KOR—indicating they are full agonists—
compounds 21, 47, and 49 appear to be partial agonists with Emax values of 84%, 65%, 
and 88%, respectively. However, their relatively low potencies (EC50 = 360 ± 60 nM, 620 
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± 140 nM, and 6,000 ± 2000 nM, respectively) hampers their potential utility. A 
comparison of the EC50 values for the remaining compounds was used to determine how 
changes to the steric and electronic properties of the furan ring affects KOR activation, 
which should provide additional insight into the furan ring binding pocket. 
 
Isoxazoles Series 
 The replacement of the furan ring with an isoxazole resulted in a drastic decrease 
in activity (Table 2.2). The least potent of these compounds, 9, contained an 
unsubstituted phenyl ring and was almost 5 orders of magnitude less potent than 1 at the 
KOR. It is somewhat interesting that substitution of this phenyl ring did lead to a slight 
increase in potency. This effect does not seem to be electronic in nature as both the 
electron-donating methoxy group (10) and electron-withdrawing trifluormethyl group 
(11) produced similar effects. The most active in this series was the trimethylsilyl- 
 
Table 2.2. KOR Activity of Isoxazole Series. 
 
Entry Compound R= EC50a (nM) Emaxb (%) 
1 Salvinorin A (1) -- 0.042 ± 0.005 101 
2 9 C6H5 4000 ± 1000 110 
3 10 2-MeOC6H4 300 ± 50 106 
4 11 2-CF3C6H4 581 ± 8 110 
5 12 CH2OH 770 ± 80 107 
6 13 Si(CH3)3 15 ± 2 104 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells. Mean ± standard error of the mean; n = 
4. b Emax = % of maximal response produced by U69,593.
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substituted 13 that was intended to serve as a precursor to the unsubstituted ring with an 
EC50  = 15 ± 2 nM, however the compound is still more than 300 times less potent than 
the parent natural product.  Whether these drops in potency relative to 1 are the result of 
substitution at the C15 position or from the electronic differences between furan and 
isoxazole is currently unclear. This will remain difficult to determine until a route to the 
unsubstituted isoxazole is discovered or a general process to introduce substitutions to the 
C15 position of 1 is made possible.  
 
Substituted Series 
 The latest binding model of 1 based on the recent antagonist bound crystal 
structure of the KOR predicts the furan ring to bind in a small pocket composed of 
Trp124, Glu209, and Cys 210.18,19 The substitution of the furan ring has now provided the! 
necessary probes needed to validate these claims. Evaluation of these compounds reveals 
that, in general, substituting 
the furan ring led to a 
decrease in potency at the 
KOR, which supports the 
hypothesis that 1 binds in a 
sterically encumbering 
portion of the binding 
pocket. Several of the 
sterically less demanding 
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Figure 2.6. Compounds containing small substitutions to C16 and their corresponding 
potencies at the KOR.
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substitutions, however, did give rise to compounds with low to sub-nanomolar potencies 
(Figure 2.6). These compounds would serve as the basis to elucidate additional SAR.  
The introduction of a phenyl group to the C16 position of the furan ring did result 
in an approximate 40-fold decrease in potency at the KOR. However using 16 as a point 
of comparison, additional ligand-receptor interactions could be identified. Such an 
interaction would be observed as an increase in potency relative to 16. Therefore,!
trifluoromethyl- and fluoro-substitutions were introduced to the phenyl to probe for 
halogen bonding interactions (18-20, 24-26). The methoxy-, nitro-, and amino-phenyl 
rings as well as the 5-membered heterocycles were included to observe potential 
hydrogen bonding. Given the relative frequency of the “methyl effect,” tolyl-substitutions 
were also examined.51 Finally the pi-system of the substitutions was extended with 
naphthyl analogues in an attempt to gain additional pi-stacking interactions. Despite the 
wide range of functionality that was introduced, screening of the 24 compounds (16, 18-
35, 36-37, 45-47) containing aromatic rings appended to C16 unfortunately revealed no 
increase in potency relative to 16 (Table 2.3). Furthermore, neither substitution position 
nor electron density appeared to have a profound effect on activity. Instead, the activity 
of the ligands appeared to be highly dependent upon the steric properties of the 
substitutions. 
A similar dependence upon steric size was observed in the bromo-, alkyl-, 
alkenyl-, and alkynyl-substituted analogues (Table 2.4). Bromination of the furan ring 
had an insignificant effect upon activity, which is consistent with previous results.27,35 
However, replacement of the bromine with small alkyl groups such as methyl, ethyl or 
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Table 2.3. KOR Activity of Aromatic-substituted Series 
 
Entry Compound R= EC50a (nM) Emaxb (%) 
1 1 H 0.030 ± 0.004 101 
2 16 Ph 1.3 ± 0.4 101 
3 18 2-CF3-C6H4 8.4 ± 2.3 102 
4 19 3-CF3-C6H4 27 ± 6.0 101 
5 20 4-CF3-C6H4 1020 ± 250 102 
6 21 2-NO2-C6H4 360 ± 60 84 
7 22 3-NO2-C6H4 450 ± 100 108 
8 23 4-NO2-C6H4 170 ± 50 106 
9 24 2-FC6H4 1.2 ± 0.1 102 
10 25 3-FC6H4 12.0 ± 3.0 93 
11 26 4-FC6H4 54.0 ± 7.0 97 
12 27 2-MeC6H4 5.4 ± 1.1 101 
13 28 3-MeC6H4 3.4 ± 1.1 102 
14 29 4-MeC6H4 2.3 ± 0.4 101 
15 30 2-MeOC6H4 10 ± 2.0 104 
16 31 3-MeOC6H4 8.6 ± 2.6 104 
17 32 4-MeOC6H4 16.0 ± 5.0 107 
18 45 2-NH2-C6H4 430 ± 60 97 
19 46 3-NH2-C6H4 630 ± 160 103 
20 47 4-NH2-C6H4 620 ± 140 65 
21 33 1-naphthyl 37.0 ± 9.0 98 
22 34 2-naphthyl 25.0 ± 7.0 98 
23 35 2-furyl 6.7 ± 1.6 99 
24 37 3-furyl 6.5 ± 1.3 105 
25 38 3-thienyl 4.3 ± 0.5 105 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells. Mean ± standard error of the mean; 
n ≥ 3. b Emax = % of maximal response produced by U69,593.  
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cyclopropyl led to a 13-33 fold decrease in potency. This potency loss is regained when 
moving from an ethyl- (44, EC50 = 2.9 ± 0.6 nM) to vinyl- (5, EC50 = 0.96 ± 0.24 nM) to 
ethynyl-substituted (53, EC50 = 0.019 ± 0.004 nM) furan rings. This effect is directly 
related to the steric parameters of each substitution (A-values: ethyl: 1.8 kcal/mol; vinyl: 
 
Table 2.4. KOR Activity of Bromo-, Alkyl-, Alkenyl-, and Alkynyl-Substituted Series. 
 
Entry Compound R= EC50a (nM) Emaxb (%) 
1 1 H 0.030 ± 0.004 101 
2 4 Br 0.040 ± 0.010 100 
3 39 Me 0.41 ± 0.15 101 
4 40 cyclopropyl 1.00 ± 0.03 102 
5 44 Et 2.9 ± 0.6 103 
6 5 CH2=C(H) 0.96 ± 0.24 101 
7 53 HC≡C 0.019 ± 0.004 100 
8 42 PhCH2CH2 38.0 ± 5.0 102 
9 41 PhC(H)=C(H) 20.0 ± 2.0 102 
10 48 PhC≡C 100 ± 5 102 
11 49 2-MeO-C6H4≡C 6000 ± 2000 88 
12 50 2-CF3-C6H4≡C 430 ± 50 107 
13 43 MeC≡C 26.0 ± 10 102 
14 51 Me(CH2)2≡C 9300 ± 300 90 
15 52 HO(CH2)3≡C 890 ± 30 108 
16 59 HOCH2 3.3 ± 0.2 102 
17 63 CHO 7.3 ± 2.5 104 
18 64 CN 9.4 ± 2.2 104 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells. Mean ± standard error of the mean; n ≥ 
3. b Emax = % of maximal response produced by U69,593. 
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1.7 kcal/mol; ethynyl: 0.5 kcal/mol).52 Additionally, decreasing the amount of saturation 
limits the rotational freedom, which could improve binding to and activation of the KOR. 
The terminal alkyne 53 is particularly interesting as it represents the only modification to 
the furan ring, to date, that has resulted in an increase in activity at the KOR. 
This same trend is not seen when a phenyl group is present at the end of the two-
carbon linker. While 41 bearing an alkene is slightly more potent than its saturated 
variant 42 (EC50 = 20 ± 5.0 nM and 38.0 ± 5.0 nM, respectively), the alkyne 48 is 
considerable less potent than both (EC50 = 100 ± 5 nM). This suggests that while 
decreasing saturation from 42 to 41 does decrease steric bulk in the binding site, the 
linear alkyne extends the phenyl ring too far into the pocket and prevents proper receptor 
activation.  
A similar trend was observed when alkyl groups were present at the end of the 
alkyne of 53. The addition of a methyl group reduced the potency from 0.019 ± 0.004 nM 
to 26.0 ± 10 nM. This effect was even more pronounced with a propyl group present at 
the end of the alkyne (EC50= 9300 ± 300 nM). The introduction of an alcohol at the end 
of this propyl chain (52) did result in a small increase in potency (EC50= 890 ± 30 nM) 
relative to 51 however these effects are still heavily outweighed by the steric bulk of the 
substitution.  
 In addition to these strong steric effects, modulation of the furan rings electronic 
character also had a measurable effect. The hydroxymethyl, aldehyde and nitrile 
functionalities in 59, 63, and 64, respectively, were anticipated to be sterically similar to 
the ethyl, vinyl, and ethynyl moieties of 44, 5, and 53. Therefore, any differences in 
activity can be mostly attributed to the electron-withdrawing nature of the aldehyde and 
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nitrile. As expected, 29 and 59, which are both sterically and electronically similar, were 
equipotent, however both 63 and 64 were significantly less potent than their all carbon 
counterparts. This indicates that an electron-rich furan is preferred for KOR activation. 
 The final series of compounds used to investigate the effects of substituting the 
furan possessed substituents at the C15 position. Because bromination occurs selectively 
at the C16 position, substitution at this position was not as straightforward. Fortunately 
the radical nature of the photoredox catalyzed trifluoromethylation led to an equal 
mixture of C15- and C16-substituted products, thus allowing for a single point of 
comparison. Given the steric and electronic effects discussed above, it is unsurprising that 
both 58 and 59 are significantly less potent than 1 (Table 2.5). However, 58 bearing the 
trifluoromethyl group at C15 is 10 times more potent at the KOR than 59. This preference 
 
Table 2.5. KOR Activity of C15-substituted Derivatives. 
 
Entry Compound R1= R2= EC50a (nM) Emaxb (%) 
1 1 H H 0.030 ± 0.004 101 
2 58 CF3 H 3.1 ± 0.3 102 
3 59 H CF3 31 ± 11 100 
4 4 H Br 0.040 ± 0.010 100 
5 15 Br Br 240 ± 50 106 
6 39 H Me 0.41 ± 0.15 101 
7 55 Me Me 250 ± 50 105 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells. Mean ± standard error of the mean; n ≥ 
3. b Emax = % of maximal response produced by U69,593. 
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for C15 substitution suggests the lack of potency in the isoxazole series (9-13) is likely 
due to decreased electron density in the heterocycles rather than from steric effects of the 
substitutions. Since the electronic differences in 58 and 59 are expected to be negligible, 
the preference for C15 substitution must be primarily due to steric differences in the 
binding pocket. Potentially the furan ring may be positioned such that C15 is located in a 
less sterically encumbering portion of the binding 
pocket. Alternatively, rotation about the C12-C13 
bond may allow the furan ring to adopt several 
different favorable binding modes. The 
disubstituted probe molecules 15 and 55 were 
useful in distinguishing between these two 
possibilities. If the C15 substitution were oriented 
toward an open pocket then an additional C15 
substitution would not be expected to have a large effect. On the other hand, if the furan 
ring rotates to position the substitutions outside of a narrow pocket, then an additional 
substitution would be less well tolerated because either C15 or C16 would need to be 
directed into the binding pocket (Figure 2.7). A comparison of 4 to 15 and 39 to 55 
(Table 2.5) clearly shows that the additional substitution results in a 600 and 6,000 fold 
drop in potency, supporting the notion that the furan ring rotates in order to accommodate 
the substitutions.  
 
 
 
produced by 1, the most efficacious of which (5a; IC50 ¼ 7 nM)
showed an inhibition level that was 20" lower than 1. The com-
pounds showing the poorest efficacy (5f, 5l, 5m) also had no sub-
stantial affinity for the KOR. Although there was not a strong
correlation between affinity and efficacy for the tested compounds
(see Fig. S1), those of the aromatic series (except 5a) tended to
showefficacy similar to those of the non-conjugated series but with
lower binding affinity. Interestingly, compound 4a, whose binding
affinity is only 6" less than 1, was 380" less efficacious.
2.1.2. Molecular modeling
We have used the crystal structure of the KOR complexed with
the antagonist JDTic (PDB ID ¼ 4DJH) to model the interaction of
various agonists with the receptor. Although technically in an
inactive state, it has been shown that large-scale movements of
amino acid residues in the orthosteric binding site of class A GPCRs
are not requisite for activation of the receptor [26]. In addition, it
has been found that virtual screening for ligands using inactive-
state GPCRs can produces agonist leads (see for example Negri
et al.) [27]. We have previously described a putative binding mode
for salvinorin A repres nting an initial rec gnitionmode based n an
extensive amount of experimental data [9,28]. This binding mode
was reproduced in the current docking studies and is shown in
Fig. 3A. In the proposed binding mode, the fused tricyclic core is
oriented toward TM2 and interacts primarily with the side chains of
V1082.53, T1112.56, Q1152.60, V1182.63, 1343.28, 1353.29 and D1383.32,
which form a highly complementary stereoelectronic binding site
for the salvinorin core structure (numbers in parentheses indicate
BallesteroseWeinstein indexes [29]). The furanyl moiety interacts
with V1182.63, W124EL1 and C210EL2, and in a slightly different pose,
may also possibly form hydrogen bonds with Y3137.36.9 The C4
methyl ester is situated in a small pocket formed by V1082.53,
T1112.56, W2876.48 and Y3207.43 and engages in hydrogen bonding
interactions with T1112.56 and Y3207.43. The C2 acetoxy group en-
gages a small subpocket delineated by D1383.32, Y1393.33 and
M1423.36.
For each of the compounds 4aeh and 5aen, a docked pose
analogous to 1 was obtained for the KOR, although the various
substituents at the C2 position bound in somewhat different ori-
entations. These varying orientations were able to provide insights
regarding the possible interaction modes of the compounds at the
KOR. For the compounds reported here, the electrophilic Michael
acceptor atom of the C2 substituent was never closer than ~7 Å
from the Sg atom of C315 in any of the solutions (taking into ac-
count C315 side chain rotameric flexibility). As discussed in Section
2.1.2 above, there may be multiple reasons for this, providing a
rationale for why these compounds do not form covalently-bound
adducts with KOR.
The putative binding mode for the most affine analog from the
conjugated/non-conjugated series (4d) is shown in Fig. 3B and is
analogous to the putative binding mode for salvinorin A (1), except
that the olefinic side chain of the C2 substituent is able to effectively
fill the small hydrophobic subpocket formed by D1383.32, Y1393.33
and M1423.36 (Fig. S2). The model shows how the presence of an
intervening methyl group between the ester and olefin function-
alities, as in 4d, allows the olefinic portion to be directed into the
Fig. 3. Putative binding mode for compounds A) 1, B) 4d, C) 5a and D) 5m.
P.R. Polepally et al. / European Journal of Medicinal Chemistry 85 (2014) 818e829 823
Figure 2.7. Proposed binding model of 1 
based on the KOR crystal structure. Figure 
adapted from reference 19.  
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In Vivo Studies  
 By synthesizing and evaluating 46 novel KOR probe molecules three potent 
agonists were identified (4, 39, and 53). Further evaluation of these three compounds 
indicated they were highly selective for the KOR, possessing no measurable activity at 
the MOR (EC50 > 10 µM). To determine whether these results would translate into in vivo 
efficacies, the agonists’ abilities to affect cocaine-primed reinstatement were assessed in 
collaboration with the Kivell laboratory at Victoria University of Wellington, New 
Zealand. 
 This animal model of drug relapse takes place in three phases.53 In the first phase, 
Sprague-Dawley rats are trained to self-administer cocaine solution intravenously by 
depressing a lever. The number of lever presses can be used to quantitate drug seeking 
behavior. In the second phase of the experiment the cocaine solution is replaced with a 
saline solution. During this “extinction” phase the number of active lever presses is 
quickly diminished because the rewarding properties of cocaine have been removed. In 
the final “reinstatement” phase, the test animals are treated with either test compounds or 
a vehicle control then given a large dose of cocaine (20 mg/kg). In this final phase the 
animals’ drug seeking behavior increases even though they are only administering saline 
solutions. Under this paradigm, a number of KOR agonists, including several derivatives 
of 1, successfully attenuate the level of drug seeking behavior in the reinstatement phase 
relative to the vehicle control.54-56 
 The agonists described in this study showed similar results to other KOR agonist 
in their ability to reduce drug seeking behavior (Figure 2.8A-C).57 The more potent 
agonists 4 and 53 both dose-dependently decreased responding during the extinction 
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period. Consistent with our in vitro results, the more potent agonist 53 was able to induce 
a statistically significant result at a lower dose (0.1 mg/kg) than that required for 4 (0.3 
mg/kg). Additionally, the methyl-substituted 39 appeared to be trending toward 
decreasing responses at increasing doses but these results were not significantly different 
from the vehicle treated animals. 
These encouraging results clearly indicate that 4 and 53 (and likely 39 at higher 
doses) are able to decrease drug seeking behavior in an animal model of relapse. 
Furthermore, the high selectivity of these compounds for the KOR indicates that these 
effects are KOR-dependent. However, the decreased responding may be the result 
sedation and decreased motor coordination that has been observed with other KOR 
agonists.55,58 To determine if these side-effects were responsible for the decreased 
Figure 2.8. Effects of salvinorin A derived compounds on drug seeking behavior and cocaine-induced spontaneous 
locomotion. Active lever responses for cocaine self-administration during baseline and extinction (pretest) and during 
reinstatement following a priming injection of cocaine (20 mg/kg) for 4 (A), 39 (B), and 53 (C). Repeated measures 
ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05; **P < 0.01) (n = 5 or 6). Effect of 4 (D) (P = 
0.9326), 39 (E) (P = 0.7289), and 53 (F) (P = 0.3659) on spontaneous locomotor activity in the rat shown as total 
ambulatory counts over 60 min. Student t test (n = 6 or 7). Figure adapted from reference 36. 
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responding, the effects of 4, 39, and 53 on cocaine-induced spontaneous locomotion was 
determined (Figure 2.8D-F). At the highest doses used, no statistical difference from 
vehicle control was observed for all three compounds, indicating they are not having a 
sedative effect. This indicates that the decrease in drug seeking behavior is not the result 
of sedation. Furthermore, these compounds appear to show at least some decrease in side 
effects in comparison to traditional KOR agonists. 
 
Conclusion 
 Taken together, these results clearly demonstrate that these modified natural 
products hold promise for validating the KOR as a potential abuse therapy target. 
Although a number of other KOR agonists have shown similar results in animal models 
of drug relapse, these and other derivatives of 1 have shown substantially different side 
effect profiles.25,58 For this reason, studies aimed at investigating the effects of 4 on drug 
self-administration and the rewarding effects of drugs of abuse—as well as other 
potential side effects—are currently being performed. Included within these studies is the 
use of non-human primates to simultaneously measure activity at the KOR and sedation. 
Preliminary results indicate that 4 causes similarly levels of KOR activation as 1 but with 
substantially less sedation. Combined with additional studies using 53, and potentially 39, 
these investigations will provide interesting insight into how substitutions to the furan 
ring affect in vivo activity.   
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III. Synthesis of Highly Potent and Selective Herkinorin Analogues  
 
Introduction 
 During early investigations into the structure-activity relationships (SAR) of 
salvinorin A at the opioid receptors, it was discovered that the replacement of the C2 
acetate with a benzoate moiety caused a decrease in affinity and potency at the KOR, 
however increased affinity and potency at the mu opioid receptor (MOR) (Figure 3.1).1 
Much like salvinorin A, the lack of a basic nitrogen in this!derivative, deemed herkinorin 
(1), made it unique amongst other known MOR agonists.  Additional interest was 
garnered when more extensive pharmacological investigations revealed that despite being 
a full MOR agonist, 1 did not recruit β-arrestin-2.2,3 This functional selectivity is 
particularly 
noteworthy since 
genetically modified 
mice lacking β-
arrestin-2 display 
prolonged and enhanced antinociception and diminished respiratory depression, 
constipation, and tolerance following morphine treatment.4-6 Therefore 1 represents an 
interesting step toward a more effective treatment option for pain management that lacks 
the negative side effects associated with opiate analgesics.  
 Unfortunately, there are several problems with 1 that limit its use as an in vivo 
probe. In a competitive binding assay, 1 shows less than 8-fold selectivity for the MOR 
over the KOR (Figure 3.1) and less than 3-fold selectivity in a [35S]GTPγS functional 
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assay.3 This marginal selectivity results in significant KOR activation that could 
potentially make it difficult to attribute any observed effects specifically to MOR 
activation. This has already been observed in a piglet model where it was demonstrated 
that 1 causes vasodilation in a KOR-dependent fashion.7 Additionally, the antinociceptive 
effects of 1 appear to be limited to the peripheral nervous system. In a rat paw formalin 
test of antinociception, 1 blocked the effects of a painful stimulus, however these effects 
appear to be limited to the site of injection.8 Potentially, rapid of metabolism by esterases 
to salvinorin B (3), which is inactive at all three opioid receptors,9 may prevent 1 from 
acting on the central nervous system thus limiting its effects to the periphery. 
 To address these metabolic issues, the ester of 1 was replaced with a more 
metabolically stable amide. Interestingly, herkamide (2) is significantly more selective 
than 1 for the MOR (Figure 3.1).3 Additionally, 2 activates the receptor more potently 
than 1.3 This increase in selectivity and potency suggests that 2 could overcome several 
of the problems that limit the utility of 1. Thus a more thorough investigation into the 
differences of how 1 and 2 interact with the MOR is warranted. Potentially the observed 
pharmacological differences could be explained by either: (1) the ligands binding at 
different sites of the MOR; (2) the ligands binding to different states of the receptor; or 
(3) the ligands inducing different receptor conformations. While it may be difficult to 
separate the latter two possibilities, the differences in receptor binding sites could be 
addressed through a parallel series of compounds based upon 1 and 2. Unfortunately, a 
lengthy and low yielding route to 2 prevents the synthesis of the large number of 
compounds that would be necessary for this study. Therefore, a compound that could be 
readily accessed and possess a similar pharmacological profile to 2 would be desirable. 
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The design of such a compound would first require an understanding of the structural 
differences between 1 and 2.  
 
Design and Synthesis of Analogues 
The most apparent difference between 1 and 2 is the ability for 2 to participate as 
a hydrogen bond donor. However, preliminary molecular modeling also indicated a more 
subtle structural difference: the phenyl ring of 2 appears to lie in plane with the 
neoclerodane core whereas the corresponding angle in 1 is larger.3 To provide additional 
support to the hypothesis that the phenyl ring configuration affects the ligands’ 
selectivities, X-ray quality crystals of 1 and 2 were grown and their structures indicate a 
similar difference in phenyl ring orientations (Figure 3.2). Although this model represents 
only two possible conformations, and not necessarily the most biologically relevant 
confirmations, it does at least suggest the notion that the orientation of the phenyl ring 
influences the ligands’ potencies and selectivities. Furthermore, the modification of the 
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C2 position would be expected to affect the potency and selectivity of the ligand. One 
such modification that has yet to be explored is the introduction of a degree of 
unsaturation between C2 and C3 as in 4 (Scheme 3.1). In addition to being readily 
accessible from 3, the sp2-hybridization of C2 would force the appendant oxygen to be 
coplanar with the diterpene core, which could in turn lead to a ligand with activity that 
mimics 2. 
This degree of unsaturation could be introduced via the oxidation of 3 to the α-
diketone 5 and subsequent tautomerization to a combination of the diosphenols 6 and 7 
(Scheme 3.1). Initial attempts to induce this oxidation under several Swern conditions 
resulted in only trace amounts of product. However, Cu(OAc)2 accomplished the 
transformation in an acceptable 56% yield.10,11 Although remaining 3 (17%) could easily 
removed from the reaction mixture via simple silica gel chromatography, the product was 
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Scheme 3.1. Oxidation and subsequent benzoylation of salvinorin B.a
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isolated as a mixture of 5, 6, and 7, presumably due to rapid equilibrium between the 
three isomers.  Fortunately, acylation with benzoyl chloride led to the selective formation 
of 4 over the other possible regioisomer 8. 
To provide additional information about how this modification to the structure of 
1 would affect activity at the opioid receptors, two parallel series of compounds 
containing substitutions to the phenyl rings were synthesized (Scheme 3.2). One series 
was derived from the acylation of 3 (9a-31a) while the other was derived from 6 (9b-
31b). Due to high variability in the quality of the commercially available acid chlorides, 
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the acylations were performed by activating the corresponding carboxylic acids in situ 
with EDC·HCl and DMAP. To expedite in the synthesis of these compounds, the reaction 
were run in parallel on a MiniBlock XT system and purified by mass-directed reverse 
phase HPLC. Although compounds 9a-31a were successfully prepared in this manner, 
9b-31b proved to be unstable to the purification process and were synthesized using 
standard benchtop chemistry and purified using a combination of silica gel 
chromatography and semi-preparatory reverse phase HPLC. This method proved 
successful for introducing substitutions to the phenyl ring as well its replacement with 
several heterocycles, however the introduction of either a 2- or 3-furan to 6 was 
unsuccessful. Despite several attempts with alternate coupling reagents, only varying 
amounts of 7 were isolated from the reaction mixtures. Potentially 30b and 31b may have 
rapidly formed and decomposed leaving the less reactive 7 as the only stable compound. 
 The carboxylic acids utilized for these series were specifically selected to identify 
potential interactions with the MOR. The substituents were introduced at the meta, ortho, 
and para positions as it was likely that any trends that were observed may be dependent 
upon their location on the ring. The electronic differences in the substitutions spanned 
from the strongly electron withdrawing nitro moiety to the electron donating methoxy 
group.  The nitro and methoxy moieties were also used to probe for hydrogen bonding 
between the ligands and the MOR. Similarly, the chloro- and fluoro-substituted rings 
would be useful in identifying potential halogen bonding interactions. The methyl groups 
were included to determine the effect that steric parameters would have on the ligands’ 
activities. Finally, the heterocycles were expected to modulate the electron density of the 
aromatic ring and provide hydrogen bond acceptors without introducing additional steric 
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bulk. 
In addition to these two series of compounds, the effects of the configuration of 
C2 on activity were further explored by inverting the stereochemistry of this position.The 
synthesis of 2-epi-herkinorin (32) has been reported, however its activity at the opioid 
receptors was not disclosed.12 Additionally, attempts to obtain 32 directly from 3 using 
the reported Mitsunobu procedure were unsuccessful. As an alternative, the C2 
stereocenter of 3 was first inverted via a Mitsunbou reaction using the more active 4-
nitro-benzoic acid (Scheme 3.3). Subsequent ester cleavage with methanolic K2CO3 
produced 2-epi-salvinorin B (33).13 Acylation of 33 with benzoyl chloride produced 32 in 
good yields.1 
 
In Vitro Studies 
 To determine if the additional degree of unsaturation in the core of 1 would affect 
potency and selectivity at the opioid receptors as predicted, 1, 2, 4, and the standard 
MOR agonists morphine and DAMGO were screened for activity at the MOR and the 
KOR using the same inhibition of forskolin-induced cAMP accumulation assay described 
in chapter 2 (Table 3.1). The desaturation of the C2-C3 bond resulted in a significant 
increase in the potency at the MOR. Additionally, all activity at the KOR was eliminated,
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Scheme 3.3. Inversion of the C2 stereocenter and synthesis of 2-epi-herkinorin.a
aReagents and conditions: a) 4-NO2-PhCO2H (3.0 equiv), DIAD (3.0 equiv), PPh3 (3.0 equiv), CH2Cl2, RT, 16 h. b) K2CO3 (1.0 
equiv), MeOH, 0 °C, 15 min. c) BzCl (2.5 equiv), DIPEA (2.5 equiv), DMAP (0.25 equiv), CH2Cl2, RT, 16 h.
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 Table 3.1. MOR and KOR Activities of Diterpene and Standard MOR Agonists. 
Entry Compound MOR EC50 (nM)a KOR EC50 (nM)a Selectivity (MOR/KOR) 
1 1 42 ± 4 170 ± 30 4.0 
2 2 3.0 ± 0.4 >10,000 >3,300 
3 4 1.2 ± 0.2 >10,000 >8,300 
4 32 >10,000 --b N/A 
4 morphine 3.7 ± 0.3 140 ± 20 38 
5 DAMGO 0.6 ± 0.1 >10,000 >10,000 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells expressing either MOR or KOR. bNot 
tested. 
 
leading to a substantial increase in selectivity compared to 1.  Inversion of the natural C2 
stereochemistry resulted in a complete loss of activity at the MOR, suggesting that the 
increased potency of 4 is not the result of decreasing the distance to an interaction on the 
α-face of the A-ring. 
It is impressive that the formal removal of two hydrogen atoms from 1—arguably 
the simplest modification that could be performed—leads to such a drastic change in 
activity and results in a compound that is more potent than morphine and with similar 
potency as the peptidic ligand DAMGO. Taken together, this activity profile is nearly 
identical to that of 2, which is also more potent and selective for the MOR than 1. This 
would suggest that 2 and 4 bind similarly to the opioid receptors. 
    To elucidate additional SAR that might lead to a further increase in potency, 9a-
29a and 9b-29b were screened for activity at the MOR (Table 3.2). Of all the compounds 
screened, all but one (24a) retained full efficacy at the MOR. A comparison of the two 
series of compounds indicated that those containing the oxidized A-ring tended to be 1-2 
orders of magnitude more potent than the corresponding saturated variant. A scatter plot 
comparison of the pEC50 for unsaturated series versus the pEC50 for the saturated series 
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Table 3.2. MOR Potencies of Two Series of Derivatives of Herkinorin Derivatives 
Bearing Parallel Substitutions.  
    
Entry Compound R= EC50 (nM)a EC50 (nM)a 
1 1 C6H5 42 ± 4 1.2 ± 0.2 
2 9 2-NO2-C6H4 2000 ± 1000 1900 ± 600 
3 10 3-NO2-C6H4 3500 ± 200 320 ± 10 
4 11 4-NO2-C6H4 1100 ± 100 31 ± 2 
5 12 2-Cl-C6H4 3400 ± 200 290 ± 20 
6 13 3-Cl-C6H4 2400 ± 100 250 ± 30 
7 14 4-Cl-C6H4 700 ± 100  29 ± 8 
8 15 2-F-C6H4 400 ± 100 4.7 ± 0.4 
9 16 3-F-C6H4 460 ± 80 15 ± 2 
10 17 4-F-C6H4 800 ± 200 5 ± 1 
11 18 2-CH3-C6H4 1600 ± 400 240 ± 40 
12 19 3-CH3-C6H4 1800 ± 300 160 ± 30 
13 20 4-CH3-C6H4 430 ± 10 21.8 ± 0.3 
14 21 2-CH3O-C6H4 3300 ± 300 2000 ± 1000 
15 22 3-CH3O-C6H4 330 ± 20 11 ± 2 
16 23 4-CH3O-C6H4 190 ± 60 8 ± 3 
17 24 2-pyridine >50,000b 410 ± 50 
18 25 3-pyridine 240 ± 20 3.3 ± 0.8 
19 26 4-pyridine 340 ± 10 6 ± 1 
20 27 2-thiophene 330 ± 70 1.4 ± 0.8 
21 28 3-thiophene 23 ± 5 1.3 ± 0.9 
22 29 2-benzofuran 1050 ± 80 31 ± 9 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells expressing either MOR or KOR. bNo 
activity observed at 50 μM. 
 
 
indicates a clear correlation in activity (Figure 3.3). Therefore parallel changes in 
structure produced parallel changes in activity, which strongly supports the hypothesis
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that compounds 9a-29a and 9b-29b bind in an identical position to the MOR and make 
similar interactions with the receptor. 
The introduction of additional substituents to the phenyl ring of 1 and 4 generally 
led to a decrease in potency, however by focusing on the more potent set of compounds 
several useful trends were observed.  The activity of the ligand was highly dependent on 
the position of the substitution on the aromatic ring: the para position was strongly 
preferred over the meta which in turn was favored over the ortho position. A similar 
dependence was observed during the limited SAR studies on 1.3,14 The lone exception to 
this trend was the fluoro-substituted rings (Table 3.2, Entries 15-17) where the ortho and 
para substituted rings were equipotent to each other and slightly more potent than the 
meta substituted ring. The small fluorine substitutions being the exception to the general 
trend suggests the effect on substituent position is primarily steric in nature. The 
electronic properties of the substitutions on the phenyl ring, however, did also have an 
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impact upon ligand potency. As the electron donating ability of the substitutions at the 
meta and para positions increased, a trend of increasing potency was observed. However, 
this trend once again failed to apply to the fluoro-substituted rings, likely due to their 
decreased steric properties. 
 Because of the negative impact of larger substitutions, bioisosteres of the phenyl 
ring were also explored (Table 3.2, Entries 17-21). Previous SAR studies on 1, had 
indicated that replacement of the phenyl ring with a 2-thiophene, 3-thiophene, or 3-
pyridine was reasonably tolerated, resulting in only small (1-4 fold) reductions in 
activity.3,14 Using the inhibition of forskolin-induced cAMP functional assay, these 
differences in activity were slightly amplified. Interestingly, in this assay 27a, bearing a 
2-thiophene, was more potent than 1. In the modified A-ring series (24b-29b), several of 
the heterocycles were also very well tolerated, especially the thiophene-containing 
derivatives, which were equipotent to 4. The 3- and 4-substitued pyridines resulted in a 
mild decrease in potency relative to 4 (2.8-fold and 5-fold, respectively) while both the 2-
pyridine and 2-benzofuran were considerable less active than 4 (340-fold and 26-fold, 
respectively). 
Based upon the SAR that had been developed several additional probe molecules 
were synthesized (Scheme 3.4) and evaluated (Table 3.3) to further probe ligand-receptor 
interactions and potentially develop more potent MOR ligands. The substitutions to the 
phenyl ring suggested that small, electron-rich groups at either the meta or para positions 
were most tolerated. This prompted the introduction of hydroxy moeties at these 
positions resulting in the phenols 34 and 35. Compound 34 was equipotent to 4 at the 
MOR making it the most potent derivative bearing a meta substitution. Consistent with
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the other substituted rings, the para phenol 35 was slightly more potent than 34, and was 
the only ligand more potent than 4. The increased potency of 34 and 35 is particularly 
encouraging considering the phenols could potentially lead to improved water solubility, 
especially if halogens were introduced to the phenyl ring to reduce the pKa of the phenol 
below 7.  
In an attempt to explore the spatial effects within the binding pocket, linkers were 
introduced between the ester carbonyl and the phenyl ring (36-38). The alkyl linkers 
resulted in greater than a 100-fold decrease in activity whereas the alkenyl linker was 
only moderately less active than 4. This suggests while there is some additional room in 
the binding pocket to allow the phenyl ring to extend away from the diterpene core, this 
increased distance reduces activity. Furthermore, additional rotational freedom in the 
alkyl linker likely prevents the phenyl ring from adopting the conformation necessary for
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Table 3.3. MOR Potencies of Additional Analogues Based on Initial SAR.a 
 
Entry Compound R= EC50 (nM)a 
1 1 C6H5 1.2 ± 0.2 
2 34 3-HO-C6H4 1.3 ± 0.3 
3 35 4-HO-C6H4 0.83 ± 0.04 
4 36 C6H5-CH2- 130 ± 50 
5 37 C6H5-CH2-CH2- 500 ± 200 
6 38 C6H5-CH=C(H)- 30 ± 10 
7 39 4-thiazole 8 ± 3 
8 40 5-thiazole >10,000 
9 41 4-oxazole 30 ± 2 
10 42 5-oxazole >10,000  
11 43 5-pyrimidine 6 ± 1 
12 44 4-CH3O-pyridine 2.5 ± 0.3 
a EC50 = Effective concentration to produce 50% of the maximal response as measured by 
inhibition of cAMP accumulation in CHO cells expressing either MOR or KOR. 
 
proper MOR activation. 
The relative success of the bioisosteric replacement of the phenyl rings with 
heterocycles also prompted additional heterocycles to be explored. The five-membered 
thiazoles and oxazoles offered some interesting results. Although the 2-thiophene and 3-
thiophene (27b and 28b) were equipotent, a significant difference was observed between 
the 4-thiazole (39, EC50 = 8 ± 3 nM) and 5-thiazole (40, EC50 > 10,000 nM). A similar 
effect was observed with the 4-oxazole (41, EC50 = 30 ± 2 nM) and 5-oxazole (42, EC50 > 
10,000 nM). The decrease in potency for 39 and 40 can be explained by the decease in 
electron density of thiazoles and oxazoles compared to thiophenes. However the 
OH H
O
O
O
O
CO2Me
Me
Me
R O
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complete loss of activity for 40 and 42 remains somewhat inexplicable. In an attempt to 
improve upon the most potent pyridine-containing analogue (25b) the pyrimidine 43 was 
synthesized. Additionally, electron density was added to 25b by incorporating a methoxy 
moiety at the 4-position (44). The additional nitrogen in 43 resulted in a slight decrease in 
activity, once again supporting the preference for an electron rich ring. 44 was 
approximately equipotent to 25b, which is likely due to competing effects between 
increased steric bulk and increased electron density in the ring. 
 
Conclusions 
 The design of 4 based on key differences identified in the crystal structures of 1 
and 2 has led to a new class of neoclerodane diterpene ligands that show remarkable 
potency and selectivity for the MOR. The additional synthesis and evaluation of two 
parallel series of compounds was useful not only in identifying that the introduction of an 
additional degree of unsaturation results in a 10-100 fold increase in potency but also 
elucidate important SAR trends. By employing these trends, a sub-nanomolar MOR 
agonist 35 was designed, which could assist in the development of safer analgesics. 
Toward this goal, 4 is currently being investigated in animal models of antinociception. 
Preliminary results indicate that 4 produces analgesia and that these effects are no longer 
limited to the site of injection. Although additional SAR studies and more in depth 
investigations into the antinociceptive and side-effect profiles of this scaffold are needed, 
the identification of this modification to the structure of 1 represents a substantial step 
towards developing a novel class of analgesics. 
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IV. Synthesis of the meta,meta-Bridged Diarylheptanoid Myricanol 
 
Introduction 
! Compounds that are able to reduce tau protein pharmacologically would be 
useful in gaining a more complete understanding of tau’s role in neurodegenerative 
diseases and could potentially be developed into a treatment for Alzheimer’s Disease 
(AD). Although such compounds are scarce, natural products have historically been a 
good source of lead compounds, particularly in the field of AD.1,2 During a recent 
campaign aimed at identifying novel anti-tau compounds, an extract from the bayberry 
plant (Myrica cerifera) was shown to decrease the concentration of tau protein in four 
different cell lines while remaining non-toxic.3 These! results were 
further confirmed in ex vivo studies using murine brain slices. 
Bioassay-guided fractionation revealed the major component of the 
extract responsible for the activity was a scalemic mixture (86% ee, 
dextrorotatory in excess) of myricanol (1, Figure 4.1). 
This meta,meta-bridged diarylheptanoid is found in several plants in the myrica 
genus, however 1 is typically isolated as a racemate or with the levorotatory enantiomer 
in excess.4-7 In addition to the point stereocenter at C11, the diortho substitution of the 
aromatic rings and the conformational constraint induced by the macrocycle prevent free-
rotation about the C1-C2 bond, leading to distinct atropisomers. Crystallographic and 
computational studies indicate the axial chirality of the C1-C2 bond is greatly influenced 
by the C11 stereocenter and 11-epi-1 is 2.72 kcal/mol higher in energy than the natural 
enantiomer.6 This potentially explains why diastereomers of 1 have not been isolated 
OH
MeO
MeO
HO HO
Figure 4.1. Structure of 
(+)-aR,11S-myricanol (1).
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from natural sources. These stereochemical issues are an important consideration because 
while the scalemic mixture of 1 isolated from M. cerifera was able to lower the levels of 
tau, a commercially available racemate was nearly inactive.3  
In a recent report occurring concurrently with the synthetic studies detailed below, 
this interesting stereochemical dependence was further explored with a synthetic 
racemate.8 This mixture was active in reducing tau levels, suggesting that the 
commercially available racemate originally used was impure or not truly composed of 1. 
Following separation of the two enantiomers using chiral HPLC, it was shown that (-)-1 
was the active enantiomer. This is rather surprising considering it is the minor enantiomer 
in M. cerifera extracts. More extensive mode of action studies indicated that (-)-1 
decreases both phosphorylated and total tau concentrations and does not affect tau 
synthesis. Using results from stable isotope labeling with amino acids in cell culture 
(SILAC) it was proposed that (-)-1 reduces tau levels via a similar mechanism to 
rapamycin: by activating autophagy. 
 These studies have provided some answers regarding the stereochemistry of 1 and 
its importance in tau clearance, however several questions still remain. Importantly, the 
assignment of the activity to the minor enantiomer is curious and confirmation of the 
absolute stereochemistry through asymmetric synthesis would be beneficial. Additionally, 
although a mode of action was proposed, the specific molecular target of 1 remains 
unknown. The synthesis of analogues will be useful not only in identifying this target but 
also in elucidating additional structural-activity relationships (SAR) for this scaffold. And 
while it is feasible that these analogues could be synthesized using the route outlined by 
Martin et. al.,8 the overall yields (0.63% over 12 steps) and use of chiral HPLC are less 
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than ideal. Thus, a synthetic route to 1 that would provide access to both enantiomers in 
an efficient manner is essential to fully understanding the effects of diarylheptanoids on 
tau. Furthermore, the macrocyclic strain and axial chirality present in 1 offer interesting 
synthetic challenges that have not been fully explored. 
  In the first reported synthesis of 1, Whiting and Wood addressed these synthetic 
challenges through a biomimetic approach (Figure 4.2).9,10 In the biosynthesis of 1, the 
linear diarlyheptanoid 2 is proposed to undergo oxidative cyclization via a biradical 
intermediate.4 However, 
despite extensive 
screening of oxidants, 
this transformation 
could not be reproduced 
in the laboratory.  
Reductive 
macrocyclization was 
accomplished from the 
bis-iodide 3 using 
stoichiometric Ni(0), 
however in only 7% 
yield. By comparison, dimethylalnusone was formed from 4 in 56% yield under nearly 
identical conditions.11 This difference in reactivity is potential the result of increased 
steric bulk at the aryl-aryl bond of dibenzyl myricanol acetate, however the presence of 
three sp3 carbons in the chain of dimethylalnusone may also improve cyclization by 
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Figure 4.2. Approaches to meta,meta-bridged diarylheptanoids.
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reducing ring strain and free rotation within the tether.  Whiting also reported that the 
bromide 5 underwent successful photochemical cyclization in basic ethanol, but once 
again in only approximately 10% yield. These low yields are a clear demonstration of the 
difficulty often encountered in synthesizing cyclophane natural products.12 !
 
First Generation Approach 
The biomimetic nature of the Whiting synthesis required that the 
macrocyclization and biaryl coupling occur simultaneously. However these two events 
also represent the two most challenging steps in the synthesis. If these two 
transformations could be separated, the overall yield of the synthesis may be improved. 
Furthermore, as demonstrated by dimethylalnusone, the presence of multiple sp2-
hybridized carbons in the tethering chain may be beneficial to ring closure. Therefore, the 
initial synthetic target for this improved synthesis was dibenzyl-Δ7,8-myricanone (Figure 
4.3, 6). Based upon recent advances in ring closing metathesis (RCM) methodology and 
its utility in numerous natural product total syntheses,13,14 6 was envisioned to be derived 
from the diene 7. Retrosyntethic cleavage of the aryl-aryl bond and olefin chain of 7 
through a Suzuki-Miyaura reaction and Weinreb ketone synthesis, respectively, revealed 
the simple styrene 8 and boronic ester 9 as the first synthons to be targeted. 
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Figure 4.3. Retrosynthesis of myricanol using ring-closing metathesis.
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The synthesis of styrene 8 was accomplished in four high yielding steps depicted 
in Scheme 4.1. Selective mono-demethylation of the commercially available 2,3,4-
trimethoxybenzaldehyde was smoothly accomplished with AlCl3 in 95% yield.15 The 
preference for demethylation ortho to the aldehyde is attributed to the chelation of the 
Lewis-acidic AlCl3 between the carbonyl oxygen and the adjacent ether, thus activating 
this position for demethylation. Subsequent bromination of the free phenol 10 with Br2 in 
acetic acid produced bromophenol 11, which was protected as a methoxymethyl (MOM-) 
ether to yield 12 in 75% yield over two steps. Conversion of the aldehyde to a terminal 
alkene using a Wittig reaction gave 8 in 83% yield. Through this process, 8 was routinely 
synthesized on multigram-scale.!
The synthesis of Weinreb amide 9 was accomplished in an equally efficient 
manner from the ethyl ester 13 (Scheme 4.2). Bromination and protection of 13 under 
identical conditions used for the conversion of 10 to 12 produced 15 in similar yields 
(78% over 2 steps).16 The ethyl ester 15 was converted directly to Weinreb amide 16 by 
treatment with the anion generated by the in situ deprotonation of N,O-
dimethylhydroxylamine with isopropylmagnesium chloride.17 Alternatively, a two step 
process involving the saponification of the ester and CDMT-promoted coupling18 with the 
N,O-dimethylhydroxylamine could be employed. Although the one step process was 
slightly higher yielding, conversion to the amide via the acid was easily performed on 
OMe
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MeO
MeO
O
H
OH
MeO
MeO
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H c
93%
Br
b
81%
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MeO
MeO
O
H d
83%
Br
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MeO
MeO
Br
a Reagents and conditions: a) AlCl3 (1.0 equiv), PhMe, 75 °C, 5 h; b) Br2 (1.0 equiv), AcOH, RT, 1.5 h; c) MOMCl (2.0 equiv), 
DIPEA (2.0 equiv), CH2Cl2, 0 °C, 3.5 h; d)[Ph3PCH3]+I- (1.9 equiv), n-BuLi (1.8 equiv), THF, 0 °C to RT.
8
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11 12
Scheme 4.1. Synthesis of styrene 8.a
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multigram scale. Attempts to borylate 16 under standard palladium-catalyzed Miyaura 
conditions (B2Pin2, PdCl2(dppf), KOAc)19 resulted in incomplete conversion, likely due to 
the electron-donating MOM-ether moiety deactivating the aryl bromide bond to oxidative 
addition.20 However, conditions developed by Buchwald et. al. employing the bulky 
biaryl phosphine ligand SPhos21 resulted in nearly quantitative yield of the desired 
product 9. Excess pinacol borane were detected in the NMR spectra of 9, however 
extensive silica gel chromatography did not improve the purity. Fortunately, the impurity 
did not affect the subsequent reactions and was consumed by treatment with excess 
Grignard reagent following the Suzuki-Miyaura reaction. 
 The success of the Buchwald ligands in the palladium-catalyzed borylation of 16 
was encouraging for the Suzuki-Miyaura reaction that would be used to join 8 and 9. 
Despite the steric encumbrance of ortho substituents on both rings and numerous 
electron-donating groups deactivating the aryl bromide bond to oxidative addition, 
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a Reagents and conditions: a) Br2 (1.0 equiv), AcOH, RT, 2 h; b) MOMCl (2.0 equiv), DIPEA (2.0 equiv), CH2Cl2, 0 °C, 3.5 h; c) 
(MeO)(Me)NH2Cl (1.55 equiv), iPrMgCl (3.0 equiv), THF, -10 °C, 30 min; d) NaOH(aq.), MeOH, RT, 3 h; e) CDMT (1.2 equiv), NMM 
(3.0 equiv), (MeO)(Me)NH2Cl (1.1 equiv), THF, RT, 16 h; f) HBPin (1.5 equiv), PdCl2(MeCN)2 (0.02 equiv), SPhos (0.08 equiv), 
Et3N (3.0 equiv), 1,4-diox., 110 °C, 4.5 h.
Scheme 4.2. Synthesis of boronate ester 9.a
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Scheme 4.3. Synthesis of diene 7.a
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employing a catalyst system composed of Pd(OAc)2 and SPhos resulted in the successful 
coupling of the two fragments in an impressive 97% yield (Scheme 4.3).22 The resulting 
biaryl (17) was treated with the Grignard reagent derived from 4-bromobutene to furnish 
the diene 7 that would serve as the substrate for subsequent RCM investigations.  
With 7 in hand, attempts to induce RCM using several ruthenium-based 
metathesis catalysts ensued (Table 4.1). Initially, exposure of 7 to Grubbs first-generation 
catalyst (G-I) in refluxing CH2Cl2 resulted in no observed reaction. However, increasing 
the temperature to 110 °C in toluene resulted in significant decomposition, likely due to 
the thermal instability of G-I. Employing the more active and thermostable Grubbs 
  
Table 4.1. Attempted Ring-Closing Metathesis Using Diene 7. 
 
Entry Catalyst Solvent Temp (°C) Yield of 6 (%)a Yield of 18 (%)a 
1 
G-I 
CH2Cl2 40 0 0 
2 G-I PhMe 110 0b 0 b 
3 G-II CH2Cl2 40 0 26 
4 
G-II 
PhMe 110 0 28 
5 
HG-II 
PhMe 110 0 29 
a Isolated yields. b Decomposition of reaction mixture. 
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second-generation catalyst (G-II) did result in 
an isolatable product. However, despite highly 
dilute conditions, no RCM was observed and 
the sole product was the result of dimerization 
(18). To confirm the assigned structure, 18 was 
reduced with Pd/C under an atmosphere of H2 and the structure of the resulting product 
(Figure 4.4, 19) was determined using COSY NMR. Similar results were seen with G-II 
and Hoveyda-Grubbs second-generation catalyst (HG-II) in refluxing toluene. 
The isolation of 19 as the lone product in the reaction mixture indicated the 
catalyst was able to bind to the olefin directly attached to! the ketone, however, was 
incapable of completing the RCM process with the styrene. This non-reactive pattern!
could potentially be the result of: (1) hindered rotation about the aryl-aryl bond 
preventing the olefins from being in close proximity, or (2) interactions between the 
MOM-ether protecting group and the catalyst interfering with proper catalytic action. To 
investigate these two possibilities, the dienes lacking either or both MOM-ethers were 
synthesized. Additionally, replacement of the MOM-protecting group with a benzyl-
protecting group resulted in a substrate devoid of catalyst chelating ability. The model 
dienes 20-24 were prepared from commercially available aldehydes and propionic acids 
in a similar fashion used to furnish 7 (Scheme 4.4).  
 With these dienes, the effects from hindered rotation about the aryl-aryl bond 
could be separated from the effects of the substituent in close proximity to the styrene. 
With both of the potentially problematic substitutents removed, as in 24, a macrocycle 
was formed. However inspection of the mass spectrum of the product indicated that a 
MOMO
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MOMO
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Figure 4.4. COSY correlations used to assign the 
structure of 19. For clarity, only correlations on half the 
molecule are shown.
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dimer had formed rather than the intended monomer (Table 4.2). Attempts to perform the 
reaction under higher dilution resulted in no reaction after 48 hours. Although 
disappointing, this result does support that at least one of the MOM-ethers was 
preventing RCM from occurring. When a MOM-ether was present at R3 (21) a similar 
dimer product was obtained. However, with a MOM-ether present at R1 (22) no cyclic 
products were isolated, suggesting an interaction between the MOM-ether and the 
catalyst was preventing the reaction from occurring. This was confirmed with substrate 
23 bearing only the MOM-ether at the R1 that produced no dimer product. Finally, the 
benzyl-protected diene 24 was also unable to give the desired monomer and produced the 
dimer in a low 22% yield, indicating that any substituent at R1 may have an influence on 
the reaction. However, whether this effect is electronic or steric in nature is unclear. 
The results from these model studies indicate that an RCM-based approach to 1 is 
unlikely to be successful. Synthetic studies on closely related ether-bridge 
diarylheptenoids have concluded similar difficulties.23 Due to the reversible nature of
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27: R1=OMOM, R2=H
28: R1=H, R2=OMe (77%)
29: R1=OBn, R2=OMe (77%)
30: R1=OMOM, R2=H (89%)
31: R3=H
32: R3=OBn
33: R3=H (99%)
34: R3=OBn (99%)
35: R3=H (68%)
36: R3=OBn (100%)
37: R1=R3=H, R2=OMe (85%)
38: R1=H, R2=OMe, R3=OMOM (81%)
39: R1=OMOM, R2=OMe, R3=H (57%)
40: R1=OMOM, R2=R3=H (54%)
41: R1=R3=OBn, R2=OMe (91%)
20: R1=R3=H, R2=OMe (76%)
21: R1=H, R2=OMe, R3=OMOM (76%)
22: R1=OMOM, R2=OMe, R3=H (83%)
23: R1=OMOM, R2=R3=H (66%)
24: R1=R3=OBn, R2=OMe (83%)
a Reagents and conditions: a )[Ph3PCH3]+I- (1.9 equiv), n-BuLi (1.8 equiv), THF, 0 ° C to RT, 3 h; b) CDMT (1.2 equiv), NMM (3.0 equiv), 
(MeO)(Me)NH2Cl (1.1 equiv), THF, RT, 16 h; c) HBPin (1.5 equiv), PdCl2(MeCN)2 (0.02 equiv), SPhos (0.08 equiv), Et3N (3.0 equiv), 1,4-diox., 
110 ° C, 4.5 h; d) Pd(OAc) 2 (0.01 equiv), SPhos (0.02 equiv). K 3PO4 (2.0 equiv), PhMe/H 2O (10:1), 100 ° C, 16 h;
e) Br(CH2)2CH=CH2 (3.0 equiv), Mg (3.5 equiv), I2 (cat.), THF, 0 °C.
Scheme 4.4. Synthesis of dienes for RCM model studies.a
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Table 4.2. RCM Experiments on Model Diene Systems. 
 
Entry Substrate R1= R2= R3= Monomer Yield 
(%)a 
Dimer Yield 
(%)a 
1 20 H OMe H 0 31 
2 21 H OMe OMOM 0 34 
3 22 OMOM OMe H 0 0 
4 23 OMOM H H 0 0 
5 24 OBn OMe OBn 0 21 
a Isolated yields. 
olefin-metathesis,24 if any monomer were to form during the course of the reaction it 
could potentially be converted into the dimer products. The observed product ratios 
would thus reflect their relative thermodynamic stabilities. The increased ring size of the 
dimers reduces ring stain within the macrocycles, which ultimately increase their 
stabilities.25 This suggests that a more irreversible reaction is required for the 
macrocyclization event. 
  
Second Generation Approach 
To address the deficiencies of the RCM approach, a revised synthesis to access 1 
was initiated. In this second generation synthesis rather than targeting 1 itself, an 
intermediate utilized in the Whiting synthesis would be the initial focus.10 Although this 
approach would be expected to suffer the same low yields for ring closure observed by 
Whiting, if the synthesis leading up to this intermediate were significantly streamlined, 
then sufficient quantities of the natural product could still be accessed. With this in mind,
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it was determined that bromide 5, used as a precursor by Whiting, could be potentially 
accessed through a tandem olefin metathesis/isomerization process (Figure 4.5). The 
required olefins 42 and 43 could be assembled through elaboration of intermediates from 
the first generation approach. 
 The conversion of benzaldehyde 26 to 42 is shown in!Scheme 4.5. Addition of the 
allyl group under aqueous Barbier conditions26 revealed 44 in excellent yield despite the 
potential for protodehalogenation.27 Lewis acid-catalyzed reduction of the benzylic 
alcohol with triethylsilane yielded 42 in 87%.  
The synthesis of allyl alcohol 43 began with protection of the phenol 13 with 
benzyl bromide (Scheme 4.5). The resulting ester 45 was converted to the corresponding 
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Weinreb amide 51 by again employing (MeO)(Me)NMgCl generated in situ with 
isopropyl magnesium chloride and N,O-dimethylhydroxylamine. Reduction with LiAH4 
at -78 °C gave 47 in 76% yield. Alternatively this two-step process could be replaced 
with a high-yielding selective reduction directly from 45 using DIBAl-H, however this 
reaction was found to be highly dependent upon the quality of commercially available 
DIBAl-H solution. Exposure of 47 to vinyl magnesium bromide furnished the allyl 
alcohol 43. 
 With 42 and 43 available in only 5 and 4 steps, respectively, from commercially 
available material, all that remained for a formal synthesis of 1 was the proposed tandem 
olefin metathesis/isomerization process. Cross-metathesis of 42 and 43 with the G-II 
catalyst in refluxing CH2Cl2 produced intermediate 48, which underwent rapid 
isomerization to enol 49 that in turn tautomerized to the ketone 5 (Scheme 4.6). In 
addition to 5, products from the homocoupling of 42 and isomerization of 43 were also 
isolated from the reaction mixture resulting in the disappointingly low 23% yield for the 
reaction. However, the synthesis of 5 does represent a formal synthesis of 1. This 
streamlined approach to 46 was accomplished in only 9 total steps (6 longest linear 
sequence) in 10% overall yield, whereas previously, Whiting et. al. arrived at this 
intermediate in 2% yield over 14 total steps (10 longest linear sequence). Unfortunately, 
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Scheme 4.6. Tandem olefin metathesis/isomerization process to access 46.a
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attempts to induce radical cyclization via photochemical fragmentation of the aryl 
bromide bond using the conditions reported by Whiting yielded a very complex reaction 
mixture (Scheme 4.7). Isolation of the peak with a similar retention time to an authentic 
sample of dibenzyl myricanone (50), using preparative HPLC, resulted in a trace amount 
of compound that clearly did not correspond to 50 by 1H NMR. 
 
Third Generation Approach 
In a final attempt to complete the synthesis of 1, a union of the first two 
generations strategies was conceived. Based upon the success of the palladium-catalyzed 
biaryl coupling in the first generation synthesis, it was envisioned that an intramolecular 
Suzuki-Miyaura reaction could be utilized to induce macrocyclization (Figure 4.6). A 
similar approach was recently utilized in the latest synthesis of myricanol that was 
reported while these studies were underway.8 However, in this reported synthesis an 
achiral ketone was used as the Suzuki-Miyaura substrate forcing the use of chiral HPLC 
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to access enantiopure 1. Potentially, if a single enantiomer of 51 were employed, the 
existing C11 stereochemistry might influence the axial chirality of the forming aryl-aryl 
bond. To test this possibility, the requisite linear precursors would be derived from an 
olefin cross-metathesis similar to that used in during the second generation approach, 
employing both enantiomer of the protected allyl alcohol 52 and the pinacol borane 53.!
The synthesis of the allyl alcohols 56 began with the careful reduction of ethyl 
ester 54 to the aldehyde 55 in 87% yield (Scheme 4.8). Subsequent treatment with vinyl 
magnesium bromide occurred in 85% yield to furnish the racemic allyl alcohol 56. 
Because terminal allyl alcohols are known substrates for lipases,28 56 represented an 
excellent opportunity to separate the two enantiomers through the use of biocatalysis. 
Thus an amano lipase from Pseudomonas fluorescens was used to selectively acetylate 
the S-enantiomer of 56 to provide a ~1:1 mixture (R)-56 and 57, which was easily 
deacetylated with methanolic K2CO3 to produce (S)-56. Both allyl alcohols were >90% ee 
as measured by chiral HPLC. The stereochemistry of (R)-56 was determined using 
Mosher ester analysis29 and was consistent with results observed with 5-phenylpent-1-en-
3-ol.30 
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a Reagents and conditions: a) (iBu)2AlH (1.0 equiv), PhMe, -78 °C; b) CH2=CHMgBr (1.5 equiv), THF, 0 °C c) Amano lipase 
(50 w/w%), vinyl acetate (1.5 equiv), 4 Å mol. sieves, iPr2O, RT, 24 h, 57 (44%), 56 (45%); d) K2CO3 (3.0 equiv), MeOH, 0 °C.
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Scheme 4.8. Synthesis and enzymatic resolution of allyl alcohol 56.a
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By providing a separable mixture of substrates containing opposite 
stereochemical configuration at C11, this enzymatic resolution could potentially allow for 
the synthesis of both enantiomers of 1 without the need for chiral HPLC separation. If 
this approach were successful, (R)-56 could be elaborated into (+)-1, whereas 57 would 
provide its enantiomer. However, only one enantiomer of 1 is able to significantly reduce 
tau protein levels.8 Therefore, to provide a synthetic route to a specific enantiomer of 1, a 
process to interconvert (R)-56 and 57 was developed (Scheme 4.9). Employing AcOH, 
PPh3, and DIAD, the alcohol of (R)-56 
was converted to the acetate with 
inversion of stereochemistry to provide 
57 in 61% yield. The C11 stereocenter 
in (S)-56 was similarly inverted and the 
intermediate ester was cleaved to reveal 
(R)-56. The use of the more acidic 4-
nitrobenzoic acid in the Mitsunobu 
reaction improved the efficiency of the inversion process to 79% over the two steps. Both 
(R)-56 and 57 produced through these means were spectroscopically identical to the 
products of the enzymatic resolution and possessed similar levels of enantiopurity as 
measured by their optical rotations. Finally, the allyl alcohols were protected as silyl 
ethers to prevent unwanted isomerization during the subsequent cross-metathesis reaction. 
 Prior to this cross-metathesis, a procedure for the borylation of 47 needed to be 
developed.  The success of the palladium-catalyzed borylation of 16 (Page 90, Scheme 
4.2) employing the Buchwald catalyst system suggested a similar transformation could be 
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a, b
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Br
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d
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Scheme 4.9. Interconversion and protection of allyl alcohols.a
a Reagents and conditions: a) AcOH (1.2 equiv), PPh3 (1.2 equiv), 
DIAD (1.2 equiv), THF, RT, 16 h; b) K2CO3 (3.0 equiv), MeOH, 0 °C; 
c) 4-NO2-C6H4CO2H (1.2 equiv), PPh3 (1.2 equiv), DIAD(1.2 equiv), 
THF, RT, 16 h; d)TBSOTf (1.0 equiv), Et3N (1.6 equiv), CH2Cl2, -78 
°C, 1 h.
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performed on 42.21 However these conditions resulted in a complex mixture due to 
competing hydroboration of the terminal olefin. Significantly cleaner reaction mixtures 
were observed when bis(pinacolato)diboron (B2Pin2) was used as the boron source. 
However, neither Pd2dba3/XPhos31 nor PdCl2(dppf)19 catalyst systems were able to fully 
convert the starting material. Fortunately, a catalyst system composed of Pd(dba)2 and 
PCy3,  was found to convert 42 to 53 in an acceptable 66% yield (Scheme 4.10). 
 With gram-scale access to (R)-52, (S)-52, and 53, their union through olefin-
metathesis was investigated 
(Scheme 4.10). The coupling 
of 52 and 53 proceeded 
smoothly with G-II, to 
provide the two enantiomers 
of the linear diarylheptenoid 
51 in good yields (79-88%). 
Cross metathesis of 53 and 
57 was also briefly explored, 
however it was found to be 
less efficient and produced 
58 in only 50% yield. The difference in reactivity between 52 and 57 suggests that 52 is a 
type II olefin, whereas 57 is type I.32 
Having synthesized both enantiomers of the bromoborane 51, investigations into 
their macrocyclization through Suzuki-Miyaura reactions were possible. Based upon 
results from similarly strained cyclic peptides and the recent synthesis of myricanone,8,33-
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35 (R)-51 was exposed to PdCl2(dppf)·CH2Cl2 and aqueous K2CO3 in toluene at 90 °C over 
24 hours. With these initial conditions, (R)-51 cyclized to (R)-59 in 18% yield, providing 
the first evidence that an intramolecular Suzuki-Miyaura reaction would lead to a 
successful synthesis of 1.  
To explore whether this initial result could be improved, optimization studies 
were performed by modifying the solvent, concentration, base, and reaction time (Table 
4.3). The yields of (R)-59 were slightly improved to 20% by switching from toluene to 
1,4-dioxane, however trace amounts of products from the protodehalogenation of (R)-51 
were still observed by HRMS of the crude reaction mixtures. Removal of H2O as the 
most likely source of protons from the reaction mixture, unfortunately, prevented 
 
Table 4.3. Intramolecular Suzuki-Miyaura Optimization Studies. 
 
Entry Solvent Conc (mM) Base Time (h) Yield (%)a 
1 Tol./H2O (30:1) 20 K2CO3 24 18 
2 Diox./H2O (30:1) 20 K2CO3 24 20 
3 Diox. 20 K2CO3 24 5 (32)b 
4 Diox./H2O (30:1) 20 K3PO4 24 26 
5 Diox./H2O (30:1) 2 K3PO4 24 6 
6 Diox./H2O (30:1) 200 K3PO4 24 12 
7 Diox./H2O (30:1) 20 K3PO4 12 23 
8 Diox./H2O (30:1) 20 K3PO4 48 15 
9 Diox./H2O (30:1) 20 K3PO4 24 25c 
a Isolated yields. b BRSM. c (S)-51 used as substrate. 
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hydrolysis of the pinacol ester resulting in recovery of unreacted starting material and 
significantly reduced yields. Switching to, more basic K3PO4, did further increase the 
yields to 26%, although neither increasing nor decreasing the reaction concentration or 
time had a positive effect (Table 4.3 Entries 5-8). These optimized reaction conditions 
produced similar yields when applied to (S)-52 (Entry 9). In all, the reactions carried out 
during this optimization study, 59 was the only product isolated, with no evidence of 
intermolecular reactions occurring. Furthermore, the 1H and 13C NMR spectra indicated 
the products were a mixture of isomers, however whether these were atropisomers or 
olefin isomers could not be determined at this point. 
All that remained for the synthesis of (+)-1 
and (-)-1, was the appropriate manipulation of (R)-59 
and (S)-59, respectively (Scheme 4.11). Simultaneous 
reduction of the olefin and dihydrogenolysis of the 
benzyl protecting groups with Pd/C revealed the silyl-
protected myricanol 60 in good overall yield (71-
78%). The removal of the tert-butyldimethyl silyl 
(TBS) protecting group, unfortunately, proved more 
troublesome than anticipated. Attempts to desilate 
(S)-60 with TBAF or CsF as fluoride sources 
produced no reactions even at elevated temperatures 
and extended reaction times. The use of Et3N·3HF did 
lead to some isolated product (40%) however after 1 
week, the reaction had yet to reach full conversion. 
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Scheme 4.11. Completetion of the total 
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Fortunately removal of the silyl-protecting group from (S)-60 and (R)-60 with aqueous 
HCl in ethanol revealed (+)-1 and (-)-1 with good levels of enantiopurity (e.e. = 92% for 
(+)-1; e.e. = 94% for (-)-1) as determined by chiral HPLC. These levels are significantly 
higher than that of 1 isolated from M. cerifera (Figure 4.7). The two compounds were 
spectroscopically identical (1H NMR, 13C NMR and HRMS) to each other and to the 
natural sample. Furthermore, they were isolated as a single atropisomer suggesting that 
the C11 stereocenter was able to completely control the axial chirality of the forming 
aryl-aryl bond during the Suzuki-Miyaura cyclization. Alternatively, the barrier of 
rotation about the aryl-aryl bond may be lower than expected and the isolated 
atropisomers are the thermodynamically more stable products.  
!
Figure 4.7.  Chiral HPLC chromatograms demonstrating increased 
enantiopurity of synthetic 1 compared to natural 1. 
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Conclusions 
 The application of strategies developed from two unsuccessful approaches has 
now resulted in the first asymmetric synthesis of either enantiomer of 1. In addition to 
eliminating the need for chiral HPLC to separate the enantiomers, this approach 
represents a significant improvement over the other reported syntheses of 1 (Table 4.4). 
Although the step count was similar to that of Whiting’s original synthesis and slightly 
greater than the more recent synthesis by Martin, the overall yield was markedly 
improved. This can largely be attributed the fact that all but two steps of this synthesis 
produced products in greater than 75% yield. 
 This successful synthesis of both enantiomers of 1 will prove useful in
determining its biological target by providing substantial material for more extensive 
studies. Furthermore, this synthetic route should prove amenable to the synthesis of other 
naturally occurring meta,meta-bridged diarylheptanoids.36-42 Many of these compounds 
have shown a diverse range of biological activities, some of which may be related to the 
activity of 1. The synthesis of these and non-naturally occurring analogues will be useful 
in elucidating SAR, which in turn could provide useful probes for studying the role of tau 
protein in neurodegenerative tauopathies such as AD. 
Table 4.4. Comparison of Total Myricanol Syntheses. 
 Current Martin8 Whiting10 
 (+)-1 (-)-1 (±)-1 (±)-1 
Total step counta 16 17 12 18 
Longest linear sequencea 10 11 9 14 
Overall yielda 2.7% 2.1% 0.63% ≤0.12%b 
Source of enantioenrichment enzymatic 
resolution 
enzymatic 
resolution 
chiral 
HPLC 
none 
aYields and step counts from commercially available materials. bYields not reported for 
final deprotection steps. 
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V. Conclusions 
 
 Through the use of semi-synthesis to modify the chemical structure of salvinorin 
A, the preceding studies have shed additional light upon the structure-activity 
relationships of this fascinating natural product. Additionally, the efforts toward the total 
synthesis of myricanol have culminated in the first enantioselective route to both 
enantiomers of the molecule. As is the case in nearly all scientific enquiries, these 
successes are likely to promote further investigations.  
 By developing new chemical processes to selectively modify the furan ring of 
salvinorin A, over 50 novel compounds were synthesized and evaluated at the KOR. 
These structure-activity relationship studies established that the furan ring binds to a 
sterically restricted portion of the binding pocket and that an electron rich ring is 
preferred for optimal receptor activation. Additionally, several compounds were shown to 
that attenuate drug seeking behavior in an animal model of relapse without inducing 
sedation (Figure 1). Preliminary studies with 16-bromosalvinorin A also suggested that 
these compounds are not depressive. Furthermore, studies with rhesus macaques indicate 
that these results may translate to non-human primates. Because these ligands appear 
activate the KOR in a way that does not produce the sedation and depression induced by 
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traditional KOR agonists, they will be extremely useful in identifying the signal 
transduction pathways that produce these side effects.  
The investigations aimed at improving the selectivity and potency of herkinorin 
were also quite successful. Guided by X-ray crystal structures, the introduction of an 
additional degree of unsaturation to the A-ring of herkinorin was shown to cause a drastic 
increase in potency at the MOR and eliminate all activity at the KOR. A more detailed 
exploration of this effect using two parallel series of analogues identified that this 
increase in potency was not the result of a different binding site. This SAR was also used 
to design the most potent neoclerodane-based MOR agonist to date, containing a phenol 
moiety on the phenyl ring. Further analogue development using this SAR will be 
particularly important in designing ligands with improved PK properties. Of particular 
interest will be the introduction of a halogen to the phenol ring, which could potentially 
reduce its pKa such that it will be ionized at physiological pH. This could potentially 
improve the water solubility of the compound, but may also negatively effect brain 
penetration.(1) Additionally, further investigations into the in vivo characteristics of these 
ligands will be crucial since preliminary results indicate that unlike herkinorin, the 
modified derivative is not peripherally restricted. 
 Finally, despite several failed approaches to synthesize the cyclophane natural 
product, an enantioselective route to myricanol has also been accomplished. In addition 
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to being the highest yielding synthesis to date, the difficult macrocyclization event was 
accomplished with complete substrate control of axial chirality leading to only a single 
atropisomer. This route will provide the material necessary for more extensive 
mechanism of action studies and should prove amenable to the synthesis of other natural 
and unnatural meta,meta-bridged diarylheptanoid products. Synthetic access to these 
compounds will be useful in determining how myricanol induces tau degradation, which 
in turn could assist in identifying a much-needed treatment option for Alzheimer’s 
Disease.   
 
References: 
(1) Rankovic, Z. CNS drug design: Balancing physicochemical properties for optimal 
brain exposure. J. Med. Chem. 2015, 58, 2584.  
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VI. Experimentals 
 
General Experimentals. All reactions were performed in glassware dried in an oven at 
120 °C overnight and cooled under a stream of argon. Solvents were obtained from a dry 
solvent system that dried solvent by passage through two columns of alumna and 
degassed by extensive argon sparging. Flash column chromatography (FCC) was 
performed on silica gel (4-60 μm) from Sorbent Technologies. Reactions and 
chromatography was monitored by thin-layer chromatography (TLC) on 0.25 mm 
Analtech GHLF silica gel plates and visualized by UV light (254 nm) and 
phosphomolybdic or vanillin TLC stain. 1H and 13C NMR spectra were acquired on a 500 
MHz Bruker AVIII spectrometer equipped with a cryogenically-cooled carbon observe 
probe or a 400 MHz Bruker AVIIIHD spectrometer. 19F NMR spectra were acquired on a 
Bruker 400 AVANCE spectrometer using either fluorobenzene or trifluorotoluene as an 
internal standard.!High resolution mass spectroscopy (HRMS) was performed using a 
LCT Premier (Micromass Ltd., Manchester UK) time of flight mass spectrometer with an 
electrospray ion source. Melting points are uncorrected and were measured on a Thomas 
Hoover Capillary Melting Point Apparatus. HPLC was carried out on a Agilent 1100 
series HPLC system with diode array detection at 209 nm on an Agilent Eclipse XDB-
C18 column (250 x 10 mm, 5 mm) eluting with 60% MeCN/40% H2O at 5.0 mL/min. 
Compounds tested in biological assays were identified as ≥95% pure by HPLC before 
testing. Commercially available reagents were used directly without further purification. 
Salvinorin A (1) was isolated from S. divinorum according to published procedures.1 
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Experimentals for Chapter II 
Gas chromatography was performed using a Shimadzu QP2010 SE GC fitted with a 
SHRXI-5MS column (30m x 0.25 mm) with injection temperature set to 260°C and 
ramping to 320°C over 2 min. Compound 7 was synthesized as reported by Simpson et. 
al.1 The synthesis of compounds 4-5, 15, 18-64 has been reported.2,3 Their experimental 
details are reproduced here for the convenience of the reader.  
General oxime oxidation/cycloaddition reaction. A solution of the oxime 8 dissolved 
in MeCN/H2O (5:1, 50 mM) was treated with a terminal alkyne (5.0 equv). PIFA (1.5 
equiv) was added in three portions over 4 hours then stirred overnight. The reaction was 
concentrated in vacuo and the residue was purified by FCC eluting with 35% 
EtOAc/Hex. 
General procedure for Table 1. An oven-dried conical vial was cooled under a stream 
of argon and charged with a stir bar, 4 (15.0 mg, 29.3 mmol), Pd2dba3 (1.1 mg, 1.2 
mmol), SPhos (1.9 mg, 4.7 mmol), PhB(OH)2 (7.2 mg, 58.7 mmol), and K3PO4 (18.7 mg, 
88.0 mmol). The vial was sealed with a Biotage Reseal cap and flushed with argon for 5 
min. Toluene (0.4 mL) was added through the septum and allowed to spin for 5 min. after 
which the reaction was heated to the indicated temperature for 16 hrs. The reaction was 
cooled to room temperature and 3.0 mg of 1,10-phenanthroline was added to the reaction, 
as an internal standard. The mixture was diluted with 1.5 ml of CH2Cl2 and a portion 
injected onto a GC-MS. Solvent was removed from the remainder of the solution and 
diluted to 1 mg/mL with MeCN. The MeCN solution was filtered through a microfilter 
and a 100 mL portion injected onto a HPLC. 
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General Procedure for Suzuki-Miyaura Reaction.  An oven-dried conical vial was 
cooled under a stream of argon and charged with 4 (60 mg, 0.117 mmol), Pd2dba3 (4.3 
mg, 0.0047 mmol), SPhos (7.7 mg, 0.019 mmol), boronic acid (0.234 mmol), and K3PO4 
(74.7 mg, 0.357 mmol). The vial was sealed with a Biotage Reseal cap and flushed with 
argon for 5 min before adding toluene (1.6 mL) through the septum. After stirring at 
room temperature for 5 min., the reaction was heated to 60°C for 16 hrs. The reaction 
was cooled to room temperature, diluted with EtOAc (2.5 mL) and filtered through a thin 
pad of silica gel. Solvent was removed in vacuo and the residue purified by FCC eluting 
with 35-45% EtOAc/Pent. 
General Procedure for Sonogashira Reaction. An oven-dried conical vial was cooled 
under a stream of argon and charged with 4 (60 mg, 0.117 mmol), PdCl2(PPH3)2 (4.1 mg, 
0.0059 mmol), and CuI (2.2 mg, 0.012 mmol). The vial was sealed with a Biotage Reseal 
cap and flushed with argon for 5 min before adding THF (1 mL) and NEt3 (1 mL) through 
the septum. After stirring at room temperature for 5 min., the terminal alkyne (0.234 
mmol) was added and the reaction was heated to 80°C for 16 hrs. The reaction was 
cooled to room temperature and filtered through Celite, rinsing with EtOAc (70 mL). The 
filtrate was rinsed with 1 N HCl (~20 mL) and brine (~20 mL). The organic layer was 
dried over Na2SO4, decanted and solvent removed in vacuo. The residue was purified by 
FCC eluting with 30-40% EtOAc/Pent. 
General Procedure for reduction. A solution of the appropriate nitrophenyl/olefin in 
MeOH/THF (5 mL, 3:2) was treated with Pd/C (10% w/w, 0.10 equiv). The suspension 
was placed under an atmosphere of H2 by applying a vacuum and backfilling with H2 
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(3×). After 5 h, the reaction was filtered through a thin pad of Celite and the solvent 
removed in vacuo. The resulting residue was purified by FCC eluting with EtOAc/Pent. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-
((hydroxyimino)methyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. A solution of 7 (751 mg, 1.90 mmol) in MeOH (30 
mL) was treated with NH2OH·HCl (529 mg, 7.62 mmol) and pyridine (1.5 mL, 19.0 
mmol). The reaction was heated to reflux for 5 hours then cooled to room temperature. 
The reaction was concentrated in vacuo and the residue dissolved in EtOAc (25 mL) and 
H2O (25 mL). The layers were separated and the aqueous layer extracted with additional 
EtOAc (2 x 25 mL). The combined organic layers were washed with HCl (2 M, 25 mL), 
dried over Na2SO4, and concentrated in vacuo. The residue was purified by FCC eluting 
with 50% EtoAc/Hex to yield 8 as a 7:2 mixture of cis/trans isomers. 1H NMR (500 
MHz, CDCl3) δ 7.58 (s, 1H), 7.42 (d, J = 5.71 Hz, 1H), 5.13 (m, 2H), 3.73 (s, 3H), 2.76 
(m, 1H), 2.39 (dd, J = 5.71, 13.60 Hz, 1H), 2.30 (m, 2H), 2.18 (s, 3H), 2.14 (m, 2H), 2.06 
(dd, J = 3.15, 11.40 Hz, 1H), 1.78 (m, 1H), 1.60 (m, 3H), 1.40 (s, 3H), 1.10 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 201.90, 171.55, 170.60, 170.10, 148.94, 75.03, 74.08, 64.05, 
53.51, 52.02, 51.09, 42.06, 39.63, 38.04, 35.23, 30.72, 20.61, 18.07, 16.33, 15.55. HRMS 
calculated for C20H27NO8 [M+Na]+: 432.1634 (calc); 432.1650 (found). 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-dimethyl-
4,10-dioxo-2-(5-phenylisoxazol-3-yl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate. Prepared from 8 (110 mg, 0.269 mmol) according to general 
oxime/oxidation/cycloaddition reaction to yield 9 as a white solid (63 mg, 46%). 1H 
NMR (500 MHz, CDCl3) δ 7.76 (m, 2H), 7.47 (m, 3H), 6.60 (s, 1H), 5.70 (dd, J = 6.19, 
10.01 Hz, 1H), 5.18 (dd, J = 8.58, 11.66 Hz, 1H), 3.73 (s, 3H), 2.74 (ddd, J = 5.61, 12.71, 
19.99 Hz, 2H), 2.31 (m, 3H), 2.17 (s, 3H), 2.16 (m, 2H), 1.97 (dd, J = 10.16, 13.70 Hz, 
1H), 1.79 (dt, J = 3.04, 13.27 Hz, 1H), 1.66 (m, 2H), 1.49 (s, 3H), 1.12 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 201.79, 171.57, 170.91, 170.77, 169.82, 163.86, 130.53, 129.07, 
126.98, 125.88, 97.94, 74.89, 71.36, 64.23, 53.48, 51.99, 50.85, 41.99, 40.72, 37.95, 
35.44, 30.76, 20.59, 18.13, 16.32, 16.05. HRMS calculated for C28H31NO8: [M+Na]+: 
532.1939 (found); 532.1947 (calc). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(5-(2-
methoxyphenyl)isoxazol-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared from 8 (50 mg, 0.122 mmol) according 
to general oxime oxidation/cycloaddition reaction to yield 10 as a white solid (13 mg, 
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20%). 1H NMR (500 MHz, CDCl3) δ 7.96 (dd, J = 1.68, 7.79 Hz, 1H), 7.42 (ddd, J = 
1.72, 7.44, 8.44 Hz, 1H), 7.07 (td, J = 0.96, 7.71 Hz, 1H), 7.02 (d, J = 8.06 Hz, 1H), 6.86 
(s, 1H), 5.71 (dd, J = 6.20, 9.92 Hz, 1H), 5.18 (dd, J = 8.50, 11.65 Hz, 1H), 3.97 (s, 3H), 
3.72 (s, 3H), 2.77 (dd, J = 5.09, 11.73 Hz, 1H), 2.69 (dd, J = 6.21, 13.81 Hz, 1H), 2.30 
(m, 3H), 2.17 (s, 3H), 2.16 (m, 3H), 2.00 (dd, J = 10.05, 13.74 Hz, 1H), 1.78 (dt, J = 
3.04, 13.22 Hz, 1H), 1.66 (m, 1H), 1.49 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.85, 171.62, 171.04, 169.82, 166.88, 163.76, 156.28, 131.55, 127.71, 
120.86, 115.95, 111.20, 101.90, 74.90, 71.54, 64.21, 55.56, 53.45, 51.98, 50.76, 41.99, 
40.72, 37.93, 35.44, 30.76, 20.59, 18.13, 16.32, 16.11. HRMS calculated for C29H33NO9: 
[M+Na]+: 562.2039 (found); 562.2053. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-dimethyl-
4,10-dioxo-2-(5-(2-(trifluoromethyl)phenyl)isoxazol-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared from 8 (50 mg, 0.122 mmol) according 
to general oxime oxidation/cycloaddition reaction to yield 11 as a white solid (30 mg, 
43%). 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.81 Hz, 1H), 7.75 (d, J = 7.70 Hz, 1H), 
7.68 (dd, J = 4.11, 11.02 Hz, 1H), 7.62 (dd, J = 3.92, 11.44 Hz, 1H), 6.62 (s, 1H), 5.73 
(dd, J = 5.91, 10.61 Hz, 1H), 5.19 (dd, J = 8.43, 11.68 Hz, 1H), 3.73 (s, 3H), 2.78 (dd, J = 
4.99, 11.86 Hz, 1H), 2.71 (dd, J = 5.93, 13.75 Hz, 1H), 2.32 (dd, J = 4.26, 7.49 Hz, 2H), 
2.28 (s, 1H), 2.17 (m, 2H), 2.17 (s, 3H), 1.96 (dd, J = 10.78, 13.60 Hz, 1H), 1.80 (dt, J = 
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2.88, 13.21 Hz, 1H), 1.64 (m, 2H), 1.50 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.82, 171.59, 170.64, 169.83, 168.00, 163.48, 132.08, 131.00, 130.45, 
128.14 (q, J = 31.55 Hz, H), 126.77 (q, J = 5.54 Hz, H), 125.79 (q, J = 1.84 Hz, H), 
123.37 (q, J = 273.51 Hz, H), 102.91 (q, J = 3.37 Hz, H). 74.90, 71.33, 64.04, 53.45, 
51.99, 51.02, 41.98, 40.79, 37.94, 35.46, 30.77, 20.59, 18.11, 16.35, 15.78. HRMS 
calculated for C29H30F3NO8: [M+Na]+: 600.1797 (found); 600.1821 (calc). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(5-
(hydroxymethyl)isoxazol-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared from 8 (50mg, 0.122 mmol) according to 
general oxime oxidation/cycloaddition reaction to yield 12 as a white solid (21 mg, 37%). 
1H NMR (500 MHz, CDCl3) δ 6.32 (s, 1H), 5.64 (dd, J = 6.02, 10.44 Hz, 1H), 5.16 (dd, J 
= 8.42, 11.63 Hz, 1H), 4.76 (d, J = 4.94 Hz, 2H), 3.73 (m, 3H), 2.77 (dd, J = 5.03, 11.81 
Hz, 1H), 2.63 (dd, J = 6.03, 13.74 Hz, 1H), 2.31 (dd, J = 4.14, 7.43 Hz, 3H), 2.27 (d, J = 
6.46 Hz, 1H), 2.17 (s, 3H), 2.15 (m, 2H), 1.86 (dd, J = 10.61, 13.61 Hz, 1H), 1.78 (dd, J 
= 6.55, 9.33 Hz, 1H), 1.67 (m, 1H), 1.46 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.86, 172.44, 171.59, 170.69, 169.93, 163.19, 100.48, 74.94, 71.26, 64.00, 
56.50, 53.42, 52.00, 50.88, 41.98, 40.74, 37.91, 35.39, 30.73, 20.60, 18.10, 16.33, 15.80. 
HRMS calculated for C23H29NO9: [M+Na]+: 486.1738 (found); 486.1740 (calc). 
OH H
O
O
AcO
CO2Me
Me
Me
N
O
HO
12
! 132 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-dimethyl-
4,10-dioxo-2-(5-(trimethylsilyl)isoxazol-3-yl)dodecahydro-1H-benzo[f]isochromene-
7-carboxylate. Prepared from 8 (171 mg, 0.418 mmol) according to general oxime 
oxidation/cycloaddition reaction to yield 13 as a white solid (127 mg, 40%). 1H NMR 
(500 MHz, CDCl3) δ 6.50 (s, 1H), 5.72 (dd, J = 6.05, 10.31 Hz, 1H), 5.15 (m, 1H), 3.72 
(s, 3H), 2.75 (dd, J = 5.60, 11.24 Hz, 1H), 2.65 (dd, J = 6.09, 13.74 Hz, 1H), 2.30 (m, 
2H), 2.23 (s, 1H), 2.16 (s, 3H), 2.14 (m, 2H), 1.88 (dd, J = 10.43, 13.65 Hz, 1H), 1.78 
(dd, J = 6.71, 9.37 Hz, 1H), 1.64 (m, 2H), 1.47 (s, 3H), 1.11 (s, 3H), 0.33 (m, 9H). 13C 
NMR (126 MHz, CDCl3) δ 201.73, 179.53, 171.56, 170.79, 169.82, 161.43, 110.95, 
74.90, 71.28, 64.16, 53.51, 51.98, 50.92, 41.99, 41.34, 37.99, 35.44, 30.74, 20.58, 18.11, 
16.32, 15.83, -1.98. HRMS calculated for C25H35NO8Si: [M+Na]+: 528.2009 (found); 
528.2030 (calc). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-cyano-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate. 
Method A: A solution 13 (73.7 mg, 0.146 mmol) in MeCN (1 mL) was slowly added to a 
suspension of CsF (29.9 mg, 0.197 mmol) in MeCN (4 ml) and EtOH (0.2 mL). After 30 
min the reaction was quenched with H2O (10 mL) and extracted with CH2Cl2 (5 x 15 
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mL). Combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
esidue was purified by Prep TLC (2 x 40% EtOAc/Hex) to yield 14 (20.4 mg, 36%) as a 
white solid. 
Method B: A solution of TBAF (1 M in THF, 0.10 mmol) was slowly added dropwise to 
a solution of 14 (50.0 mg, 0.0989 mmol) in CH2Cl2 (5 mL) cooled to 0 °C. After 30 min 
at this temperature, the reaction was quenched with H2O (5 mL) and extracted with 
CH2Cl2 (3 x 10 mL). The combined organic layers was washed with saturated NaHCO3 
(aq.) and brine then dried over Na2SO4. The solvent was removed in vacuo and residue 
purified by FCC eluting with 40% EtOAc/Hex to yield 14 (19.4 mg, 50%) as a white 
solid.  
Method C: To a solution of 8 (100 mg, 0.245 mmol) in CH2Cl2 (10 mL) was added TsCl 
(49 mg, 0.258 mmol) and DIPEA (0.09 mL, 0.503 mmol). After stirring for 24 hours at 
room temperature, the reaction was diluted with CH2Cl2 (20 mL) and rinsed with HCl (2 
M, 10 mL) and brine. The organic layer was dried over Na2SO4 and concentrated in 
vacuo. The resulting residue was purified by FCC: 40% EtOAc/Hex to yield 14 (58.2 mg, 
60%) as a white solid. 
 1H NMR (500 MHz, CDCl3) δ 5.26 (dd, J = 7.36, 8.18 Hz, 1H), 5.17 (m, 1H), 3.73 (s, 
3H), 2.79 (dd, J = 4.47, 12.33 Hz, 1H), 2.66 (dd, J = 7.29, 14.05 Hz, 1H), 2.39 (dd, J = 
3.13, 11.51 Hz, 1H), 2.32 (dt, J = 7.22, 18.64 Hz, 2H), 2.31 (s, 1H), 2.18 (s, 3H), 2.12 (m, 
1H), 1.82 (ddd, J = 5.68, 9.99, 12.71 Hz, 2H), 1.66 (ddd, J = 5.02, 13.66, 25.10 Hz, 2H), 
1.35 (s, 3H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.67, 171.38, 169.90, 168.65, 
116.81, 74.89, 64.15, 62.92, 53.24, 52.07, 49.65, 41.99, 40.24, 37.51, 35.28, 30.57, 20.55, 
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18.07, 16.68, 16.21. HRMS calculated for C20H25NO7: [M+Na]+: 414.1529 (found); 
414.1544 (calc). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-bromofuran-
3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate. An oven-dried flask was charged with a stir bar, 1 (450 mg, 1.04 mmol), 
and N-bromosuccinimide (260 mg, 1.46 mmol). CH2Cl2 (50 mL) was added to the 
reaction followed by a single drop of Br2. After stirring at room temperature for 30 min 
the reaction mixture was applied directly to a silica gel column and eluted with 
EtOAc/CH2Cl2 (0-5%) to yield 4 as a white solid (261 mg, 49%). 1H NMR (500 MHz, 
CDCl3) δ 7.42 (d, J = 2.1 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 5.43 (dd, J = 12.1, 5.1 Hz, 
1H), 5.13 (m, 1H), 3.73 (s, 3H), 2.76 (m, 1H), 2.39 (dd, J = 13.6, 5.2 Hz, 1H), 2.30 (m, 
2H), 2.19 (m, 2H), 2.16 (s, 3H), 2.11 (dd, J = 11.5, 2.9 Hz, 1H), 1.81 (m, 1H), 1.62 (m, 
3H), 1.47 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.90, 171.53, 170.92, 
169.98, 144.66, 122.75, 121.39, 110.75, 75.02, 71.92, 63.91, 53.59, 52.02, 51.59, 42.86, 
42.12, 38.16, 35.51, 30.74, 20.58, 18.13, 16.44, 14.98. HRMS calculated for C23H27BrO8: 
[M+K]+: 549.0499 (found); 549.0526 (calc). Melting point: 195-197 °C. 
OH H
O
O
O
AcO
CO2Me
Me
Me
Br
4
! 135 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2,5-
dibromofuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. An oven-dried flask was charged with a stir bar, 1 
(200 mg, 0.462 mmol), and N-bromosuccinimide (115 mg, 0.646 mmol). CH2Cl2 (20 mL) 
was added to the reaction followed by Br2 (24 mL, 0.46 mmol) dropwise. After stirring at 
room temperature for 30 min the reaction mixture was applied to a silica gel column and 
eluted with EtOAc/CH2Cl2 (0-5%) to yield 15 as a white solid (99 mg, 36%). 1H NMR 
(500 MHz, CDCl3) δ 6.36 (s, 1H), 5.37 (dd, J = 12.1, 5.2 Hz, 1H), 5.11 (m, 1H), 3.73 (s, 
3H), 2.76 (dd, J = 10.3, 6.5 Hz, 1H), 2.38 (dd, J = 13.6, 5.2 Hz, 1H), 2.30 (s, 1H), 2.29 
(dd, J = 13.5, 7.2 Hz, 1H), 2.17 (m, 2H), 2.16 (s, 3H), 2.10 (dd, J = 11.3, 2.9 Hz, 1H), 
1.80 (m, 1H), 1.59 (m, 3H), 1.45 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
201.93, 171.51, 170.66, 169.98, 125.95, 123.02, s120.91, 112.59, 75.03, 71.53, 63.80, 
53.56, 52.04, 51.53, 42.62, 42.11, 38.12, 35.50, 30.72, 20.58, 18.11, 16.43, 14.98. HRMS 
calculated for C23H26O8Br2: [M+Na]+: 626.9626 (found); 626.9632 (calc). Melting point: 
202-205°C (dec). 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-phenylfuran-3-yl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.55 (dd, J = 4.4, 3.8 Hz, 2H), 7.45 (m, 3H), 
7.38 (m, 1H), 6.49 (d, J = 1.9 Hz, 1H), 5.69 (dd, J = 12.0, 5.0 Hz, 1H), 5.14 (m, 1H), 3.73 
(s, 3H), 2.77 (m, 1H), 2.42 (dd, J = 13.7, 5.0 Hz, 1H), 2.30 (s, 1H), 2.29 (m, 1H), 2.21 
(m, 2H), 2.15 (m, 1H), 2.14 (s, 3H), 1.81 (m, 1H), 1.69 (m, 3H), 1.44 (s, 3H), 1.12 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 201.92, 171.57, 171.23, 169.94, 151.72, 142.17, 
130.03, 128.84, 128.47, 127.12, 119.24, 110.17, 74.99, 71.97, 64.01, 53.59, 52.00, 51.62, 
43.29, 42.12, 38.20, 35.55, 30.75, 20.56, 18.18, 16.45, 15.05. HRMS calculated for 
C29H32O8: [M+Na]+: 531.1979 (found); 531.1995 (calc).  Melting point: 260°C (dec). 
 (2S,4aS,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-phenylfuran-3-yl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.50 (m, 2H), 7.44 (m, 3H), 7.36 (m, 1H), 
6.56 (d, J = 1.9 Hz, 1H), 5.42 (dd, J = 12.0, 1.4 Hz, 1H), 5.15 (t, 1H), 3.71 (s, 3H), 2.80 
(dd, J = 8.8, 8.0 Hz, 1H), 2.48 (d, J = 3.1 Hz, 1H), 2.39 (dd, J = 15.1, 1.9 Hz, 1H), 2.30 
(m, 3H), 2.22 (m, 1H), 2.16 (s, 3H), 2.05 (td, J = 13.8, 3.9 Hz, 1H), 1.85 (m, 1H), 1.63 (s, 
3H), 1.62 (m, 2H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.37, 173.68, 171.89, 
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169.88, 150.86, 142.18, 130.26, 128.85, 128.31, 126.78, 118.18, 110.49, 75.31, 69.81, 
64.33, 52.94, 51.81, 47.96, 45.21, 42.31, 34.70, 34.01, 30.70, 24.55, 20.58, 17.63, 15.26. 
HRMS calculated for C29H32O8: [M+Na]+: 509.2171 (found); 509.2175 (calc).  Melting 
Point: 116-118°C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(2-(trifluoromethyl)phenyl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 7.6 Hz, 
1H), 7.64 (dd, J = 7.5, 6.8 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H), 
7.50 (d, J = 1.9 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 5.33 (dd, J = 11.8, 5.2 Hz, 1H), 5.14 
(dd, J = 11.9, 8.2 Hz, 1H), 3.73 (s, 3H), 2.76 (dd, J = 12.2, 4.7 Hz, 1H), 2.31 (m, 3H), 
2.17 (m, 2H), 2.15 (s, 3H), 2.07 (dd, J = 11.6, 2.7 Hz, 1H), 1.78 (dd, J = 10.0, 2.8 Hz, 
1H), 1.63 (m, 3H), 1.33 (s, 3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.85, 
171.57, 171.10, 169.86, 148.75, 143.00, 132.51, 131.75, 130.10 (q, 2JCF = 30.95), 129.60, 
127.76 (q, 3JCF = 1.69 Hz), 126.97 (q, 3JCF = 5.15 Hz), 123.53 (q, 1JCF = 273.60 Hz), 
121.54, 109.38, 74.90, 71.71, 64.02, 53.55, 52.01, 51.45, 43.23, 42.06, 38.13, 35.47, 
30.79, 20.59, 18.15, 16.38, 14.94. 19F NMR (376 MHz, CDCl3) δ -59.65. HRMS 
calculated for C30H31F3O8: [M+Na]+ calcd 599.1869, found 599.1895. Melting point 184-
188°C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(3-(trifluoromethyl)phenyl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.84 (s, 1H), 7.74 
(d, J = 7.6 Hz, 1H), 7.60 (d, J = 17.7 Hz, 1H), 7.60 (t, J = 16.6 Hz, 1H), 7.49 (d, J = 1.9 
Hz, 1H), 6.52 (d, J = 1.9 Hz, 1H), 5.67 (dd, J = 12.1, 4.9 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 
3H), 2.77 (m, 1H), 2.43 (dd, J = 13.7, 4.9 Hz, 1H), 2.30 (m, 2H), 2.18 (m, 3H), 2.14 (s, 
3H), 1.82 (m, 1H), 1.66 (m, 3H), 1.46 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 201.82, 171.53, 170.98, 169.99, 149.87, 131.37 (q, 2JCF = 32.49 Hz), 130.77, 129.97, 
129.42, 124.94 (q, 3JCF = 3.70 Hz), 123.87 (q, 1JCF = 272.60 Hz), 123.77 (q, 3JCF = 3.85 
Hz), 120.59, 110.55, 75.00, 71.65, 64.00, 53.62, 52.03, 51.72, 43.14, 42.12, 38.19, 35.56, 
30.73, 20.56, 18.16, 16.49, 15.04. 19F NMR (376 MHz, CDCl3) δ -62.49. HRMS 
calculated for C30H31F3O8: [M+Na]+: 599.1885 (found); 599.1869 (calc). Melting point: 
167-169°C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(4-(trifluoromethyl)phenyl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.70 (q, J = 8.6 Hz, 
4H), 7.49 (d, J = 1.9 Hz, 1H), 6.53 (d, J = 1.9 Hz, 1H), 5.68 (dd, J = 12.0, 4.9 Hz, 1H), 
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5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.43 (dd, J = 13.6, 5.0 Hz, 1H), 2.30 (m, 2H), 
2.20 (s, 1H), 2.17 (m, 2H), 2.14 (s, 3H), 1.82 (m, 1H), 1.66 (m, 3H), 1.46 (s, 3H), 1.13 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 201.87, 171.52, 170.98, 169.99, 150.00, 142.98, 
133.30, 130.14 (q, 2JCF = 32.81 Hz), 127.09, 125.85 (q, 3JCF = 3.74 Hz), 123.99 (q, 1JCF = 
272.10), 120.96, 110.55, 75.00, 71.57, 64.01, 53.62, 52.04, 51.70, 43.12, 42.12, 38.18, 
35.56, 30.73, 20.56, 18.17, 16.48, 15.10. 19F NMR (376 MHz, CDCl3) δ -62.29. HRMS 
calculated for C30H31F3O8: [M+Na]+: 599.1873 (found); 599.1869 (calc). Melting point 
190-194°C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-2-(2-(2-nitrophenyl)furan-3-yl)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.46 (t, J = 1.90 
Hz, 1H), 8.21 (ddd, J = 0.99, 2.27, 8.24 Hz, 1H), 7.91 (ddd, J = 1.03, 1.61, 7.77 Hz, 1H), 
7.64 (t, J = 8.00 Hz, 1H), 7.52 (d, J = 1.96 Hz, 1H), 6.54 (d, J = 1.94 Hz, 1H), 5.71 (dd, J 
= 4.86, 12.07 Hz, 1H), 5.13 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.45 (dd, J = 4.88, 13.66 
Hz, 1H), 2.30 (m, 2H), 2.18 (m, 3H), 2.14 (s, 3H), 1.82 (m, 1H), 1.68 (m, 3H), 1.48 (s, 
3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.81, 171.51, 170.85, 170.01, 
148.69, 148.62, 143.15, 132.25, 131.63, 129.97, 122.81, 121.62, 121.49, 110.86, 75.00, 
71.50, 64.00, 53.61, 52.04, 51.74, 43.00, 42.12, 38.17, 35.60, 30.72, 20.56, 18.15, 16.50, 
15.15. HRMS calculated for C29H31NO10: [M+Na]+: 576.1855 (found); 576.1846 (calc). 
Melting point: 196-198 °C.  
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-2-(2-(3-nitrophenyl)furan-3-yl)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.46 (t, J = 1.89 
Hz, 1H), 8.21 (ddd, J = 0.97, 2.26, 8.22 Hz, 1H), 7.91 (ddd, J = 1.05, 1.56, 7.77 Hz, 1H), 
7.64 (t, J = 8.02 Hz, 1H), 7.52 (d, J = 1.93 Hz, 1H), 6.54 (d, J = 1.93 Hz, 1H), 5.70 (dd, J 
= 4.86, 12.07 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.45 (dd, J = 4.87, 13.66 
Hz, 1H), 2.30 (m, 2H), 2.19 (m, 3H), 2.14 (s, 3H), 1.82 (m, 1H), 1.70 (m, 3H), 1.48 (s, 
3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.83, 171.51, 170.87, 170.01, 
148.68, 148.61, 143.14, 132.24, 131.62, 129.97, 122.80, 121.61, 121.49, 110.86, 75.00, 
71.50, 63.97, 53.59, 52.04, 51.72, 42.98, 42.11, 38.16, 35.59, 30.71, 20.56, 18.15, 16.50, 
15.15. HRMS calculated for C29H31NO10: [M+Na]+: 576.1843 (found); 576.1846 (calc). 
Melting point:119-123 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-2-(2-(4-nitrophenyl)furan-3-yl)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 9.00 
Hz, 2H), 7.75 (d, J = 9.00 Hz, 2H), 7.54 (d, J = 1.86 Hz, 1H), 6.57 (d, J = 1.92 Hz, 1H), 
5.70 (dd, J = 4.89, 12.04 Hz, 1H), 5.13 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.45 (dd, J = 
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4.92, 13.64 Hz, 1H), 2.31 (m, 2H), 2.22 (m, 2H), 2.16 (m, 1H), 2.14 (s, 3H), 1.83 (m, 
1H), 1.68 (m, 3H), 1.47 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.87, 
171.48, 170.81, 170.01, 148.99, 147.14, 143.69, 135.89, 127.18, 124.29, 122.56, 111.03, 
75.00, 71.34, 63.96, 53.60, 52.05, 51.72, 42.91, 42.11, 38.14, 35.56, 30.70, 20.55, 18.15, 
16.50, 15.14.  HRMS calculated for C29H31NO10: [M+Na]+: 576.1860 (found); 576.1846 
(calc). Melting point: 184-188 °C.  
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(2-
fluorophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.50 (m, 2H), 7.39 
(m, 1H), 7.20 (m, 2H), 6.49 (d, J = 1.9 Hz, 1H), 5.57 (dd, J = 11.9, 5.0 Hz, 1H), 5.13 (m, 
1H), 3.73 (s, 3H), 2.76 (dd, J = 10.6, 6.3 Hz, 1H), 2.45 (dd, J = 13.6, 5.0 Hz, 1H), 2.29 
(m, 2H), 2.15 (s, 3H), 2.15 (m, 3H), 1.80 (dd, J = 10.0, 3.0 Hz, 1H), 1.62 (m, 3H), 1.42 
(s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.80, 171.60, 171.22, 169.89, 
159.20 (d, 1JCF = 249.50 Hz), 145.63, 143.36, 130.68 (3JCF = 2.23 Hz), 130.64 (3JCF = 
3.35), 124.43 (3JCF = 3.52 Hz), 121.95, 118.04 (2JCF = 14.11 Hz), 116.27 (2JCF = 21.99), 
109.96, 74.96, 72.07, 64.06, 53.62, 52.00, 51.62, 43.50, 42.11, 38.23, 35.52, 30.79, 20.59, 
18.16, 16.44, 15.02. 19F NMR (376 MHz, CDCl3) δ -115.25. HRMS calculated for 
C29H31FO8: [M+Na]+: 549.1891 (found); 549.1901 (calc).  Melting point 245-247°C (dec). 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(3-
fluorophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 1.9 Hz, 
1H), 7.42 (td, J = 8.0, 5.9 Hz, 1H), 7.33 (m, 1H), 7.29 (m, 1H), 7.07 (m, 1H), 6.50 (d, J = 
1.9 Hz, 1H), 5.69 (dd, J = 12.0, 4.9 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 
2.42 (dd, J = 13.6, 5.0 Hz, 1H), 2.30 (s, 1H), 2.30 (m, 1H), 2.22 (m, 2H), 2.14 (s, 3H), 
2.13 (m, 1H), 1.82 (m, 1H), 1.66 (m, 3H), 1.46 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.87, 171.54, 171.04, 169.96, 162.95 (d, 1JCF = 246.35 Hz), 150.24 (d, 4JCF = 
2.61 Hz), 142.52, 131.98 (d, 3JCF = 8.47 Hz), 130.49 (d, 3JCF = 8.48 Hz), 122.58 (d, 4JCF = 
2.89 Hz), 120.14, 115.38 (d, 2JCF = 21.24 Hz), 113.89 (d, 2JCF = 23.18 Hz), 110.39, 75.00, 
71.66, 64.03, 53.61, 52.02, 51.68, 43.17, 42.12, 38.20, 35.56, 30.75, 20.56, 18.18, 16.47, 
15.09. 19F NMR (376 MHz, CDCl3) δ -113.49. HRMS calculated for C29H31FO8: 
[M+Na]+: 549.1920 (found); 549.1901 (calc).  Melting point 230-232°C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(4-
fluorophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J = 8.9, 
5.3 Hz, 2H), 7.43 (d, J = 1.9 Hz, 1H), 7.15 (t, J = 8.7 Hz, 2H), 6.48 (d, J = 2.0 Hz, 1H), 
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5.61 (dd, J = 12.0, 5.0 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.40 (dd, J = 
13.6, 5.0 Hz, 1H), 2.30 (s, 1H), 2.30 (m, 1H), 2.16 (m, 3H), 2.14 (s, 3H), 1.81 (m, 1H), 
1.66 (m, 3H), 1.44 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.93, 171.54, 
171.14, 169.97, 162.79 (d, 1JCF = 248.79 Hz), 150.97, 142.15, 129.06 (d, 3JCF = 8.25 Hz), 
126.26 (d, 4JCF = 3.29), 119.04, 115.96 (d, 2JCF = 21.82 Hz), 110.15, 75.01, 71.86, 64.03, 
53.61, 52.03, 51.65, 43.19, 42.13, 38.20, 35.53, 30.75, 20.56, 18.18, 16.46, 15.06. 19F 
NMR (376 MHz, CDCl3) δ -114.01. HRMS calculated for C29H31FO8: [M+Na]+: 
549.1907 (found); 549.1901 (calc). Melting point 200-201°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(o-tolyl)furan-3-yl)dodecahydro-1H-benzo[f]isochromene-
7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 1.95 Hz, 1H), 7.33 (m, 1H), 
7.29 (dd, J = 1.62, 5.81 Hz, 2H), 7.26 (m, 1H), 6.47 (d, J = 1.99 Hz, 1H), 5.38 (dd, J = 
5.17, 11.90 Hz, 1H), 5.13 (dd, J = 8.84, 11.26 Hz, 1H), 3.73 (s, 3H), 2.76 (dd, J = 5.51, 
11.36 Hz, 1H), 2.32 (m, 3H), 2.29 (s, 3H), 2.17 (m, 2H), 2.15 (s, 3H), 2.06 (m, 1H), 1.79 
(dd, J = 2.93, 10.00 Hz, 1H), 1.64 (m, 3H), 1.34 (s, 3H), 1.09 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 201.94, 171.58, 171.28, 169.97, 152.35, 142.17, 138.36, 130.76, 130.47, 
129.33, 129.05, 125.74, 120.36, 109.29, 75.00, 72.07, 64.05, 53.59, 52.01, 51.47, 43.53, 
42.11, 38.20, 35.50, 30.75, 20.59, 20.30, 18.16, 16.39, 14.95. HRMS calculated for 
C30H34O8: [M+Na]+: 545.2157 (found); 545.2151 (calc). Melting point: 166-167 °C (dec.). 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(m-tolyl)furan-3-yl)dodecahydro-1H-benzo[f]isochromene-
7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 1.87 Hz, 1H), 7.37 (m, 1H), 
7.34 (d, J = 4.11 Hz, 2H), 7.19 (m, 1H), 6.47 (d, J = 1.96 Hz, 1H), 5.70 (dd, J = 4.95, 
12.03 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.41 (dd, J = 5.12, 13.50 Hz, 
1H), 2.41 (s, 3H), 2.30 (m, 2H), 2.17 (m, 3H), 2.14 (s, 3H), 1.81 (m, 1H), 1.66 (m, 3H), 
1.44 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.86, 171.58, 171.25, 169.94, 
151.79, 142.05, 138.54, 129.97, 129.28, 128.73, 127.75, 124.28, 119.16, 110.14, 74.98, 
72.07, 64.04, 53.61, 52.01, 51.67, 43.36, 42.12, 38.23, 35.55, 30.77, 21.51, 20.57, 18.19, 
16.46, 15.05. HRMS calculated for C30H34O8: [M+Na]+: 545.2157 (found); 545.2151 
(calc). Melting point: 172-175 °C (dec.). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(p-tolyl)furan-3-yl)dodecahydro-1H-benzo[f]isochromene-
7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.43 (dd, J = 4.99, 10.86 Hz, 3H), 7.26 (d, 
J = 6.26 Hz, 2H), 6.47 (d, J = 1.96 Hz, 1H), 5.67 (dd, J = 4.98, 12.02 Hz, 1H), 5.14 (m, 
1H), 3.74 (s, 3H), 2.77 (dd, J = 5.67, 11.17 Hz, 1H), 2.41 (m, 1H), 2.40 (s, 3H), 2.30 (m, 
2H), 2.19 (m, 3H), 2.14 (s, 3H), 1.81 (m, 1H), 1.66 (m, 3H), 1.44 (s, 3H), 1.12 (s, 3H). 
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13C NMR (126 MHz, CDCl3) δ 201.89, 171.58, 171.28, 169.93, 151.99, 141.88, 138.47, 
129.53, 127.24, 127.07, 118.65, 110.05, 74.99, 72.08, 64.05, 53.61, 52.01, 51.63, 43.31, 
42.12, 38.22, 35.54, 30.76, 21.34, 20.56, 18.19, 16.45, 15.04. HRMS calculated for 
C30H34O8: [M+Na]+: 545.2142 (found); 545.2151 (calc). Melting point: 204-206 °C (dec.). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(2-
methoxyphenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 1.9 Hz, 
1H), 7.42 (dd, J = 7.6, 1.7 Hz, 1H), 7.38 (ddd, J = 8.4, 7.5, 1.7 Hz, 1H), 7.04 (td, J = 7.5, 
0.9 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.46 (d, J = 2.0 Hz, 1H), 5.54 (dd, J = 11.9, 4.8 Hz, 
1H), 5.14 (dd, J = 11.4, 8.7 Hz, 1H), 3.89 (s, 3H), 3.73 (s, 3H), 2.77 (dd, J = 11.4, 5.4 Hz, 
1H), 2.52 (dd, J = 13.7, 4.8 Hz, 1H), 2.29 (m, 2H), 2.19 (s, 1H), 2.15 (s, 3H), 2.13 (m, 
2H), 1.80 (m, 1H), 1.62 (m, 3H), 1.39 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 202.06, 171.63, 171.48, 169.78, 156.32, 147.77, 142.83, 131.01, 130.34, 121.16, 
120.75, 119.12, 111.10, 109.66, 75.00, 72.79, 64.08, 55.39, 53.61, 51.99, 51.74, 43.21, 
42.13, 38.28, 35.43, 30.84, 20.58, 18.14, 16.45, 14.95. HRMS calculated for C30H34O9: 
[M+Na]+: 561.2076 (found); 561.2101 (calc).  Melting point: 165-167°C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(3-
methoxyphenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 1.9 Hz, 
1H), 7.36 (t, J = 8.0 Hz, 1H), 7.14 (dd, J = 7.6, 0.9 Hz, 1H), 7.10 (m, 1H), 6.93 (ddd, J = 
8.3, 2.6, 0.8 Hz, 1H), 6.48 (d, J = 1.9 Hz, 1H), 5.72 (dd, J = 12.1, 4.9 Hz, 1H), 5.14 (m, 
1H), 3.86 (s, 3H), 3.74 (s, 3H), 2.77 (dd, J = 10.8, 6.1 Hz, 1H), 2.43 (dd, J = 13.6, 4.9 Hz, 
1H), 2.30 (m, 2H), 2.21 (m, 1H), 2.20 (s, 1H), 2.14 (s, 3H), 2.13 (m, 1H), 1.81 (m, 1H), 
1.66 (m, 3H), 1.45 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.87, 171.57, 
171.17, 169.94, 159.85, 151.47, 142.11, 131.25, 129.91, 119.46, 114.88, 111.86, 110.21, 
74.99, 71.96, 64.03, 55.36, 53.61, 52.02, 51.68, 43.29, 42.12, 38.22, 35.56, 30.76, 20.56, 
18.18, 16.47, 15.09. HRMS calculated for C30H34O9: [M+Na]+: 561.2092 (found); 
561.2101 (calc). Melting point 165-167°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(4-
methoxyphenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 8.9 Hz, 
2H), 7.40 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.46 (d, J = 2.0 Hz, 1H), 5.63 (dd, 
J = 12.0, 5.0 Hz, 1H), 5.14 (m, 1H), 3.86 (s, 3H), 3.73 (s, 3H), 2.77 (m, 1H), 2.40 (dd, J = 
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13.6, 5.0 Hz, 1H), 2.30 (s, 1H), 2.29 (m, 1H), 2.20 (m, 2H), 2.14 (s, 3H), 2.12 (m, 1H), 
1.81 (dd, J = 10.1, 2.9 Hz, 1H), 1.66 (m, 3H), 1.43 (s, 3H), 1.12 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 201.93, 171.59, 171.30, 169.94, 159.79, 151.96, 141.63, 128.62, 122.76, 
118.03, 114.29, 109.99, 75.00, 72.15, 64.04, 55.36, 53.59, 52.01, 51.61, 43.26, 42.13, 
38.21, 35.53, 30.76, 20.56, 18.19, 16.45, 15.05. HRMS calculated for C30H34O9: [M+K]+: 
577.1863 (found); 577.1840 (calc).  Melting point: 118-121°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-2-(2-(naphthalen-1-yl)furan-3-yl)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate.1H NMR (500 MHz, CDCl3) δ 7.94 (m, 1H), 7.91 
(m, 1H), 7.85 (m, 1H), 7.59 (d, J = 2.0 Hz, 1H), 7.54 (m, 4H), 6.58 (d, J = 2.0 Hz, 1H), 
5.43 (dd, J = 11.7, 5.2 Hz, 1H), 5.09 (dd, J = 11.7, 8.4 Hz, 1H), 3.72 (s, 3H), 2.71 (dd, J = 
11.8, 5.0 Hz, 1H), 2.36 (dd, J = 13.7, 5.2 Hz, 1H), 2.27 (m, 2H), 2.16 (m, 1H), 2.14 (s, 
3H), 2.10 (s, 1H), 2.05 (dd, J = 11.1, 3.1 Hz, 1H), 1.77 (dd, J = 10.1, 3.0 Hz, 1H), 1.69 
(m, 1H), 1.58 (m, 2H), 1.27 (s, 3H), 1.06 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.80, 
171.56, 171.27, 169.92, 151.36, 142.79, 133.77, 132.15, 129.91, 128.84, 128.30, 127.01, 
126.86, 126.31, 125.83, 125.20, 121.70, 109.71, 74.96, 72.05, 64.01, 53.54, 51.99, 51.40, 
43.41, 42.06, 38.16, 35.47, 30.73, 20.58, 18.14, 16.35, 14.99. HRMS calculated for 
C33H34O9: [M+Na]+: 581.2131 (found); 581.2151 (calc).  Melting point: 137-140°C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-2-(2-(naphthalen-2-yl)furan-3-yl)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.02 (d, J = 0.8 Hz, 
1H), 7.92 (d, J = 8.8 Hz, 2H), 7.87 (m, 1H), 7.69 (dd, J = 8.5, 1.6 Hz, 1H), 7.52 (m, 2H), 
7.50 (d, J = 1.9 Hz, 1H), 6.53 (d, J = 1.9 Hz, 2H), 5.79 (dd, J = 12.0, 4.9 Hz, 1H), 5.14 
(m, 1H), 3.73 (s, 3H), 2.77 (m, 1H), 2.47 (dd, J = 13.7, 4.9 Hz, 1H), 2.29 (m, 2H), 2.17 
(m, 3H), 2.13 (s, 3H), 1.81 (m, 1H), 1.74 (m, 1H), 1.65 (m, 2H), 1.46 (s, 3H), 1.12 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 201.85, 171.56, 171.24, 169.93, 151.68, 142.37, 
133.23, 132.99, 128.60, 128.46, 127.73, 127.46, 126.61, 126.60, 126.38, 124.68, 119.72, 
110.39, 74.98, 72.12, 64.02, 53.60, 52.01, 51.72, 43.34, 42.12, 38.22, 35.57, 30.76, 20.56, 
18.20, 16.48, 15.10. HRMS calculated for C33H34O8: [M+K]+: 597.1896 (found); 
597.1891 (calc).  Melting point: 160-163°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-([2,2'-bifuran]-3-yl)-9-
acetoxy-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 1.7, 0.7 Hz, 1H), 7.36 (d, J = 
1.9 Hz, 1H), 6.60 (dd, J = 3.4, 0.6 Hz, 1H), 6.48 (dd, J = 3.4, 1.8 Hz, 1H), 6.43 (d, J = 1.9 
Hz, 1H), 6.04 (dd, J = 12.0, 5.0 Hz, 1H), 5.12 (m, 1H), 3.73 (s, 3H), 2.76 (m, 1H), 2.48 
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(dd, J = 13.6, 5.1 Hz, 1H), 2.30 (m, 2H), 2.20 (m, 2H), 2.15 (m, 1H), 2.14 (s, 3H), 1.81 
(m, 1H), 1.64 (m, 3H), 1.51 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.91, 
171.59, 171.31, 169.91, 145.77, 142.62, 142.53, 142.01, 119.81, 111.38, 110.18, 107.45, 
74.99, 71.75, 64.04, 53.61, 52.00, 51.62, 43.67, 42.13, 38.26, 35.61, 30.78, 20.57, 18.19, 
16.47, 15.09. HRMS calculated for C27H30O9: [M+Na]+: 521.1804 (found); 521.1788 
(calc). Melting point: 240-245°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-([2,3'-bifuran]-3-yl)-9-
acetoxy-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.71 (m, 1H), 7.49 (t, J = 1.7 Hz, 1H), 7.37 
(d, J = 2.0 Hz, 1H), 6.65 (dd, J = 1.8, 0.7 Hz, 1H), 6.43 (d, J = 2.0 Hz, 1H), 5.61 (dd, J = 
12.0, 4.9 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.77 (m, 1H), 2.40 (dd, J = 13.6, 4.9 Hz, 
1H), 2.30 (m, 2H), 2.16 (m, 3H), 2.15 (s, 3H), 1.81 (m, 1H), 1.64 (m, 3H), 1.48 (s, 3H), 
1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.91, 171.56, 171.14, 169.96, 145.23, 
143.66, 141.72, 139.85, 119.03, 116.20, 109.73, 108.84, 74.99, 71.68, 64.03, 53.60, 
52.02, 51.64, 43.02, 42.11, 38.19, 35.51, 30.75, 20.57, 18.16, 16.48, 15.13. HRMS 
calculated for C27H30O9: [M+Na]+: 521.1793 (found); 521.1788 (calc). Melting point: 
235°C (dec.). 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(thiophen-2-yl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. An oven-dried conical vial was cooled under a 
stream of argon and charged with 4 (60 mg, 0.117 mmol), Pd(OAc)2 (1.3 mg, 0.0059 
mmol), SPhos (4.8 mg, 0.012 mmol), and 2-thiopheneboronic acid MIDA ester (33.7 mg, 
0.141 mmol). The vial was sealed with a Biotage Reseal cap and flushed with argon for 5 
min before adding toluene (1.6 mL) through the septum. After stirring at room 
temperature for 10 min., a solution of K3PO4 (aq., 3.0 M, 0.880 mmol) the reaction was 
heated to 65°C for 24 hrs. The reaction was cooled to room temperature, diluted with a 
10% NaOH solution (1 mL) and extracted with Et2O (3 x 10 mL). Combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. The resulting residue was 
purified by FCC eluting with 35% EtOAc/Pent to yield 37 as a white solid (28.3 mg, 
47%) and 4 (13.2 mg, 22%). 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 1.9 Hz, 1H), 7.36 
(dd, J = 5.1, 1.1 Hz, 1H), 7.27 (m, 1H), 7.10 (dd, J = 5.1, 3.7 Hz, 1H), 6.46 (d, J = 1.9 
Hz, 1H), 5.80 (dd, J = 12.1, 4.9 Hz, 1H), 5.14 (m, 1H), 3.73 (s, 3H), 2.77 (m, 1H), 2.45 
(dd, J = 13.6, 4.9 Hz, 1H), 2.30 (m, 2H), 2.20 (m, 2H), 2.14 (s, 3H), 2.14 (m, 1H), 1.81 
(m, 1H), 1.65 (m, 3H), 1.49 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 200.85, 
170.55, 170.15, 168.90, 145.18, 140.92, 130.52, 126.65, 125.01, 124.35, 118.35, 109.26, 
73.93, 70.84, 62.97, 52.56, 50.98, 50.66, 42.10, 41.08, 37.17, 34.57, 29.74, 19.55, 17.14, 
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15.47, 14.09. HRMS calculated for C27H30O8S: [M+MeOH+Na]+: 569.1830 (found); 
569.1821 (calc). Melting point: 230-232°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(thiophen-3-yl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate.1H NMR (500 MHz, CDCl3) δ 7.49 (dd, J = 2.9, 
1.2 Hz, 1H), 7.41 (dd, J = 5.0, 3.0 Hz, 1H), 7.38 (d, J = 1.9 Hz, 1H), 7.33 (dd, J = 5.0, 1.2 
Hz, 1H), 6.45 (d, J = 1.9 Hz, 1H), 5.71 (dd, J = 12.0, 4.9 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 
3H), 2.77 (m, 1H), 2.42 (dd, J = 13.7, 5.0 Hz, 1H), 2.30 (m, 2H), 2.19 (m, 3H), 2.15 (s, 
3H), 1.81 (m, 1H), 1.66 (m, 3H), 1.47 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 201.91, 171.57, 171.19, 169.94, 148.17, 141.53, 130.94, 126.47, 126.10, 122.58, 
118.70, 109.88, 74.98, 71.83, 64.05, 53.60, 52.02, 51.65, 43.06, 42.12, 38.20, 35.54, 
30.76, 20.57, 18.18, 16.48, 15.13. HRMS HRMS calculated for C27H30O8S: [M+K]+: 
553.1292 (found); 553.1299. Melting point: 244-245°C (dec.). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-dimethyl-
2-(2-methylfuran-3-yl)-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 1.9 Hz, 1H), 6.25 (d, J = 1.9 Hz, 
1H), 5.45 (dd, J = 12.0, 5.1 Hz, 1H), 5.13 (m, 1H), 3.73 (s, 3H), 2.77 (dd, J = 9.7, 7.1 Hz, 
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1H), 2.32 (m, 3H), 2.27 (s, 3H), 2.18 (m, 2H), 2.16 (s, 3H), 2.08 (m, 1H), 1.80 (m, 1H), 
1.63 (m, 3H), 1.47 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.06, 171.57, 
171.32, 169.97, 149.48, 140.92, 118.25, 108.64, 75.07, 72.08, 64.03, 53.61, 52.01, 51.55, 
43.66, 42.16, 38.21, 35.50, 30.76, 20.57, 18.16, 16.42, 15.04, 11.89. HRMS calculated 
for C24H30O8: [M+Na]+: 485.1584 (found); 485.1578 (calc). Melting point: 112-116°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-
cyclopropylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.14 (d, J = 1.9 Hz, 
1H), 6.24 (d, J = 2.0 Hz, 1H), 5.63 (dd, J = 12.0, 5.1 Hz, 1H), 5.14 (m, 1H), 3.73 (s, 3H), 
2.77 (m, 1H), 2.39 (dd, J = 13.6, 5.1 Hz, 1H), 2.31 (s, 1H), 2.30 (dd, J = 13.5, 7.0 Hz, 
1H), 2.18 (m, 2H), 2.16 (s, 3H), 2.09 (dd, J = 11.5, 3.0 Hz, 1H), 1.83 (m, 2H), 1.64 (m, 
3H), 1.48 (s, 3H), 1.12 (s, 3H), 0.89 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 202.08, 
171.59, 171.43, 169.97, 153.32, 140.03, 118.27, 108.91, 75.07, 71.91, 64.05, 53.61, 
52.01, 51.55, 43.70, 42.16, 38.22, 35.53, 30.77, 20.58, 18.18, 16.43, 15.06, 7.41, 6.61, 
6.50. HRMS calculated for C26H32O8: [M+K]+: 549.0499 (found); 549.0526 (calc). 
Melting point: 130-133°C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-((E)-styryl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 7.3 Hz, 
2H), 7.36 (dd, J = 8.5, 6.7 Hz, 3H), 7.10 (d, J = 16.1 Hz, 1H), 6.89 (d, J = 16.1 Hz, 1H), 
6.38 (d, J = 1.9 Hz, 1H), 5.67 (dd, J = 11.9, 5.1 Hz, 1H), 5.14 (m, 1H), 3.73 (s, 3H), 2.77 
(dd, J = 9.7, 7.1 Hz, 1H), 2.44 (dd, J = 13.6, 5.1 Hz, 1H), 2.30 (s, 1H), 2.30 (dd, J = 13.5, 
7.1 Hz, 1H), 2.16 (m, 3H), 2.15 (s, 3H), 1.81 (m, 1H), 1.61 (m, 3H), 1.51 (s, 3H), 1.13 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 201.99, 171.56, 171.11, 169.93, 149.68, 142.19, 
136.65, 128.92, 128.72, 127.97, 126.63, 121.01, 113.66, 110.07, 75.02, 71.58, 63.99, 
53.59, 52.02, 51.58, 43.73, 42.14, 38.17, 35.61, 30.76, 20.56, 18.17, 16.44, 15.15. HRMS 
calculated for C31H34O8: [M+K]+: 573.1876 (found); 573.1891 (calc). Melting point: 170-
172°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-phenethylfuran-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.27 (m, 5H), 7.05 
(d, J = 8.3 Hz, 1H), 6.20 (d, J = 2.0 Hz, 1H), 5.13 (m, 2H), 3.73 (s, 3H), 2.91 (m, 4H), 
2.73 (dd, J = 11.7, 5.1 Hz, 1H), 2.29 (m, 2H), 2.19 (s, 3H), 2.15 (m, 1H), 2.04 (s, 1H), 
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1.94 (ddd, J = 13.5, 12.4, 3.8 Hz, 2H), 1.77 (m, 1H), 1.59 (m, 3H), 1.32 (s, 3H), 1.08 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 201.67, 171.59, 171.27, 169.94, 151.92, 141.14, 
140.86, 128.52, 128.49, 126.40, 119.11, 108.64, 75.01, 71.96, 63.82, 53.62, 51.99, 51.35, 
43.48, 42.11, 38.17, 35.34, 34.63, 30.79, 28.74, 20.61, 18.09, 16.34, 14.88. HRMS 
calculated for C31H36O8: [M+K]+: 575.2057 (found); 575.2047 (calc). Melting point: 149-
151°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(prop-1-yn-1-yl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. A conical vial was charged with 4 (50.0 mg, 
0.0978 mmol), potassium propynyltrifluoroborate (15.7 mg, 0.108 mmol), Cs2CO3 (95.6 
mg, 0.293 mmol), and PdCl2(dppf)·CH2Cl2 (7.2 mg, 0.0088 mmol). The vial was fitted 
with a Biotage Reseal cap and flushed with argon for 5 min before the addition of THF 
(1.0 mL) and argon-sparged H2O (0.05 mL). The reaction was heated to 65 °C for 16 h 
and then cooled to room temperature. The layers were separated, and the organic layer 
was filtered through a thin pad of silica, with rinsing with EtOAc. Solvent was removed 
in vacuo and residue purified by FCC eluting with 30% EtOAc/Pent to yield 43 (20.7 mg, 
45%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 2.0 Hz, 1H), 6.35 (d, J 
= 2.0 Hz, 1H), 5.57 (dd, J = 11.7, 5.3 Hz, 1H), 5.13 (m, 1H), 3.73 (s, 3H), 2.76 (m, 1H), 
2.48 (dd, J = 13.6, 5.4 Hz, 1H), 2.31 (m, 1H), 2.30 (s, 1H), 2.18 (m, 2H), 2.16 (s, 3H), 
2.11 (s, 3H), 2.10 (m, 1H), 1.80 (m, 1H), 1.62 (m, 3H), 1.47 (s, 3H), 1.12 (s, 3H). 13C 
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NMR (126 MHz, CDCl3) δ 201.98, 171.56, 171.11, 169.90, 142.89, 127.10, 109.16, 
94.61, 75.02, 72.02, 68.53, 64.01, 53.60, 52.01, 51.50, 43.22, 42.12, 38.21, 35.53, 30.75, 
20.56, 18.16, 16.39, 15.07, 4.67. HRMS calculated for C26H30O8: [M+Na]+: 493.1828 
(found); 493.1838 (calc). Melting point: 210-212 °C (dec.)  
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-dimethyl-
4,10-dioxo-2-(2-vinylfuran-3-yl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate. A conical vial was charged with 4 (50.0 mg, 0.0978 mmol), potassium 
vinyltrifluoroborate (14.4 mg, 0.108 mmol), Cs2CO3 (95.6 mg, 0.293 mmol), and 
PdCl2(dppf)·CH2Cl2 (7.2 mg, 0.0088 mmol). The vial was fitted with a Biotage Reseal 
cap and flushed with argon for 5 min before the addition of THF (1.0 mL) and argon-
sparged H2O (0.05 mL). The reaction was heated to 65 °C for 16 h and then cooled to 
room temperature. The layers were separated, and the organic layer was filtered through a 
thin pad of silica, with rinsing with EtOAc. Solvent was removed in vacuo and residue 
purified by FCC eluting with 30% EtOAc/Pent to yield 43 (10.5 mg, 23%) as a white 
solid that was spectroscopically identical to that prepared by Beguin et. al.4 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-ethylfuran-3-
yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate. 
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Synthesized from 5 (23.0 mg, 0.0502 mmol) using general procedure for reduction to 
yield 44 (20.3 mg, 88%) as a white solid. 1H NMR (500 MHz, CDCl3): δ 7.26 (d, J = 1.96 
Hz, 1H), 6.25 (d, J = 1.96 Hz, 1H), 5.47 (dd, J = 5.10, 11.97 Hz, 1H), 5.13 (m, 1H), 3.73 
(s, 3H), 2.77 (m, 1H), 2.63 (ddd, J = 4.66, 7.57, 15.09 Hz, 2H), 2.32 (m, 3H), 2.17 (m, 
2H), 2.16 (s, 3H), 2.09 (dd, J = 2.98, 11.41 Hz, 1H), 1.80 (m, 1H), 1.61 (m, 3H), 1.46 (s, 
3H), 1.22 (t, J = 7.56 Hz, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 202.05, 
171.58, 171.34, 169.94, 154.47, 140.96, 117.41, 108.51, 75.04, 71.89, 64.01, 53.58, 
52.00, 51.50, 43.83, 42.14, 38.20, 35.50, 30.76, 20.57, 19.69, 18.16, 16.41, 15.04, 12.94. 
HRMS calculated for C25H32O8: [M+Na]+: 483.1973 (found); 483.1995 (calc). Melting 
point: 160−162 °C (dec). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(2-
aminophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Synthesized from 21 (34.9 mg, 0.0630 mmol) 
using general reduction procedure to yield 45 (20.1 mg, 61%) as a white solid. 1H NMR 
(500 MHz, CDCl3): δ 7.48 (d, J = 1.87 Hz, 1H), 7.20 (m, 2H), 6.80 (td, J = 1.05, 7.53 
Hz, 1H), 6.76 (d, J = 7.99 Hz, 1H), 6.49 (d, J = 1.99 Hz, 1H), 5.54 (dd, J = 5.15, 11.84 
Hz, 1H), 5.12 (dd, J = 9.67, 10.47 Hz, 1H), 4.07 (s, 2H), 3.73 (s, 3H), 2.75 (m, 1H), 2.36 
(dd, J = 5.18, 13.62 Hz, 1H), 2.29 (s, 1H), 2.29 (m, 1H), 2.15 (m, 2H), 2.14 (s, 3H), 2.08 
(dd, J = 2.86, 11.31 Hz, 1H), 1.79 (dd, J = 2.97, 10.10 Hz, 1H), 1.62 (m, 3H), 1.37 (s, 
3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.85, 171.57, 171.29, 169.96, 
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150.43, 145.32, 142.41, 130.84, 130.44, 120.69, 118.17, 116.08, 114.58, 109.87, 75.00, 
72.00, 64.03, 53.59, 52.00, 51.47, 43.28, 42.11, 38.21, 35.52, 30.74, 20.58, 18.16, 16.39, 
15.03. HRMS calculated for C29H33O8: [M+Na]+: 546.2097 (found); 546.2104 (calc).!
Melting point: 200− 202 °C (dec). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(3-
aminophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Synthesized from 22 (30.3 mg, 0.0547 mmol) 
using general reduction procedure to yield 46 (17.8 mg, 62%) as a solid. 1H NMR (500 
MHz, CDCl3): δ 7.41 (d, J = 1.90 Hz, 1H), 7.23 (t, J = 7.83 Hz, 1H), 6.92 (m, 1H), 6.88 
(m, 1H), 6.69 (ddd, J = 0.88, 2.36, 8.02 Hz, 1H), 6.46 (d, J = 1.95 Hz, 1H), 5.70 (dd, J = 
5.00, 12.01 Hz, 1H), 5.14 (m, 1H), 3.73 (s, 3H), 2.77 (m, 1H), 2.40 (dd, J = 5.02, 13.66 
Hz, 1H), 2.29 (m, 2H), 2.21 (m, 2H), 2.14 (s, 3H), 2.12 (m, 1H), 1.80 (m, 1H), 1.65 (m, 
3H), 1.44 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.90, 171.59, 171.33, 
169.94, 151.91, 146.77, 141.92, 130.98, 129.79, 119.12, 117.48, 115.26, 113.49, 110.15, 
74.98, 72.05, 64.01, 53.58, 52.00, 51.62, 43.28, 42.11, 38.20, 35.53, 30.76, 20.57, 18.18, 
16.45, 15.09. HRMS calculated for C29H33O8: [M+Na]+: 546.2089 (found); 546.2104 
(calc).! Melting point: 123−127 °C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(4-
aminophenyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Synthesized from 23 (63.2 mg, 0.114 mmol) using 
general reduction procedure to yield 47 (49.6 mg, 83%) as a white solid. 1H NMR (500 
MHz, CDCl3): δ 7.36 (m, 3H), 6.74 (d, J = 8.65 Hz, 2H), 6.43 (d, J = 1.98 Hz, 1H), 5.62 
(dd, J = 5.00, 11.99 Hz, 1H), 5.14 (m, 1H), 3.83 (s, 2H), 3.73 (s, 3H), 2.77 (m, 1H), 2.39 
(dd, J = 5.01, 13.66 Hz, 1H), 2.29 (m, 2H), 2.21 (m, 2H), 2.14 (s, 3H), 2.12 (m, 1H), 1.80 
(m, 1H), 1.64 (m, 3H), 1.43 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.92, 
171.60, 171.40, 169.92, 152.62, 146.79, 141.22, 128.58, 120.46, 117.24, 115.08, 109.90, 
74.99, 72.31, 64.06, 53.59, 52.00, 51.59, 43.25, 42.12, 38.22, 35.52, 30.77, 20.57, 18.19, 
16.44, 15.05. HRMS calculated for C29H33O8: [M+Na]+: 546.2112 (found); 546.2104 
(calc).! Melting point: 222− 223 °C (dec). 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(phenylethynyl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.53 (m, 2H), 7.37 
(dd, J = 6.4, 2.6 Hz, 4H), 6.42 (d, J = 1.9 Hz, 1H), 5.66 (dd, J = 11.8, 5.4 Hz, 1H), 5.11 
(m, 1H), 3.72 (s, 3H), 2.72 (m, 1H), 2.55 (dd, J = 13.6, 5.4 Hz, 1H), 2.29 (s, 1H), 2.29 
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(dd, J = 13.6, 6.7 Hz, 1H), 2.17 (m, 3H), 2.15 (s, 3H), 1.79 (dt, J = 13.3, 2.9 Hz, 1H), 
1.65 (m, 3H), 1.49 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.95, 171.55, 
171.08, 169.89, 143.77, 134.58, 131.58, 129.05, 128.90, 128.48, 121.85, 109.72, 97.20, 
77.64, 75.01, 72.13, 63.95, 53.55, 52.00, 51.53, 43.33, 42.09, 38.15, 35.59, 30.74, 20.56, 
18.17, 16.39, 15.06. HRMS calculated for C31H32O8: [M+Na]+: 555.1982 (found); 
555.1995 (calc).!Melting point 110-113°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-((2-
methoxyphenyl)ethynyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.48 (dd, J = 7.6, 
1.7 Hz, 1H), 7.35 (m, 2H), 6.96 (td, J = 7.5, 0.9 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.41 
(d, J = 1.9 Hz, 1H), 5.69 (dd, J = 11.7, 5.4 Hz, 1H), 5.10 (m, 1H), 3.92 (s, 3H), 3.72 (s, 
3H), 2.71 (dd, J = 10.2, 6.7 Hz, 1H), 2.50 (dd, J = 13.6, 5.4 Hz, 1H), 2.28 (s, 1H), 2.28 
(m, 1H), 2.16 (m, 4H), 2.14 (s, 3H), 1.78 (dt, J = 13.4, 3.1 Hz, 1H), 1.72 (m, 1H), 1.64 
(m, 1H), 1.49 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.93, 171.58, 
171.21, 169.85, 160.17, 143.54, 135.11, 133.29, 130.57, 128.56, 120.54, 111.22, 110.74, 
109.82, 93.88, 81.46, 75.00, 72.20, 63.92, 55.87, 53.55, 51.99, 51.38, 43.17, 42.10, 38.15, 
35.61, 30.77, 20.56, 18.20, 16.38, 15.07. HRMS calculated for C32H34O9: [M+K]+: 
639.1611 (found); 639.1608 (calc).! Melting point: 108-110°C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-((2-(trifluoromethyl)phenyl)ethynyl)furan-3-
yl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) 
δ 7.69 (t, J = 6.8 Hz, 2H), 7.55 (t, J = 7.7 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.41 (d, J = 
1.9 Hz, 1H), 6.45 (d, J = 1.9 Hz, 1H), 5.72 (dd, J = 12.0, 5.1 Hz, 1H), 5.12 (m, 1H), 3.73 
(s, 3H), 2.74 (m, 1H), 2.50 (dd, J = 13.6, 5.1 Hz, 1H), 2.29 (s, 1H), 2.29 (m, 1H), 2.16 
(m, 3H), 2.14 (s, 3H), 1.80 (m, 1H), 1.65 (m, 3H), 1.51 (s, 3H), 1.13 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 201.68, 171.59, 171.07, 169.90, 144.48, 134.09, 133.68, 131.59, 
131.01 (q, 2JCF=30.64 Hz), 130.13, 128.59, 125.97 (3JCF=5.03 Hz), 123.48 (1JCF=273.47 
Hz), 120.16 (3JCF=2.08), 109.84, 93.15, 82.89, 74.98, 71.87, 63.91, 53.63, 51.99, 51.57, 
43.36, 42.08, 38.20, 35.65, 30.77, 20.56, 18.14, 16.44, 14.85. 19F NMR (376 MHz, 
CDCl3) δ -61.50. HRMS calculated for C32H31F3O8: [M+Na]+: 585.2113 (found); 
585.2101 (calc).!Melting point: 112-114°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-6a,10b-
dimethyl-4,10-dioxo-2-(2-(pent-1-yn-1-yl)furan-3-yl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 2.2 Hz, 
1H), 6.35 (d, J = 2.0 Hz, 1H), 5.57 (dd, J = 11.8, 5.3 Hz, 1H), 5.13 (m, 1H), 3.73 (s, 3H), 
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2.75 (m, 1H), 2.47 (dd, J = 13.6, 5.2 Hz, 1H), 2.44 (t, J = 7.0 Hz, 2H), 2.30 (s, 1H), 2.30 
(dd, J = 13.5, 7.2 Hz, 1H), 2.18 (m, 2H), 2.16 (s, 3H), 2.10 (dd, J = 11.7, 2.9 Hz, 1H), 
1.80 (m, 1H), 1.63 (m, 5H), 1.47 (s, 3H), 1.12 (s, 3H), 1.05 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 201.93, 171.56, 171.14, 169.89, 142.81, 135.21, 127.13, 109.18, 
98.90, 75.00, 72.14, 69.39, 64.00, 53.62, 52.01, 51.54, 43.26, 42.11, 38.22, 35.54, 30.76, 
21.77, 21.54, 20.56, 18.16, 16.40, 15.01, 13.59. HRMS calculated for C28H34O8: 
[M+Na]+: 521.2162 (found); 521.2151 (calc).! Melting point: 87-91°C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(5-
hydroxypent-1-yn-1-yl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 2.2 Hz, 
1H), 6.37 (d, J = 1.9 Hz, 1H), 5.58 (dd, J = 11.7, 5.4 Hz, 1H), 5.14 (m, 1H), 3.78 (dd, J = 
10.3, 5.0 Hz, 2H), 3.73 (s, 3H), 2.76 (m, 1H), 2.60 (td, J = 6.7, 1.4 Hz, 2H), 2.55 (dd, J = 
13.6, 5.4 Hz, 1H), 2.30 (s, 1H), 2.30 (dd, J = 13.5, 6.7 Hz, 1H), 2.18 (m, 2H), 2.17 (s, 
3H), 2.11 (dd, J = 11.6, 2.9 Hz, 1H), 1.85 (m, 3H), 1.63 (m, 3H), 1.46 (s, 3H), 1.12 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 202.37, 171.55, 171.28, 170.19, 142.79, 134.21, 
127.95, 109.38, 98.28, 75.04, 72.36, 69.98, 63.94, 61.13, 53.51, 52.01, 51.48, 43.10, 
42.11, 38.15, 35.46, 30.80, 30.74, 20.58, 18.16, 16.42, 16.00, 15.12. HRMS calculated 
for C28H34O9: [M+Na]+: 537.2090 (found); 537.2101 (calc).!Melting point 80-84°C. 
OH H
O
O
O
AcO
CO2Me
Me
Me
52
OH
! 162 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-
ethynylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. The silyl-protected alkyne was prepared according 
to general Sonogashira proceduring using 4 (75 mg, 0.147 mmol), PdCl2(PPh3)2 (5.1 mg, 
0.0073 mmol), CuI (2.8 mg, 0.015 mmol), and ethynyltrimethylsilane (0.03 mL, 0.22 
mmol) in THF/NEt3 (1:1, 2 mL). Reaction residue was purified by column 
chromatography (30% EtOAc/Pent.) to produce an inseparable mixture (42.8 mg). The 
resulting mixture was dissolved in CH2Cl2 (10 mL) and a solution of TBAF in THF (0.16 
mL, 0.16 mmol) was added dropwise. After stirring for 30 min., reaction concentrated in 
vacuo. The residue was purified by column chromatography (30 to 33% EtOAc/Pent.) to 
yield 53 as a white solid (11 mg, 16%).  1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 1.9 
Hz, 1H), 6.40 (d, J = 1.9 Hz, 1H), 5.59 (dd, J = 11.6, 5.3 Hz, 1H), 5.13 (m, 1H), 3.73 (s, 
3H), 3.61 (s, 1H), 2.76 (dd, J = 9.5, 7.4 Hz, 1H), 2.50 (dd, J = 13.6, 5.4 Hz, 1H), 2.30 (m, 
2H), 2.17 (m, 2H), 2.16 (s, 3H), 2.11 (dd, J = 11.6, 2.8 Hz, 1H), 1.80 (m, 1H), 1.63 (m, 
3H), 1.47 (s, 3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.95, 171.55, 171.01, 
169.94, 143.97, 133.53, 130.11, 109.52, 85.97, 75.04, 72.30, 71.80, 63.96, 53.60, 52.01, 
51.42, 43.01, 42.14, 38.17, 35.52, 30.74, 20.57, 18.13, 16.40, 15.19. HRMS calculated 
for C25H28O8: [M+K]+: 495.1407 (found); 495.1421 (calc).! Melting point: 170-173°C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2,5-
diphenylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared according to general procedure for 
Suzuki-Miyaura reaction using 15 (60.5 mg, 0.103 mmol), PhB(OH)2 (12.5 mg, 0.103 
mmol), Pd2dba3 (3.8 mg, 0.0041 mmol), SPhos (6.7 mg, 0.016 mmol), and K3PO4 (65.3 
mg, 0.308 mmol). Purification of the reaction mixture by column chromatography 
yielded 15 (19.2 mg, 32%) and 54 (24.4 mg, 40%) as white solids. 1H NMR (500 MHz, 
CDCl3) δ 7.71 (m, 2H), 7.64 (dd, J = 8.1, 1.0 Hz, 2H), 7.48 (t, J = 7.6 Hz, 2H), 7.40 (m, 
3H), 7.29 (m, 1H), 6.76 (s, 1H), 5.73 (dd, J = 12.0, 5.0 Hz, 1H), 5.15 (m, 1H), 3.74 (s, 
3H), 2.78 (dd, J = 10.6, 6.3 Hz, 1H), 2.48 (dd, J = 13.7, 5.0 Hz, 1H), 2.30 (m, 2H), 2.19 
(m, 3H), 2.13 (s, 3H), 1.81 (m, 2H), 1.64 (m, 2H), 1.47 (s, 3H), 1.13 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 201.90, 171.56, 171.18, 169.89, 153.31, 150.91, 130.19, 130.02, 
128.90, 128.72, 128.44, 127.79, 127.00, 123.91, 121.44, 105.48, 74.98, 72.04, 64.10, 
53.65, 52.02, 51.71, 43.29, 42.14, 38.25, 35.62, 30.78, 20.55, 18.21, 16.47, 15.09. HRMS 
calculated for C35H36O8: [M+Na]+: 607.2328 (found); 607.2308 (calc).! Melting point: 
210-215°C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2,5-
dimethylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared according to general Suzuki-Miyaura 
procedure using 15 (50.0 mg, 0.0847 mmol), MeB(OH)2 (20.3 mg, 0.339 mmol), Pd2dba3 
(3.1 mg, 0.0034 mmol), SPhos (5.6 mg, 0.014 mmol), and K3PO4 (89.8 mg, 0.254 mmol) 
to yield 55 (17.9 mg, 46%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 5.84 (s, 1H), 
5.39 (dd, J = 5.12, 11.93 Hz, 1H), 5.12 (m, 1H), 3.73 (s, 3H), 2.76 (m, 1H), 2.30 (m, 2H), 
2.22 (s, 3H), 2.20 (s, 3H), 2.17 (m, 3H), 2.16 (s, 3H), 2.06 (dd, J = 3.04, 11.52 Hz, 1H), 
1.80 (m, 1H), 1.61 (m, 3H), 1.45 (s, 3H), 1.11 (s, 3H).13C NMR (126 MHz, CDCl3) δ 
202.07, 171.59, 171.43, 169.97, 150.47, 147.51, 118.72, 104.36, 75.08, 72.28, 64.06, 
53.63, 52.01, 51.49, 43.65, 42.16, 38.24, 35.46, 30.76, 20.57, 18.16, 16.39, 15.02, 13.38, 
11.77. HRMS calculated for C25H32O8: [M+Na]+: 483.1987 (found); 483.1995 (calc). 
Melting point: 125-128 °C (dec.). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(5,5''-
diformyl-[2,2':5',2''-terfuran]-3'-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared according to general Suzuki-Miyaura 
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procedure using 15 (125 mg, 0.212 mmol), 2-formyl-5-furanylboronic acid (119 mg, 
0.847 mmol), Pd2dba3 (7.8 mg, 0.0085 mmol), SPhos (13.9 mg, 0.0334 mmol), and 
K3PO4 (270 mg, 1.272 mmol) to yield 55 (18.8 mg, 14%) as a white solid.  1H NMR (500 
MHz, CDCl3) δ 9.67 (s, 1H), 9.65 (s, 1H), 7.33 (dd, J = 3.78, 8.38 Hz, 2H), 6.95 (d, J = 
3.78 Hz, 1H), 6.85 (d, J = 3.75 Hz, 1H), 5.90 (dd, J = 4.95, 12.26 Hz, 1H), 5.11 (m, 1H), 
2.82 (dd, J = 6.96, 9.89 Hz, 1H), 2.77 (d, J = 10.67 Hz, 1H), 2.53 (dd, J = 4.98, 13.46 Hz, 
1H), 2.29 (m, 4H), 2.17 (s, 1H), 2.14 (s, 3H), 1.94 (t, J = 12.88 Hz, 1H), 1.83 (m, 2H), 
1.55 (s, 3H), 1.15 (s, 3H).13C NMR (126 MHz, CDCl3) δ 202.15, 177.14, 176.72, 171.73, 
171.38, 170.04, 152.43, 152.23, 149.72, 149.40, 145.08, 141.88, 126.74, 123.41 (broad), 
122.80 (broad), 111.41, 110.42, 109.18, 75.12, 71.92, 63.76, 53.52, 51.98, 50.61, 42.63, 
42.23, 38.00, 35.82, 30.79, 20.58, 18.10, 16.49, 15.22. HRMS calculated for C33H32O12: 
[M+Na]+: 643.1803 (found); 643.1791 (calc). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(5,5''-
diformyl-[2,2':5',2''-terfuran]-3'-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. Prepared according to general Suzuki-Miyaura 
procedure using 15 (125 mg, 0.212 mmol), 2-formyl-5-thienylboronic acid (132 mg, 
0.847 mmol), Pd2dba3 (7.8 mg, 0.0085 mmol), SPhos (13.9 mg, 0.0334 mmol), and 
K3PO4 (270 mg, 1.272 mmol) to yield 55 (17.6 mg, 13%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 9.95 (s, 1H), 9.91 (s, 1H), 7.78 (d, J = 4.01 Hz, 1H), 7.72 (d, J = 3.98 Hz, 
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1H), 7.46 (d, J = 4.00 Hz, 1H), 7.42 (d, J = 3.96 Hz, 1H), 6.86 (s, 1H), 5.86 (dd, J = 4.82, 
12.09 Hz, 1H), 5.14 (m, 1H), 3.74 (s, 3H), 2.78 (m, 1H), 2.53 (dd, J = 4.85, 13.60 Hz, 
1H), 2.31 (dd, J = 7.23, 13.58 Hz, 2H), 2.23 (d, J = 8.62 Hz, 2H), 2.19 (m, 1H), 2.14 (s, 
3H), 1.84 (m, 1H), 1.69 (dt, J = 13.31, 25.58 Hz, 3H), 1.54 (s, 3H), 1.15 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 201.75, 182.64, 182.62, 171.47, 170.55, 169.97, 148.58, 
145.25, 143.39, 142.79, 140.50, 139.32, 137.04, 136.75, 126.03, 125.31, 124.46, 109.57, 
74.96, 71.02, 63.92, 53.60, 52.06, 51.79, 42.71, 42.10, 38.13, 35.71, 30.71, 20.58, 18.13, 
16.54, 15.23. HRMS calculated for C33H32O10S2: [M+Na]+: 675.1328 (found); 675.1335 
(calc). 
  (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-
acetoxy-2-(5,5''-diformyl-[2,2':5',2''-terfuran]-3'-yl)-6a,10b-dimethyl-4,10-
dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (58) and 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(5,5''-diformyl-[2,2':5',2''-
terfuran]-3'-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate (59). An oven-dried glass tube was charged with 1 (200 mg, 1.0 equiv), 
K2HPO4 (238 mg, 3.0 equiv), and Ru(phen)3Cl2·H2O (6.6 mg, 0.02 equiv) and fitted with 
a Teflon screwcap. The reaction vessel was flushed with argon. Dry, degassed 
acetonitrile (4 mL) was added. After stirring for 10 min, triflyl chloride (0.10 mL, 2.0 
equiv) was added and the reaction vessel was placed next to a fluorescent light bulb. Two 
additional portions of 0.05 mL of triflyl chloride were added after 3 and 24 h. After 48 h, 
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the reaction was quenched by the addition of H2O (10 mL) and extracted with Et2O (3 × 
10 mL) and CH2Cl2 (3 × 10 mL). The combined organic layers were dried over Na2SO4 
and decanted, and the solvent was removed in vacuo. The resulting residue was purified 
by flash column chromatography (30−45% EtOAc/pentane) to yield 59 (70.6 mg, 31%) 
and 58 (74.8 mg, 32%) as white solids. 58: 1H NMR (500 MHz, CDCl3): δ 7.51 (s, 1H), 
6.80 (s, 1H), 5.52 (dd, J = 4.98, 11.87 Hz, 1H), 5.14 (m, 1H), 3.73 (s, 3H), 2.75 (m, 1H), 
2.52 (dd, J = 5.10, 13.39 Hz, 1H), 2.30 (s, 1H), 2.30 (dd, J = 6.28, 14.49 Hz, 1H), 2.17 (s, 
3H), 2.16 (m, 2H), 2.08 (dd, J = 2.87, 11.62 Hz, 1H), 1.80 (m, 1H), 1.60 (m, 3H), 1.46 (s, 
3H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 202.02, 171.48, 170.63, 170.00, 
143.02 (q, J = 43.05 Hz), 141.41, 126.42, 118.68 (q, J = 267.33 Hz), 110.18 (q, J = 2.69 
Hz), 75.01, 71.28, 63.88, 53.56, 52.02, 51.47, 43.18, 42.07, 38.08, 35.48, 30.72, 20.57, 
18.09, 16.43, 15.15. HRMS calculated for C24H27F3O8: [M+Na]+: 523.1570 (found); 
523.1556 (calc).!Melting point: 104−106 °C. 59: 1H NMR (500 MHz, CDCl3): δ 7.48 (s, 
1H), 6.48 (s, 1H), 5.73 (dd, J = 5.03, 12.04 Hz, 1H), 5.12 (m, 1H), 3.73 (s, 3H), 2.76 (m, 
1H), 2.41 (dd, J = 5.07, 13.56 Hz, 1H), 2.29 (s, 1H), 2.29 (dd, J = 6.37, 14.59 Hz, 1H), 
2.16 (s, 3H), 2.15 (m, 3H), 1.80 (m, 1H), 1.60 (m, 3H), 1.46 (s, 3H), 1.12 (s, 3H). 13C 
NMR (126 MHz, CDCl3): δ 201.78, 171.53, 170.62, 169.94, 144.58, 137.20 (q, J = 41.81 
Hz), 126.83 (q, J = 1.97 Hz), 119.33 (q, J = 268.22 Hz), 110.21, 74.94, 70.45, 63.75, 
53.52, 52.01, 51.45, 43.76, 42.05, 38.06, 35.63, 30.74, 20.58, 18.11, 16.46, 15.01. HRMS 
calculated for C24H27F3O8: [M+Na]+: 523.1539 (found); 523.1556 (calc).!  Melting point: 
147−150 °C. 
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(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-(hydroxymethyl)furan-3-yl)-
6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate 
(60), (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2,5-
bis(hydroxymethyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (61), (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-
acetoxy-2-(2-(acetoxymethyl)furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-
1H-benzo[f]isochromene-7-carboxylate (62), and (3-((2S,4aR,6aR,7R,9S,10aS,10bR)-
9-Acetoxy-7-(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromen-2-yl)furan-2,5-diyl)bis(methylene) diacetate (63). A mixture of 1 
(305 mg, 1.0 equiv) and paraformaldehyde (115 mg, 5.43 equiv) was dissolved in glacial 
acetic acid (5 mL) under an atmosphere of argon. The reaction was slowly warmed to 75 
°C. After 20 h, reaction was cooled to room temperature and the solvent removed in 
vacuo. The resulting residue was purified by flash column chromatography (40 → 100% 
EtOAc/pentane) to yield 1 (60.9 mg, 20%), 62 (51.4 mg, 14%), and 63 (45.2 mg, 11%), 
as well as the previously described 60 (42.2 mg, 13%) and 61 (14.7 mg, 4%). Compounds 
60 and 61 were identical to that reported by Munro et. al.5 62: 1H NMR (500 MHz, 
CDCl3): δ 7.38 (d, J = 1.88 Hz, 1H), 6.33 (d, J = 1.89 Hz, 1H), 5.65 (dd, J = 5.01, 11.99 
Hz, 1H), 5.10 (dd, J = 19.97, 28.28 Hz, 1H), 5.08 (d, J = 9.32 Hz, 2H), 3.73 (s, 3H), 2.76 
(m, 1H), 2.37 (dd, J = 5.02, 13.53 Hz, 1H), 2.29 (dd, J = 6.36, 13.55 Hz, 2H), 2.16 (m, 
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3H), 2.15 (s, 3H), 2.08 (s, 3H), 1.80 (m, 1H), 1.62 (m, 3H), 1.48 (s, 3H), 1.12 (s, 3H). 
13C NMR (126 MHz, CDCl3): δ 201.85, 171.56, 171.09, 170.57, 169.95, 146.17, 
143.25, 123.77, 109.19, 75.03, 71.61, 63.91, 56.08, 53.57, 52.00, 51.42, 43.73, 42.09, 
38.17, 35.52, 30.72, 20.78, 20.57, 18.12, 16.45, 15.06. HRMS calculated for C26H32O10: 
[M+Na]+: 527.1867 (found); 527.1893 (calc).!Melting point: 81−85 °C. 63: 1H NMR (500 
MHz, CDCl3): δ 6.36 (s, 1H), 5.62 (dd, J = 5.02, 12.00 Hz, 1H), 5.06 (d, J = 5.29 Hz, 
2H), 5.05 (m, 1H), 4.99 (d, J = 4.53 Hz, 2H), 3.73 (s, 3H), 2.76 (dd, J = 7.38, 9.44 Hz, 
1H), 2.36 (dd, J = 5.07, 13.59 Hz, 1H), 2.30 (dd, J = 6.87, 13.52 Hz, 2H), 2.16 (m, 3H), 
2.15 (s, 3H), 2.09 (s, 3H), 2.09 (s, 3H), 1.80 (m, 1H), 1.59 (m, 3H), 1.47 (s, 3H), 1.12 (s, 
3H). 13C NMR (126 MHz, CDCl3): δ 201.81, 171.55, 170.94, 170.57, 170.53, 169.99, 
150.34, 146.62, 124.73, 110.05, 75.07, 71.40, 63.92, 57.71, 56.01, 53.62, 52.01, 51.44, 
43.66, 42.12, 38.20, 35.52, 30.71, 20.87, 20.79, 20.57, 18.11, 16.43, 15.03. HRMS 
calculated for C29H36O12: [M+Na]+: 599.2110 (found); 599.2105 (calc).!Melting point: 
78−81 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-
formylfuran-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. A solution DMSO (0.08 mL, 27 equiv) in CH2Cl2 
(0.5 mL) was added to a solution of oxalyl chloride (0.05 mL, 14 equiv) in CH2Cl2 (2 
mL) at −78 °C. After 40 min, a solution of 60 (19.0 mg, 1.0 equiv) in CH2Cl2 (0.4 mL) 
was added slowly. After an additional 30 min, Et3N (0.03 mL, 5.2 equiv) was added 
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dropwise and the reaction slowly warmed to room temperature and stirred for 3 h. 
Reaction was quenched with the addition of H2O and extracted with CH2Cl2 (3 × 10 mL). 
Combined organic layers were washed sequentially with HCl (2M), saturated NaHCO3, 
and brine and then dried over Na2SO4. Solvent was removed in vacuo and the resulting 
residue purified by flash column chromatography (55% EtOAc/pentane) to yield 64 (15.3 
mg, 81%) as a solid. 1H NMR (500 MHz, CDCl3) δ 9.83 (s, 1H), 7.59 (d, J = 1.70 Hz, 
1H), 6.58 (d, J = 1.63 Hz, 1H), 5.97 (dd, J = 5.13, 11.99 Hz, 1H), 5.09 (m, 1H), 3.73 (s, 
3H), 2.74 (m, 1H), 2.52 (dd, J = 5.15, 13.34 Hz, 1H), 2.29 (s, 1H), 2.29 (m, 2H), 2.22 (m, 
1H), 2.15 (s, 1H), 2.15 (s, 3H), 1.81 (m, 1H), 1.62 (m, 3H), 1.50 (s, 3H), 1.13 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 201.65, 179.50, 171.54, 170.78, 169.98, 147.88, 147.17, 
134.31, 112.10, 74.98, 71.65, 63.85, 53.59, 52.01, 51.31, 42.79, 42.09, 38.14, 35.71, 
30.73, 20.59, 18.09, 16.45, 15.06. HRMS calculated for C24H28O9: [M+Na]+: 483.1623 
(found); 483.1631 (calc). Melting point: 215-220 °C (dec.). 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-acetoxy-2-(2-cyanofuran-
3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-
carboxylate. To a solution of 64 (30.5 mg, 1.0 equiv) in MeOH (5 mL) was added 
NH2OH·HCl (18.4 mg, 4.0 equiv) and pyridine (0.05 mL, 9.3 equiv). The resulting 
solution was heated to reflux for 5 h and then cooled to room temperature. Solvent was 
removed in vacuo, the resulting residue was extracted with CH2Cl2 (20 mL) and H2O (10 
mL), and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2 × 20 
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mL). The combined organic layers were washed sequentially with 2 N HCl and brine and 
then dried over Na2SO4. The solvent was removed in vacuo, and the resulting residue was 
placed under an atmosphere of argon and dissolved in dry CH2Cl2 (5 mL). To this 
solution were added TsCl (13.9 mg, 1.1 equiv) and DIPEA (0.03 mL, 2.6 equiv). The 
reaction was stirred at room temperature overnight before being diluted with CH2Cl2 (10 
mL) and HCl (6 M, 10 mL). The layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3 × 10 mL). Combined organic layers were washed sequentially 
with saturated NaHCO3 and brine and then dried over Na2SO4. The solvent was removed 
in vacuo and the resulting residue was purified by flash column chromatography 
(45→50% EtOAc/pentane) to give 65 (23.8 mg, 79%) as a solid. 1H NMR (500 MHz, 
CDCl3): δ 7.53 (d, J = 1.86 Hz, 1H), 6.50 (d, J = 1.88 Hz, 1H), 5.61 (dd, J = 5.17, 12.04 
Hz, 1H), 5.12 (m, 1H), 3.73 (s, 3H), 2.75 (m, 1H), 2.51 (dd, J = 5.18, 13.52 Hz, 1H), 2.31 
(s, 1H), 2.31 (m, 1H), 2.17 (m, 3H), 2.17 (s, 3H), 1.81 (m, 1H), 1.63 (m, 3H), 1.48 (s, 
3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 201.83, 171.46, 170.01, 169.99, 
147.51, 137.13, 123.63, 110.51, 110.45, 75.00, 70.98, 63.72, 53.53, 52.04, 51.50, 43.29, 
42.09, 37.99, 35.71, 30.69, 20.57, 18.06, 16.43, 14.99. HRMS calculated for C24H27NO8: 
[M+Na]+: 480.1626 (found); 480.1634 (calc). Melting point: 108−114 °C. 
 
Experimentals for Chapter III 
Compounds 1,6 2,7 3,8 9-11a,7 21a-23a,7 25a,7 27a-29a,7 32,9 and 3310 were synthesized 
according to published procedures. Compounds 9a-31a were synthesized according to the 
general acylation procedure using MiniBlock XT Parallel synthesizer and compounds 9b-
! 172 
31b and 36-44 were synthesized using general acylation procedure using standard 
glassware. 
General acylation procedure using MiniBlock XT Parallel Synthesizer. To 24 plastic 
tubes in a MiniBlock XT system, was added 3 (40 mg, 0.103 mmol) and the appropriate 
benzoic acid (0.154 mmol). The tubes were placed under an atmosphere of argon and to 
each was added a solution of EDC·HCl (29.5 mg, 0.154 mmol) and DMAP (18.8 mg, 
0.154 mmol) in CH2Cl2 (8 mL). After 5 h, reactions were concentrated to ~4 mL and 
rinsed sequentially with HCl (1 M, 4 mL), saturated NaHCO3 (4 mL), and brine (4 mL). 
The reaction mixtures were concentrated using a Genevac DD-4 evaporator. The 
concentrated samples were purified using mass-directed reverse phase HPLC.  
General acylation procedure using standard benchtop glassware. An oven-dried flask 
was charged with 6 (40 mg, 0.103 mmo), EDC·HCl (29.5 mg, 0.154 mmol), DMAP (18.8 
mg, 0.154 mmol), and the appropriate benzoic acid (0.154 mmol). To the flask was added 
CH2Cl2 (8 mL). After stirring overnight at RT the reaction was quenched with HCl (1 M, 
8 mL) and the organic layer rinsed sequentially with saturaded NaHCO3 (8 mL) and 
brine (8 mL) then dried over Na2SO4. The solvent was removed in vacuo and the 
resulting residue purified by FCC eluting with 30-35% EtOAc/Pent. Compounds <95% 
pure as indicated by HPLC were further purified by reverse phase semi-preparatory 
HPLC. 
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 (2S,4aR,6aR,7R,10aR,10bR)-methyl 2-(furan-3-yl)-9-hydroxy-
6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. A combination of CH2Cl2 (40 mL) and MeOH (40 
mL) was added to a flask containing 3 (250 mg, 0.640 mmol) and Cu(OAc)2 (349 mg, 
1.92 mmol). After stirring overnight at RT the reaction was concentrated in vacuo. The 
residue was redissovled in CH2Cl2 (40 mL) and H2O (40 mL). The aqueous layer was 
reextracted with CH2Cl2 (2 ×40 mL). The combined organic layers were washed with 
saturated NH4Cl (50 mL) and brine (50 mL) then dried over Na2SO4. The solvent was 
removed in vacuo and the residue purified FCC eluting with 12.5% EtOAc/CH2Cl2 to 
yield 3 (43 mg, 17%) and an inseparable mixture of 5, 6, and 7 (139 mg, 52%).  1H NMR 
(500 MHz, CDCl3) δ 7.44 (m, 1H), 7.42 (m, 1H), 6.41 (dd, J = 0.80, 1.79 Hz, 1H), 6.02 
(d, J = 2.50 Hz, 1H), 5.59 (dd, J = 5.25, 11.62 Hz, 1H), 3.76 (s, 3H), 3.41 (d, J = 2.49 Hz, 
1H), 3.14 (dd, J = 5.13, 13.35 Hz, 1H), 2.33 (s, 1H), 2.18 (m, 2H), 2.01 (m, 1H), 1.67 (m, 
3H), 1.36 (s, 3H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.70, 171.32, 171.25, 
146.69, 143.77, 139.38, 125.46, 112.18, 108.42, 71.92, 62.70, 55.98, 52.24, 51.27, 44.67, 
43.88, 38.20, 35.78, 17.86, 16.64, 14.72. HRMS calculated for C21H24O7: [M+Na]+: 
411.1409 (found); 411.1420 (calc). Melting point: 165-170 °C (dec). 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((2-chlorobenzoyl)oxy)-
2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. A mixture of 5, 6, and 7 (40 mg, 0.103 mmol) in 
CH2Cl2 (8 mL) was treated with benzoyl chloride (24 μL, 0.206 mmol), DIPEA (36 μL, 
0.206 mmol), and DMAP (1.3 mg, 0.206 mmol). After stirring overningt the reaction 
mixture was rinsed with HCl (1 M, 8 mL), saturated NaHCO3 (8 mL), and brine (8 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The resulting 
residue was purified by FCC 30%EtOAc/Pent. to yield 4 as a white solid (26.4 mg, 52%). 
1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 7.14 Hz, 2H), 7.62 (t, J = 7.45 Hz, 1H), 7.48 
(t, J = 7.74 Hz, 2H), 7.41 (s, 1H), 7.39 (t, J = 1.66 Hz, 1H), 6.66 (d, J = 2.15 Hz, 1H), 
6.39 (d, J = 0.95 Hz, 1H), 5.54 (dd, J = 5.28, 11.47 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 
2.13 Hz, 1H), 3.07 (dd, J = 5.34, 13.66 Hz, 1H), 2.47 (s, 1H), 2.20 (dd, J = 5.66, 8.50 Hz, 
2H), 2.12 (m, 1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 190.91, 171.39, 170.41, 164.61, 145.47, 143.67, 139.37, 133.94, 130.28, 129.98, 
128.63, 128.28, 125.43, 108.45, 72.07, 63.47, 56.51, 52.48, 51.39, 44.20, 43.81, 38.46, 
35.85, 17.95, 16.83, 14.86. HRMS calculated for C28H28O8: [M-H]-: 491.1704 (found); 
491.1711 (calc). Melting point 104-108 °C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((2-
chlorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.99 (m, 1H), 7.47 
(m, 2H), 7.42 (m, 1H), 7.40 (t, J = 1.70 Hz, 1H), 7.35 (ddd, J = 2.10, 6.53, 7.81 Hz, 1H), 
6.39 (dd, J = 0.78, 1.79 Hz, 1H), 5.52 (dd, J = 5.09, 11.69 Hz, 1H), 5.41 (m, 1H), 3.74 (s, 
3H), 2.84 (m, 1H), 2.53 (dd, J = 5.17, 13.49 Hz, 1H), 2.45 (m, 1H), 2.45 (s, 1H), 2.28 (s, 
1H), 2.18 (m, 1H), 2.11 (dd, J = 2.97, 11.36 Hz, 1H), 1.82 (m, 1H), 1.63 (dt, J = 7.15, 
20.47 Hz, 3H), 1.47 (s, 3H), 1.16 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.60, 171.55, 
171.15, 164.35, 143.73, 139.50, 134.09, 133.13, 131.92, 131.19, 128.87, 126.72, 125.14, 
108.44, 75.78, 72.04, 64.07, 53.55, 52.04, 51.36, 43.33, 42.19, 38.15, 35.48, 30.80, 18.15, 
16.49, 15.22. HRMS calculated for C28H29ClO8: [M-H]-: 535.1434 (found), 527.1449 
(calc). Melting point: 175-178 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((3-
chlorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.06 (t, J = 1.75 Hz, 
1H), 7.97 (m, 1H), 7.57 (ddd, J = 1.08, 2.16, 8.01 Hz, 1H), 7.42 (m, 2H), 7.40 (m, 1H), 
6.39 (s, 1H), 5.52 (dd, J = 5.09, 11.69 Hz, 1H), 5.39 (dd, J = 8.47, 11.69 Hz, 1H), 3.75 (s, 
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3H), 2.84 (dd, J = 5.16, 11.66 Hz, 1H), 2.52 (m, 1H), 2.46 (m, 1H), 2.46 (d, J = 11.76 Hz, 
1H), 2.26 (s, 1H), 2.19 (m, 1H), 2.11 (dd, J = 2.96, 11.42 Hz, 1H), 1.83 (m, 1H), 1.64 (m, 
3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.57, 171.50, 171.12, 
164.35, 143.73, 139.46, 134.67, 133.55, 130.81, 129.94, 129.84, 128.03, 125.18, 108.40, 
75.78, 72.04, 64.10, 53.58, 52.06, 51.40, 43.39, 42.22, 38.20, 35.49, 30.85, 18.15, 16.51, 
15.22. HRMS calculated for C28H29ClO8: [M-H]-: 527.1453 (found), 527.1478 (calc). 
Melting point: 211-213 °C. 
(2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((4-
chlorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 8.21 
Hz, 2H), 7.42 (dd, J = 7.54, 12.72 Hz, 4H), 6.38 (s, 1H), 5.52 (dd, J = 5.06, 11.68 Hz, 
1H), 5.38 (t, J = 10.01 Hz, 1H), 3.75 (s, 3H), 2.83 (m, 1H), 2.54 (dd, J = 5.00, 13.45 Hz, 
1H), 2.46 (m, 2H), 2.25 (s, 1H), 2.19 (d, J = 12.77 Hz, 1H), 2.10 (d, J = 10.90 Hz, 1H), 
1.83 (d, J = 12.43 Hz, 1H), 1.61 (m, 3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.71, 171.53, 171.10, 164.67, 143.74, 140.04, 139.45, 131.28, 128.87, 
127.53, 125.17, 108.39, 75.64, 72.04, 64.13, 53.59, 52.06, 51.42, 43.42, 42.22, 38.21, 
35.50, 30.90, 18.15, 16.51, 15.22. HRMS calculated for C28H29ClO8: [M-H]-: 527.1452 
(found), 527.1478 (calc). Melting point: 187-189 °C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((2-
fluorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.01 (td, J = 1.81, 
7.61 Hz, 1H), 7.56 (m, 1H), 7.42 (m, 1H), 7.40 (t, J = 1.70 Hz, 1H), 7.23 (td, J = 1.03, 
7.79 Hz, 1H), 7.16 (ddd, J = 0.78, 8.37, 10.74 Hz, 1H), 6.39 (dd, J = 0.76, 1.76 Hz, 1H), 
5.51 (dd, J = 5.09, 11.70 Hz, 1H), 5.41 (m, 1H), 3.75 (s, 3H), 2.84 (m, 1H), 2.53 (dd, J = 
5.15, 13.46 Hz, 1H), 2.46 (m, 1H), 2.46 (m, 1H), 2.29 (s, 1H), 2.20 (dd, J = 3.52, 6.22 
Hz, 1H), 2.11 (dd, J = 2.95, 11.37 Hz, 1H), 1.82 (m, 1H), 1.63 (m, 3H), 1.46 (s, 3H), 1.17 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.60, 171.57, 171.18, 163.01 (d, J = 3.66 Hz), 
162.25 (d, J = 261.26 Hz), 143.73, 139.51, 135.11 (d, J = 9.09 Hz),132.25, 125.15, 
124.08 (d, J = 3.92 Hz), 117.68 (d, J = 9.12 Hz), 117.11 (d, J = 22.02 Hz), 108.44, 75.65, 
72.05, 64.03, 53.59, 52.03, 51.38, 43.31, 42.21, 38.18, 35.48, 30.84, 18.16, 16.49, 15.21. 
HRMS calculated for C28H29FO8: [M-H]-: 535.1756 (found), 535.1744 (calc). Melting 
point: 203-205 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((3-
fluorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 7.68 
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Hz, 1H), 7.76 (d, J = 9.24 Hz, 1H), 7.45 (dd, J = 7.84, 13.65 Hz, 1H), 7.41 (d, J = 6.85 
Hz, 2H), 7.30 (t, J = 8.42 Hz, 1H), 6.39 (s, 1H), 5.52 (dd, J = 5.05, 11.64 Hz, 1H), 5.39 
(m, 1H), 3.75 (s, 3H), 2.84 (dd, J = 6.66, 10.10 Hz, 1H), 2.54 (m, 1H), 2.47 (dd, J = 8.03, 
13.38 Hz, 2H), 2.26 (s, 1H), 2.19 (d, J = 11.76 Hz, 1H), 2.10 (d, J = 11.31 Hz, 1H), 1.84 
(d, J = 12.48 Hz, 1H), 1.65 (m, 3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 201.60, 171.51, 171.11, 164.41 (d, J = 3.05 Hz), 162.54 (d, J = 247.45 Hz), 
143.74, 139.46, 131.21 (d, J = 7.54 Hz), 130.19 (d, J = 7.75 Hz), 125.66 (d, J = 3.05 Hz), 
125.18, 120.63 (d, J = 21.24 Hz), 116.80 (d, J = 23.20 Hz)108.40, 75.76, 72.05, 64.12, 
53.59, 52.07, 51.41, 43.41, 42.22, 38.21, 35.50, 30.86, 18.16, 16.51, 15.22. HRMS 
calculated for C28H29FO8: [M-H]-: 511.1755 (found), 511.1774 (calc). Melting point: 168-
170 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((4-
fluorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (400 MHz, CDCl3) δ 8.11 (dd, J = 5.56, 
8.04 Hz, 2H), 7.41 (d, J = 6.28 Hz, 2H), 7.13 (t, J = 8.38 Hz, 2H), 6.38 (s, 1H), 5.52 (dd, 
J = 5.26, 11.68 Hz, 1H), 5.38 (t, J = 9.93 Hz, 1H), 3.75 (s, 3H), 2.83 (m, 1H), 2.54 (dd, J 
= 5.02, 13.46 Hz, 1H), 2.47 (dd, J = 7.18, 13.51 Hz, 1H), 2.45 (d, J = 9.27 Hz, 1H), 2.25 
(s, 1H), 2.19 (d, J = 12.23 Hz, 1H), 2.10 (d, J = 10.65 Hz, 1H), 1.83 (d, J = 12.13 Hz, 
1H), 1.65 (m, 3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.60, 
171.51, 171.11, 166.11 (d, J = 254.86 Hz), 143.74, 139.46, 132.53 (d, J = 9.47 Hz), 
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125.32 (d, J = 2.92 Hz), 125.18, 115.72 (d, J = 22.06 Hz), 108.40, 75.76, 72.05, 64.12, 
53.59, 52.07, 51.41, 43.41, 42.22, 38.21, 35.50, 30.86, 18.16, 16.51, 15.22. HRMS 
calculated for C28H29FO8: [M-H]-: 511.1757 (found), 511.1774 (calc). Melting point: 139-
142 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((2-methylbenzoyl)oxy)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.01 (m, 1H), 7.43 
(m, 2H), 7.40 (t, J = 1.71 Hz, 1H), 7.26 (m, 2H), 6.39 (dd, J = 0.80, 1.81 Hz, 1H), 5.53 
(dd, J = 5.09, 11.68 Hz, 1H), 5.39 (m, 1H), 3.75 (s, 3H), 2.83 (dd, J = 7.74, 9.10 Hz, 1H), 
2.60 (s, 3H), 2.55 (dd, J = 5.17, 13.49 Hz, 1H), 2.45 (td, J = 2.09, 9.61 Hz, 2H), 2.25 (s, 
1H), 2.19 (m, 1H), 2.11 (dd, J = 2.98, 11.54 Hz, 1H), 1.82 (m, 1H), 1.65 (m, 3H), 1.48 (s, 
3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.96, 171.63, 171.16, 166.41, 
143.73, 140.52, 139.46, 132.50, 131.72, 130.93, 128.55, 125.84, 125.19, 108.42, 75.26, 
72.07, 64.16, 53.69, 52.03, 51.45, 43.46, 42.18, 38.20, 35.49, 30.96, 21.72, 18.16, 16.49, 
15.23. HRMS calculated for C29H32O8: [M-H]-: 507.2002 (found), 507.2024 (calc). 
Melting point: 108-112 °C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((3-methylbenzoyl)oxy)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (400 MHz, CDCl3) δ 7.82 (m, 2H), 7.40 
(m, 3H), 7.34 (t, J = 7.52 Hz, 1H), 6.39 (d, J = 0.97 Hz, 1H), 5.52 (dd, J = 5.12, 11.62 
Hz, 1H), 5.40 (m, 1H), 3.75 (s, 3H), 2.83 (dd, J = 5.79, 11.05 Hz, 1H), 2.55 (dd, J = 5.15, 
13.45 Hz, 1H), 2.47 (m, 2H), 2.41 (s, 3H), 2.26 (s, 1H), 2.19 (m, 1H), 2.10 (dd, J = 2.95, 
11.29 Hz, 1H), 1.83 (dd, J = 2.81, 10.10 Hz, 1H), 1.61 (m, 3H), 1.47 (s, 3H), 1.18 (s, 
3H).13C NMR (126 MHz, CDCl3) δ 201.91, 171.62, 171.18, 165.71, 143.72, 139.46, 
138.32, 134.30, 130.38, 128.96, 128.40, 127.07, 125.20, 108.41, 75.41, 72.08, 64.11, 
53.66, 52.03, 51.44, 43.41, 42.22, 38.23, 35.49, 30.95, 21.26, 18.17, 16.51, 15.22. HRMS 
calculated for C29H32O8: [M-H]-: 507.2001 (found), 507.2024 (calc). Melting point: 147-
149 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 2-(furan-3-yl)-
6a,10b-dimethyl-9-((4-methylbenzoyl)oxy)-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.20 
Hz, 2H), 7.41 (m, 2H), 7.25 (d, J = 0.56 Hz, 2H), 6.39 (dd, J = 0.82, 1.80 Hz, 1H), 5.52 
(dd, J = 5.09, 11.68 Hz, 1H), 5.38 (dd, J = 9.70, 10.47 Hz, 1H), 3.75 (s, 3H), 2.83 (m, 
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1H), 2.55 (dd, J = 5.19, 13.46 Hz, 1H), 2.45 (m, 2H), 2.42 (s, 3H), 2.25 (s, 1H), 2.18 (m, 
1H), 2.10 (dd, J = 2.94, 11.53 Hz, 1H), 1.82 (m, 1H), 1.60 (dd, J = 11.58, 23.61 Hz, 3H), 
1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.96, 171.63, 171.18, 165.58, 
144.31, 143.71, 139.45, 129.94, 129.20, 126.31, 125.20, 108.41, 75.29, 72.08, 64.12, 
53.67, 52.02, 51.45, 43.42, 42.20, 38.22, 35.49, 30.98, 21.75, 18.17, 16.50, 15.22. HRMS 
calculated for C29H32O8: [M-H]-: 507.2002 (found), 507.2024 (calc). Melting point: 188-
190 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromen-9-yl picolinate. 1H NMR (500 MHz, CDCl3) δ 8.82 (ddd, J = 0.79, 
1.58, 4.71 Hz, 1H), 8.17 (dt, J = 0.97, 7.85 Hz, 1H), 7.87 (td, J = 1.74, 7.74 Hz, 1H), 7.52 
(ddd, J = 1.17, 4.74, 7.63 Hz, 1H), 7.42 (m, 1H), 7.40 (t, J = 1.70 Hz, 1H), 6.38 (dd, J = 
0.79, 1.76 Hz, 1H), 5.50 (m, 2H), 3.74 (s, 3H), 2.85 (dd, J = 3.64, 13.09 Hz, 1H), 2.53 
(m, 3H), 2.28 (s, 1H), 2.19 (m, 1H), 2.11 (dd, J = 2.97, 11.45 Hz, 1H), 1.83 (m, 1H), 1.63 
(m, 3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.24, 171.45, 
171.15, 164.07, 150.23, 147.13, 143.72, 139.39, 137.09, 127.30, 125.58, 125.23, 108.38, 
76.24, 72.09, 64.14, 53.69, 52.03, 51.41, 43.34, 42.27, 38.22, 35.51, 30.85, 18.17, 16.54, 
15.21. HRMS calculated for C27H29O8: [M-H]-: 494.1804 (found), 494.1820 (calc). 
Melting point: 243 °C (dec). 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromen-9-yl isonicotinate. 1H NMR (500 MHz, CDCl3) δ 8.82 (s, 2H), 7.89 
(d, J = 5.48 Hz, 2H), 7.42 (m, 1H), 7.40 (t, J = 1.70 Hz, 1H), 6.39 (dd, J = 0.81, 1.78 Hz, 
1H), 5.53 (dd, J = 5.09, 11.69 Hz, 1H), 5.40 (dd, J = 8.49, 11.65 Hz, 1H), 3.76 (s, 3H), 
2.85 (dd, J = 5.19, 11.64 Hz, 1H), 2.52 (dd, J = 5.04, 13.53 Hz, 1H), 2.47 (m, 2H), 2.27 
(s, 1H), 2.20 (m, 1H), 2.11 (dd, J = 2.94, 11.38 Hz, 1H), 1.83 (m, 1H), 1.65 (ddd, J = 
7.44, 17.21, 30.97 Hz, 3H), 1.46 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
201.21, 171.43, 171.02, 164.15, 150.74, 143.76, 139.46, 136.32, 125.16, 123.00, 108.38, 
76.12, 72.00, 64.14, 53.51, 52.11, 51.38, 43.40, 42.25, 38.20, 35.51, 30.76, 18.15, 16.52, 
15.22. HRMS calculated for C27H29O8: [M-H]-: 494.1807 (found), 494.1820 (calc). 
Melting point: 110-116 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((furan-3-
carbonyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.10 (dd, J = 0.76, 
1.51 Hz, 1H), 7.45 (m, 1H), 7.41 (dt, J = 0.84, 1.59 Hz, 1H), 7.40 (t, J = 1.71 Hz, 1H), 
6.77 (dd, J = 0.75, 1.90 Hz, 1H), 6.38 (dd, J = 0.82, 1.80 Hz, 1H), 5.52 (dd, J = 5.09, 
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11.70 Hz, 1H), 5.32 (m, 1H), 3.74 (s, 3H), 2.81 (m, 1H), 2.53 (dd, J = 5.17, 13.46 Hz, 
1H), 2.42 (m, 1H), 2.40 (d, J = 10.04 Hz, 1H), 2.24 (s, 1H), 2.18 (m, 1H), 2.10 (dd, J = 
2.94, 11.60 Hz, 1H), 1.82 (m, 1H), 1.63 (m, 3H), 1.46 (s, 3H), 1.15 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 201.88, 171.57, 171.13, 161.90, 148.44, 143.97, 143.73, 139.45, 
125.18, 118.28, 109.84, 108.40, 74.99, 72.05, 64.08, 53.61, 52.04, 51.42, 43.40, 42.19, 
38.21, 35.48, 30.86, 18.16, 16.49, 15.21. HRMS calculated for C26H28O9: [M-H]-: 
494.1641 (found), 483.1661 (calc). Melting point: 214-215 °C. 
 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((furan-2-
carbonyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.62 (dd, J = 0.82, 
1.71 Hz, 1H), 7.41 (dt, J = 0.81, 1.58 Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 7.29 (dd, J = 
0.81, 3.52 Hz, 1H), 6.55 (dd, J = 1.73, 3.52 Hz, 1H), 6.38 (dd, J = 0.82, 1.80 Hz, 1H), 
5.52 (dd, J = 5.07, 11.69 Hz, 1H), 5.37 (dd, J = 8.55, 11.64 Hz, 1H), 3.74 (s, 3H), 2.82 
(dd, J = 5.21, 11.60 Hz, 1H), 2.53 (dd, J = 5.17, 13.46 Hz, 1H), 2.45 (m, 1H), 2.44 (d, J = 
11.30 Hz, 1H), 2.25 (s, 1H), 2.18 (m, 1H), 2.10 (dd, J = 2.93, 11.51 Hz, 1H), 1.82 (m, 
1H), 1.63 (m, 3H), 1.46 (s, 3H), 1.16 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.58, 
171.49, 171.14, 157.44, 147.05, 143.72, 143.60, 139.42, 125.19, 119.22, 112.10, 108.39, 
75.28, 72.07, 64.06, 53.59, 52.04, 51.38, 43.32, 42.20, 38.19, 35.48, 30.84, 18.15, 16.50, 
15.21. HRMS calculated for C26H28O9: [M-H]-: 494.1641 (found), 483.1661 (calc). 
Melting point: 140-145 °C. 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((2-nitrobenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.01 (dd, J = 
1.13, 7.99 Hz, 1H), 7.95 (m, 1H), 7.75 (td, J = 1.34, 7.55 Hz, 1H), 7.70 (m, 1H), 7.43 (dt, 
J = 0.80, 1.57 Hz, 1H), 7.40 (t, J = 1.71 Hz, 1H), 6.76 (d, J = 2.17 Hz, 1H), 6.40 (dd, J = 
0.79, 1.82 Hz, 1H), 5.57 (dd, J = 5.27, 11.50 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.17 Hz, 
1H), 3.07 (dd, J = 5.34, 13.66 Hz, 1H), 2.47 (s, 1H), 2.20 (dt, J = 2.62, 5.97 Hz, 2H), 2.13 
(m, 1H), 1.70 (m, 3H), 1.39 (s, 3H), 1.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.65, 
171.30, 170.03, 163.26, 147.79, 144.66, 143.72, 139.44, 133.33, 132.39, 130.97, 130.36, 
126.32, 125.39, 124.17, 108.48, 71.99, 63.50, 56.42, 52.54, 51.31, 44.20, 43.72, 38.35, 
35.83, 17.91, 16.77, 14.84. HRMS calculated for C28H27NO10: [M-H]-: 536.1539 (found), 
536.1562 (calc). Melting point: 114-118 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((3-nitrobenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.95 (m, 1H), 
8.49 (ddd, J = 1.08, 2.27, 8.22 Hz, 1H), 8.43 (m, 1H), 7.72 (t, J = 8.01 Hz, 1H), 7.42 (d, J 
= 0.73 Hz, 1H), 7.39 (t, J = 1.69 Hz, 1H), 6.73 (d, J = 2.15 Hz, 1H), 6.39 (dd, J = 0.73, 
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1.71 Hz, 1H), 5.55 (dd, J = 5.27, 11.54 Hz, 1H), 3.81 (s, 3H), 3.62 (d, J = 2.14 Hz, 1H), 
3.05 (dd, J = 5.35, 13.65 Hz, 1H), 2.50 (s, 1H), 2.22 (m, 2H), 2.14 (m, 1H), 1.71 (m, 3H), 
1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.55, 171.28, 170.21, 162.48, 
148.32, 145.11, 143.71, 139.38, 135.84, 130.56, 130.14, 129.98, 128.29, 125.40, 125.24, 
108.44, 71.99, 63.45, 56.42, 52.56, 51.29, 44.29, 43.77, 38.41, 35.87, 17.94, 16.82, 14.85. 
HRMS calculated for C28H27NO10: [M-H]-: 536.1553 (found), 536.1562 (calc). Melting 
point: 117-121 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((4-nitrobenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 
8.82 Hz, 2H), 8.29 (d, J = 8.81 Hz, 2H), 7.41 (d, J = 9.79 Hz, 2H), 6.72 (d, J = 2.00 Hz, 
1H), 6.39 (s, 1H), 5.55 (dd, J = 5.26, 11.50 Hz, 1H), 3.81 (s, 3H), 3.62 (d, J = 1.92 Hz, 
1H), 3.05 (dd, J = 5.31, 13.62 Hz, 1H), 2.49 (s, 1H), 2.22 (m, 2H), 2.13 (d, J = 13.50 Hz, 
1H), 1.71 (m, 3H), 1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.55, 
171.24, 170.23, 162.69, 151.02, 145.12, 143.72, 139.39, 133.73, 131.41, 130.56, 125.39, 
123.76, 108.43, 71.98, 63.49, 56.42, 52.57, 51.31, 44.29, 43.80, 38.43, 35.88, 17.93, 
16.82, 14.85. HRMS calculated for C28H27NO10: [M-H]-: 536.1551 (found), 536.1562 
(calc). Melting point: 125 °C (dec). 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((2-chlorobenzoyl)oxy)-
2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.06 (m, 1H), 7.50 
(m, 2H), 7.42 (dt, J = 0.86, 1.62 Hz, 1H), 7.39 (t, J = 1.73 Hz, 1H), 7.37 (ddd, J = 2.71, 
5.96, 7.87 Hz, 1H), 6.69 (d, J = 2.18 Hz, 1H), 6.39 (dd, J = 0.81, 1.81 Hz, 1H), 5.55 (dd, 
J = 5.24, 11.52 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.18 Hz, 1H), 3.08 (dd, J = 5.33, 13.67 
Hz, 1H), 2.46 (s, 1H), 2.20 (ddd, J = 2.78, 6.26, 9.64 Hz, 2H), 2.12 (m, 1H), 1.69 (m, 
3H), 1.39 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.73, 171.35, 170.30, 
163.02, 145.20, 143.69, 139.39, 134.79, 133.65, 132.39, 131.41, 130.30, 127.73, 126.78, 
125.40, 108.45, 72.06, 63.53, 56.50, 52.49, 51.37, 44.20, 43.82, 38.43, 35.85, 17.94, 
16.85, 14.85. HRMS calculated for C28H27ClO8: [M-H]-: 525.1306 (found), 525.1322 
(calc). Melting point: 93-96 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((3-chlorobenzoyl)oxy)-
2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.09 (s, 1H), 7.99 
(m, 1H), 7.60 (ddd, J = 1.07, 2.15, 8.02 Hz, 1H), 7.44 (d, J = 7.97 Hz, 1H), 7.41 (dd, J = 
0.86, 1.60 Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 6.67 (d, J = 2.18 Hz, 1H), 6.39 (dd, J = 
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0.81, 1.80 Hz, 1H), 5.54 (dd, J = 5.26, 11.51 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 2.18 Hz, 
1H), 3.05 (dd, J = 5.33, 13.66 Hz, 1H), 2.47 (s, 1H), 2.21 (m, 2H), 2.12 (m, 1H), 1.69 (m, 
3H), 1.37 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.73, 171.33, 170.30, 
163.38, 145.26, 143.68, 139.37, 134.80, 133.96, 130.28, 130.21, 130.03, 129.97, 128.38, 
125.42, 108.45, 72.03, 63.43, 56.45, 52.50, 51.33, 44.23, 43.78, 38.43, 35.85, 17.94, 
16.81, 14.84. HRMS calculated for C28H27ClO8: [M-H]-: 525.1309 (found), 525.1322 
(calc). Melting point: 103-108 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((4-
chlorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H 
NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.25 Hz, 2H), 7.46 (d, J = 8.10 Hz, 2H), 7.40 (d, 
J = 7.59 Hz, 2H), 6.67 (s, 1H), 6.39 (s, 1H), 5.54 (dd, J = 5.28, 11.34 Hz, 1H), 3.80 (s, 
3H), 3.59 (s, 1H), 3.06 (dd, J = 5.25, 13.62 Hz, 1H), 2.46 (s, 1H), 2.20 (m, 2H), 2.12 (d, J 
= 13.38 Hz, 1H), 1.71 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
190.82, 171.32, 170.34, 163.73, 145.31, 143.69, 140.53, 139.38, 131.64, 130.16, 129.02, 
126.75, 125.42, 108.44, 72.03, 63.48, 56.48, 52.50, 51.37, 44.23, 43.82, 38.46, 35.86, 
17.94, 16.82, 14.86. HRMS calculated for C28H27ClO8: [M-H]-: 525.1307 (found), 
525.1322 (calc). Melting point: 165-167 °C. 
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 (2S,4aR,6aR,7R,9S,10aS,10bR)-Methyl 9-((2-
fluorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.05 (td, J = 1.80, 
7.60 Hz, 1H), 7.60 (m, 1H), 7.41 (m, 1H), 7.39 (t, J = 1.71 Hz, 1H), 7.25 (dd, J = 0.92, 
7.60 Hz, 1H), 7.19 (ddd, J = 0.83, 8.39, 10.75 Hz, 1H), 6.68 (d, J = 2.17 Hz, 1H), 6.39 
(dd, J = 0.78, 1.78 Hz, 1H), 5.54 (dd, J = 5.24, 11.50 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 
2.18 Hz, 1H), 3.07 (dd, J = 5.34, 13.67 Hz, 1H), 2.46 (s, 1H), 2.20 (m, 2H), 2.12 (m, 1H), 
1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.69, 171.38, 
170.31, 162.45 (d, J = 262.15 Hz), 161.86 (d, J = 3.97 Hz), 145.22, 143.68, 139.37, 
135.66 (d, J = 9.16 Hz), 132.63, 130.20, 125.42, 124.21 (d, J = 3.85 Hz, H), 117.21 (d, J 
= 22.01 Hz), 116.81 (d, J = 9.10 Hz), 108.45, 72.05, 63.47, 56.48, 52.47, 51.34, 44.19, 
43.81, 38.41, 35.85, 17.94, 16.83, 14.84. HRMS calculated for C28H27FO8: [M-H]-: 
509.1601 (found), 509.1617 (calc). Melting point: 99-102 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((3-fluorobenzoyl)oxy)-
2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.91 (m, 1H), 7.79 
(ddd, J = 1.54, 2.51, 9.11 Hz, 1H), 7.47 (td, J = 5.47, 8.03 Hz, 1H), 7.41 (m, 1H), 7.39 (t, 
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J = 1.70 Hz, 1H), 7.33 (tdd, J = 0.95, 2.64, 8.31 Hz, 1H), 6.68 (d, J = 2.17 Hz, 1H), 6.39 
(dd, J = 0.79, 1.78 Hz, 1H), 5.54 (dd, J = 5.26, 11.54 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 
2.17 Hz, 1H), 3.06 (dd, J = 5.34, 13.66 Hz, 1H), 2.47 (s, 1H), 2.20 (m, 2H), 2.12 (m, 1H), 
1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H).13C NMR (126 MHz, CDCl3) δ 190.74, 171.33, 
170.31, 163.45 (d, J = 3.07 Hz), 162.54 (d, J = 247.83 Hz), 145.29, 143.69, 139.37, 
130.37 (d, J = 15.18 Hz), 130.28 (d, J = 21.81 Hz), 126.05 (d, J = 3.05 Hz), 125.42, 
121.07 (d, J = 21.24 Hz), 117.15 (d, J = 23.33 Hz)108.44, 72.03, 63.46, 56.46, 52.50, 
51.35, 44.23, 43.80, 38.44, 35.86, 17.94, 16.81, 14.85. HRMS calculated for C28H27FO8: 
[M-H]-: 509.1610 (found), 509.1617 (calc). Melting point: 101-105 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((4-
fluorobenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H 
NMR (500 MHz, CDCl3) δ 8.13 (m, 2H), 7.41 (m, 1H), 7.39 (t, J = 1.70 Hz, 1H), 7.16 (t, 
J = 8.66 Hz, 2H), 6.66 (d, J = 2.17 Hz, 1H), 6.39 (dd, J = 0.79, 1.76 Hz, 1H), 5.54 (dd, J 
= 5.27, 11.53 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 2.16 Hz, 1H), 3.06 (dd, J = 5.34, 13.66 
Hz, 1H), 2.47 (s, 1H), 2.21 (m, 2H), 2.12 (m, 1H), 1.70 (m, 3H), 1.38 (s, 3H), 1.24 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 190.91, 171.35, 170.37, 166.34 (d, J = 255.72 
Hz),163.58, 145.35, 143.68, 139.38, 132.96 (d, J = 9.55 Hz), 130.12, 125.43, 124.55 (d, J 
= 2.94 Hz), 115.90 (d, J = 22.11 Hz), 108.45, 72.03, 63.46, 56.47, 52.49, 51.36, 44.22, 
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43.81, 38.45, 35.85, 17.95, 16.82, 14.85. HRMS calculated for C28H27FO8: [M-H]-: 
509.1611 (found), 509.1617 (calc). Melting point: 98-101 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((2-methylbenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 8.07 (dd, J = 
1.35, 8.12 Hz, 1H), 7.46 (td, J = 1.39, 7.54 Hz, 1H), 7.42 (m, 1H), 7.39 (t, J = 1.70 Hz, 
1H), 7.29 (m, 2H), 6.64 (d, J = 2.18 Hz, 1H), 6.39 (dd, J = 0.79, 1.78 Hz, 1H), 5.55 (dd, J 
= 5.25, 11.54 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.17 Hz, 1H), 3.08 (dd, J = 5.31, 13.68 
Hz, 1H), 2.61 (s, 3H), 2.46 (s, 1H), 2.20 (m, 2H), 2.11 (m, 1H), 1.68 (m, 3H), 1.38 (s, 
3H), 1.25 (d, J = 3.55 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 191.04, 171.40, 170.45, 
165.16, 145.51, 143.66, 141.37, 139.39, 133.01, 131.86, 131.35, 129.94, 127.46, 125.94, 
125.44, 108.48, 72.06, 63.50, 56.52, 52.45, 51.39, 44.16, 43.80, 38.43, 35.84, 21.72, 
17.95, 16.85, 14.85. HRMS calculated for C29H30O8: [M-H]-: 505.1859 (found), 505.1868 
(calc). Melting point: 94-101 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((3-methylbenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.93 (m, 1H), 
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7.91 (d, J = 8.09 Hz, 1H), 7.43 (d, J = 7.49 Hz, 1H), 7.41 (dt, J = 0.86, 1.60 Hz, 1H), 7.39 
(t, J = 1.71 Hz, 1H), 7.37 (t, J = 7.63 Hz, 1H), 6.65 (d, J = 2.18 Hz, 1H), 6.39 (dd, J = 
0.78, 1.79 Hz, 1H), 5.54 (dd, J = 5.29, 11.58 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 2.18 Hz, 
1H), 3.07 (dd, J = 5.34, 13.67 Hz, 1H), 2.48 (s, 1H), 2.41 (s, 3H), 2.20 (m, 2H), 2.12 (m, 
1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.95, 
171.41, 170.42, 164.79, 145.50, 143.66, 139.38, 138.48, 134.72, 130.76, 129.89, 128.53, 
128.17, 127.44, 125.44, 108.47, 72.06, 63.42, 56.49, 52.45, 51.36, 44.19, 43.78, 38.45, 
35.84, 21.25, 17.95, 16.82, 14.85. HRMS calculated for C29H30O8: [M-H]-: 505.1856 
(found), 505.1868 (calc). Melting point: 96-102 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-9-((4-methylbenzoyl)oxy)-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-
1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 
8.21 Hz, 2H), 7.41 (m, 1H), 7.39 (t, J = 1.70 Hz, 1H), 7.28 (d, J = 7.99 Hz, 2H), 6.64 (d, 
J = 2.18 Hz, 1H), 6.39 (dd, J = 0.78, 1.77 Hz, 1H), 5.54 (dd, J = 5.25, 11.54 Hz, 1H), 
3.80 (s, 3H), 3.59 (d, J = 2.18 Hz, 1H), 3.07 (dd, J = 5.34, 13.67 Hz, 1H), 2.47 (s, 1H), 
2.43 (s, 3H), 2.20 (m, 2H), 2.12 (m, 1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 190.99, 171.41, 170.43, 164.66, 145.50, 144.84, 143.66, 
139.38, 130.32, 129.87, 129.34, 125.51, 125.44, 108.47, 72.07, 63.45, 56.51, 52.45, 
51.38, 44.18, 43.80, 38.46, 35.84, 21.80, 17.96, 16.82, 14.86. HRMS calculated for 
C29H30O8: [M-H]-: 505.1856 (found), 505.1868 (calc). Melting point: 184-185 °C (dec). 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-9-((2-
methoxybenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
8.03 (dd, J = 1.81, 8.14 Hz, 1H), 7.55 (m, 1H), 7.41 (dt, J = 0.80, 1.54 Hz, 1H), 7.39 (t, J 
= 1.71 Hz, 1H), 7.02 (dd, J = 4.45, 11.25 Hz, 2H), 6.62 (d, J = 2.19 Hz, 1H), 6.39 (dd, J = 
0.78, 1.79 Hz, 1H), 5.54 (dd, J = 5.23, 11.55 Hz, 1H), 3.92 (s, 3H), 3.79 (s, 3H), 3.57 (d, 
J = 2.19 Hz, 1H), 3.08 (dd, J = 5.32, 13.69 Hz, 1H), 2.44 (s, 1H), 2.19 (dt, J = 2.79, 8.76 
Hz, 2H), 2.11 (m, 1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 191.03, 171.46, 170.44, 163.24, 160.28, 145.48, 143.66, 139.37, 134.93, 
132.71, 129.88, 125.43, 120.22, 117.30, 112.04, 108.47, 72.10, 63.49, 56.57, 56.03, 
52.41, 51.40, 44.13, 43.86, 38.44, 35.83, 17.96, 16.85, 14.84. HRMS calculated for 
C29H30O9: [M-H]-: 505.1802 (found), 521.1817 (calc). Melting point: 110-114 °C. 
  (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-9-((3-
methoxybenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
7.71 (m, 1H), 7.60 (dd, J = 1.53, 2.55 Hz, 1H), 7.41 (m, 1H), 7.39 (m, 2H), 7.17 (ddd, J = 
0.93, 2.68, 8.29 Hz, 1H), 6.66 (d, J = 2.18 Hz, 1H), 6.39 (dd, J = 0.77, 1.77 Hz, 1H), 5.55 
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(dd, J = 5.25, 11.53 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.60 (d, J = 2.18 Hz, 1H), 3.07 
(dd, J = 5.34, 13.67 Hz, 1H), 2.47 (s, 1H), 2.21 (m, 2H), 2.12 (m, 1H), 1.69 (m, 3H), 1.38 
(s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.85, 171.38, 170.41, 164.50, 
159.67, 145.48, 143.68, 139.38, 129.95, 129.66, 129.48, 125.43, 122.74, 120.78, 114.31, 
108.46, 72.06, 63.47, 56.50, 55.50, 52.48, 51.38, 44.21, 43.82, 38.47, 35.85, 17.96, 16.82, 
14.86. HRMS calculated! for! C29H30O9: [M-H]-: 505.1799 (found), 521.1817 (calc). 
Melting point: 106-108 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-9-((4-
methoxybenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
8.06 (d, J = 9.01 Hz, 2H), 7.41 (dt, J = 0.85, 1.61 Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 6.95 
(d, J = 9.01 Hz, 2H), 6.63 (d, J = 2.19 Hz, 1H), 6.39 (dd, J = 0.81, 1.80 Hz, 1H), 5.54 
(dd, J = 5.24, 11.53 Hz, 1H), 3.88 (s, 3H), 3.80 (s, 3H), 3.59 (d, J = 2.19 Hz, 1H), 3.07 
(dd, J = 5.34, 13.67 Hz, 1H), 2.47 (s, 1H), 2.20 (m, 2H), 2.12 (m, 1H), 1.70 (m, 3H), 1.38 
(s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.11, 171.42, 170.46, 164.30, 
164.15, 145.53, 143.66, 139.37, 132.46, 129.82, 125.44, 120.54, 113.90, 108.46, 72.08, 
63.46, 56.53, 55.53, 52.45, 51.41, 44.18, 43.82, 38.48, 35.84, 17.96, 16.82, 14.87. HRMS 
calculated for C29H30O9: [M-H]-: 505.1801 (found), 521.1817 (calc). Melting point: 192-
195 °C. 
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  (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl picolinate. 1H NMR (500 MHz, CDCl3) δ 8.82 
(ddd, J = 0.87, 1.69, 4.72 Hz, 1H), 8.20 (dt, J = 1.00, 7.85 Hz, 1H), 7.90 (td, J = 1.74, 
7.75 Hz, 1H), 7.55 (ddd, J = 1.18, 4.73, 7.66 Hz, 1H), 7.41 (m, 1H), 7.39 (t, J = 1.71 Hz, 
1H), 6.75 (d, J = 2.17 Hz, 1H), 6.38 (dd, J = 0.80, 1.77 Hz, 1H), 5.54 (dd, J = 5.28, 11.52 
Hz, 1H), 3.79 (s, 3H), 3.61 (d, J = 2.17 Hz, 1H), 3.07 (dd, J = 5.35, 13.67 Hz, 1H), 2.49 
(s, 1H), 2.20 (m, 2H), 2.14 (m, 1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 190.40, 171.38, 170.21, 163.14, 150.19, 146.40, 145.41, 143.69, 
139.32, 137.24, 130.33, 127.70, 125.99, 125.45, 108.43, 72.07, 63.40, 56.51, 52.46, 
51.34, 44.22, 43.72, 38.45, 35.85, 17.95, 16.81, 14.85. HRMS calculated for C27H27NO8: 
[M+Na]+: 516.1619 (found), 516.1634 (calc). Melting point: 185-190 °C (dec). 
  (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl nicotinate. 1H NMR (500 MHz, CDCl3) δ 9.31 
(s, 1H), 8.85 (d, J = 3.16 Hz, 1H), 8.37 (dt, J = 1.90, 7.97 Hz, 1H), 7.45 (dd, J = 4.89, 
7.94 Hz, 1H), 7.42 (m, 1H), 7.40 (t, J = 1.71 Hz, 1H), 6.71 (d, J = 2.17 Hz, 1H), 6.39 (dd, 
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J = 0.80, 1.78 Hz, 1H), 5.55 (dd, J = 5.28, 11.52 Hz, 1H), 3.81 (s, 3H), 3.61 (d, J = 2.17 
Hz, 1H), 3.06 (dd, J = 5.35, 13.65 Hz, 1H), 2.48 (s, 1H), 2.21 (m, 2H), 2.13 (m, 1H), 1.70 
(m, 3H), 1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.65, 171.29, 
170.26, 163.28, 154.29, 151.45, 145.15, 143.71, 139.38, 137.67, 130.45, 125.41, 124.48, 
123.50, 108.43, 72.02, 63.50, 56.46, 52.54, 51.35, 44.26, 43.83, 38.44, 35.88, 17.94, 
16.83, 14.86. HRMS calculated for C27H27NO8: [M-H]-: 492.1640 (found), 492.1664 
(calc). Melting point: 109-112 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl isonicotinate. 1H NMR (500 MHz, CDCl3) δ 
8.84 (dd, J = 1.39, 4.55 Hz, 2H), 7.91 (dd, J = 1.61, 4.42 Hz, 2H), 7.42 (m, 1H), 7.40 (t, J 
= 1.69 Hz, 1H), 6.71 (d, J = 2.15 Hz, 1H), 6.39 (dd, J = 0.73, 1.69 Hz, 1H), 5.55 (dd, J = 
5.27, 11.53 Hz, 1H), 3.81 (s, 3H), 3.61 (d, J = 2.14 Hz, 1H), 3.05 (dd, J = 5.35, 13.65 Hz, 
1H), 2.47 (s, 1H), 2.21 (m, 2H), 2.14 (m, 1H), 1.69 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 190.47, 171.24, 170.22, 163.18, 150.87, 145.12, 143.72, 
139.38, 135.59, 130.49, 125.40, 123.19, 108.42, 72.00, 63.52, 56.44, 52.56, 51.34, 44.28, 
43.83, 38.45, 35.88, 17.94, 16.82, 14.85. HRMS calculated for C27H27NO8: [M+Na]+: 
492.1624 (found), 492.1664 (calc). Melting point: 112-114 °C. 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxo-9-((thiophene-3-carbonyl)oxy)-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
8.26 (dd, J = 1.20, 3.03 Hz, 1H), 7.58 (dd, J = 1.20, 5.10 Hz, 1H), 7.41 (dd, J = 0.76, 1.52 
Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 7.36 (dd, J = 3.05, 5.10 Hz, 1H), 6.64 (d, J = 2.17 Hz, 
1H), 6.39 (dd, J = 0.80, 1.78 Hz, 1H), 5.54 (dd, J = 5.25, 11.52 Hz, 1H), 3.80 (s, 3H), 
3.59 (d, J = 2.16 Hz, 1H), 3.07 (dd, J = 5.33, 13.66 Hz, 1H), 2.47 (s, 1H), 2.20 (m, 2H), 
2.12 (m, 1H), 1.70 (m, 3H), 1.38 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
190.98, 171.39, 170.39, 160.29, 145.19, 143.67, 139.37, 134.68, 131.42, 130.05, 128.13, 
126.56, 125.43, 108.45, 72.06, 63.43, 56.48, 52.47, 51.36, 44.20, 43.80, 38.45, 35.84, 
17.95, 16.81, 14.86. HRMS calculated for C26H26O8S: [M+Na]+: 521.1231 (found), 
521.1246 (calc). Melting point: 175-176 °C (dec). 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxo-9-((thiophene-2-carbonyl)oxy)-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
7.92 (dd, J = 1.26, 3.79 Hz, 1H), 7.67 (dd, J = 1.25, 4.96 Hz, 1H), 7.41 (dt, J = 0.81, 1.58 
Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 7.16 (dd, J = 3.81, 4.97 Hz, 1H), 6.67 (d, J = 2.18 Hz, 
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1H), 6.39 (dd, J = 0.79, 1.79 Hz, 1H), 5.54 (dd, J = 5.25, 11.52 Hz, 1H), 3.80 (s, 3H), 
3.59 (d, J = 2.17 Hz, 1H), 3.07 (dd, J = 5.34, 13.66 Hz, 1H), 2.46 (s, 1H), 2.20 (ddd, J = 
2.73, 6.71, 11.74 Hz, 2H), 2.12 (m, 1H), 1.68 (m, 3H), 1.38 (s, 3H), 1.23 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 190.83, 171.37, 170.33, 159.89, 145.06, 143.68, 139.37, 
135.24, 134.08, 131.34, 130.25, 128.14, 125.43, 108.44, 72.07, 63.46, 56.48, 52.48, 
51.37, 44.21, 43.82, 38.45, 35.85, 17.95, 16.82, 14.86. HRMS calculated for C26H26O8S: 
[M-H]-: 521.1254 (found), 521.1246 (calc). Melting point: 150-152 °C (dec). 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-((benzofuran-2-
carbonyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 
1H NMR (500 MHz, CDCl3) δ 7.72 (dd, J = 0.91, 7.76 Hz, 1H), 7.70 (d, J = 0.93 Hz, 
1H), 7.61 (dd, J = 0.79, 8.45 Hz, 1H), 7.50 (ddd, J = 1.25, 7.22, 8.46 Hz, 1H), 7.41 (m, 
1H), 7.39 (t, J = 1.70 Hz, 1H), 7.34 (td, J = 0.89, 7.62 Hz, 1H), 6.73 (d, J = 2.17 Hz, 1H), 
6.39 (dd, J = 0.79, 1.77 Hz, 1H), 5.55 (dd, J = 5.27, 11.51 Hz, 1H), 3.80 (s, 3H), 3.61 (d, 
J = 2.17 Hz, 1H), 3.06 (dd, J = 5.36, 13.67 Hz, 1H), 2.50 (s, 1H), 2.20 (dt, J = 6.36, 14.91 
Hz, 2H), 2.13 (m, 1H), 1.70 (m, 3H), 1.38 (s, 3H), 1.23 (s, 3H).13C NMR (126 MHz, 
CDCl3) δ 190.54, 171.35, 170.24, 157.05, 156.17, 144.73, 143.69, 143.64, 139.36, 
130.48, 128.41, 126.76, 125.41, 124.11, 123.13, 116.22, 112.49, 108.44, 72.06, 63.40, 
56.46, 52.51, 51.31, 44.23, 43.71, 38.45, 35.84, 17.95, 16.82, 14.85. HRMS calculated 
for C30H28O9: [M+Na]+: 555.1611 (found), 555.1631 (calc). Melting point: 126-130 °C. 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-9-((3-
hydroxybenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. Synthesized according to general 
acylation procedure using standard benchtop glassware using 6 (40.0 mg, 0.103 mmol) 
and 3-((tert-butyldimethylsilyl)oxy)benzoic acid (39.0 mg, 0.154 mmol). The resulting 
silyl-protected phenol was dissolved in THF (5 mL) and treated with a solution of TBAF 
(1.0 M, 0.12 mmol) at 0 °C. After 10 min, the reaction was quenched with saturated 
NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine and dried over Na2SO4 then concentrated in vacuo. The residue was 
purified by FCC eluting with 50% EtOAc/Pent. to yield 34 as white solid (26.7mg, 51%). 
1H NMR (500 MHz, CDCl3) δ 7.66 (m, 1H), 7.55 (dd, J = 1.56, 2.49 Hz, 1H), 7.39 (dt, J 
= 0.82, 1.58 Hz, 1H), 7.38 (t, J = 1.71 Hz, 1H), 7.33 (t, J = 7.94 Hz, 1H), 7.10 (ddd, J = 
0.86, 2.61, 8.13 Hz, 1H), 6.65 (d, J = 2.16 Hz, 1H), 6.37 (dd, J = 0.81, 1.80 Hz, 1H), 6.02 
(s, 1H), 5.54 (dd, J = 5.25, 11.47 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.16 Hz, 1H), 3.04 
(dd, J = 5.36, 13.68 Hz, 1H), 2.47 (s, 1H), 2.20 (m, 2H), 2.11 (m, 1H), 1.70 (m, 3H), 1.36 
(s, 3H), 1.23 (s, 3H).13C NMR (126 MHz, CDCl3) δ 190.91, 171.83, 170.43, 164.51, 
156.09, 145.40, 143.67, 139.43, 130.13, 129.95, 129.49, 125.34, 122.52, 121.35, 116.82, 
108.47, 72.19, 63.40, 56.44, 52.50, 51.31, 44.20, 43.69, 38.39, 35.84, 17.93, 16.80, 14.86. 
HRMS calculated for C28H28O9: [M+Na]+: 531.1611 (found), 531.1631 (calc). Melting 
point: 124-126 °C. 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-9-((4-
hydroxybenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. Synthesized according to general 
acylation procedure using standard benchtop glassware using 6 (40.0 mg, 0.103 mmol) 
and 4-((tert-butyldimethylsilyl)oxy)benzoic acid (39.0 mg, 0.154 mmol). The resulting 
silyl-protected phenol was dissolved in THF (5 mL) and treated with a solution of TBAF 
(1.0 M, 0.12 mmol) at 0 °C. After 10 min, the reaction was quenched with saturated 
NH4Cl and extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine and dried over Na2SO4 then concentrated in vacuo. The residue was 
purified by FCC eluting with 45% EtOAc/Pent. to yield 35 as white solid (12.6 mg, 
24%).  1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 8.84 Hz, 2H), 7.40 (dd, J = 0.75, 1.50 
Hz, 1H), 7.39 (t, J = 1.70 Hz, 1H), 6.88 (d, J = 8.85 Hz, 2H), 6.64 (d, J = 2.18 Hz, 1H), 
6.38 (dd, J = 0.79, 1.77 Hz, 1H), 6.02 (s, 1H), 5.54 (dd, J = 5.25, 11.52 Hz, 1H), 3.80 (s, 
3H), 3.59 (d, J = 2.18 Hz, 1H), 3.06 (dd, J = 5.35, 13.69 Hz, 1H), 2.47 (s, 1H), 2.20 (m, 
2H), 2.12 (m, 1H), 1.69 (m, 3H), 1.37 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 191.22, 171.66, 170.52, 164.34, 160.82, 145.48, 143.69, 139.40, 132.78, 129.99, 
125.37, 120.56, 115.51, 108.45, 72.17, 63.42, 56.51, 52.49, 51.38, 44.21, 43.76, 38.47, 
35.83, 17.94, 16.83, 14.88. HRMS calculated for C28H28O9: [M+Na]+: 531.1625 (found), 
531.1631 (calc). Melting point: 136-139 °C. 
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 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxo-9-(2-phenylacetoxy)-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 0.65 
Hz, 1H), 7.39 (t, J = 1.65 Hz, 1H), 7.32 (m, 5H), 6.50 (d, J = 2.15 Hz, 1H), 6.39 (d, J = 
0.96 Hz, 1H), 5.55 (dd, J = 5.25, 11.53 Hz, 1H), 3.83 (s, 2H), 3.76 (s, 3H), 3.50 (d, J = 
2.12 Hz, 1H), 3.04 (dd, J = 5.32, 13.63 Hz, 1H), 2.37 (s, 1H), 2.16 (m, 2H), 2.06 (m, 1H), 
1.65 (m, 3H), 1.35 (s, 3H), 1.16 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.72, 171.37, 
170.30, 169.55, 145.26, 143.67, 139.43, 132.89, 129.89, 129.42, 128.70, 127.41, 125.40, 
108.50, 71.99, 63.38, 56.34, 52.42, 51.29, 44.10, 43.69, 40.30, 38.35, 35.79, 17.90, 16.71, 
14.81. HRMS calculated for C29H30O8: [M+Na]+: 529.1826 (found), 529.1838 (calc). 
Melting point: 157-159 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxo-9-((3-phenylpropanoyl)oxy)-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 
7.42 (m, 1H), 7.39 (t, J = 1.70 Hz, 1H), 7.30 (m, 2H), 7.22 (m, 3H), 6.47 (d, J = 2.18 Hz, 
1H), 6.40 (dd, J = 0.78, 1.78 Hz, 1H), 5.56 (dd, J = 5.25, 11.49 Hz, 1H), 3.78 (s, 3H), 
3.51 (d, J = 2.17 Hz, 1H), 3.03 (m, 3H), 2.83 (m, 2H), 2.39 (s, 1H), 2.17 (m, 2H), 2.08 
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(m, 1H), 1.66 (m, 3H), 1.36 (s, 3H), 1.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.95, 
171.37, 170.78, 170.32, 145.17, 143.69, 139.96, 139.41, 129.84, 128.59, 128.28, 126.43, 
125.42, 108.48, 72.01, 63.35, 56.36, 52.42, 51.30, 44.12, 43.72, 38.38, 35.80, 35.16, 
30.69, 17.91, 16.73, 14.82. HRMS calculated for C30H32O8: [M+Na]+: 543.1973 (found), 
543.1995 (calc). Melting point: 162-165 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-Methyl 9-(cinnamoyloxy)-2-
(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-decahydro-1H-
benzo[f]isochromene-7-carboxylate. 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 16.01 
Hz, 1H), 7.55 (m, 2H), 7.42 (m, 4H), 7.39 (t, J = 1.71 Hz, 1H), 6.61 (d, J = 2.19 Hz, 1H), 
6.55 (d, J = 15.99 Hz, 1H), 6.39 (dd, J = 0.78, 1.81 Hz, 1H), 5.56 (dd, J = 5.26, 11.49 Hz, 
1H), 3.80 (s, 3H), 3.57 (d, J = 2.19 Hz, 1H), 3.08 (dd, J = 5.34, 13.68 Hz, 1H), 2.45 (s, 
1H), 2.20 (m, 2H), 2.11 (m, 1H), 1.69 (dd, J = 7.09, 17.84 Hz, 3H), 1.38 (s, 3H), 1.21 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 191.07, 171.40, 170.40, 164.66, 147.64, 145.29, 
143.68, 139.38, 133.92, 130.93, 129.83, 129.00, 128.39, 125.44, 115.75, 108.46, 72.07, 
63.42, 56.47, 52.45, 51.38, 44.19, 43.78, 38.47, 35.85, 17.95, 16.79, 14.86. HRMS 
calculated for C30H30O8: [M+Na]+: 541.1824 (found), 541.1838 (calc). Melting point: 178 
°C (dec). 
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 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl thiazole-4-carboxylate. 1H NMR (500 MHz, 
CDCl3) δ 8.90 (d, J = 2.08 Hz, 1H), 8.41 (d, J = 2.07 Hz, 1H), 7.41 (m, 1H), 7.39 (t, J = 
1.71 Hz, 1H), 6.72 (d, J = 2.17 Hz, 1H), 6.38 (dd, J = 0.79, 1.77 Hz, 1H), 5.54 (dd, J = 
5.30, 11.51 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J = 2.17 Hz, 1H), 3.06 (dd, J = 5.35, 13.68 Hz, 
1H), 2.49 (s, 1H), 2.20 (ddd, J = 2.69, 6.54, 9.86 Hz, 2H), 2.13 (m, 1H), 1.69 (m, 3H), 
1.37 (s, 3H), 1.22 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.54, 171.36, 170.25, 158.78, 
153.91, 146.10, 145.02, 143.70, 139.33, 130.34, 129.45, 125.43, 108.42, 72.07, 63.38, 
56.47, 52.48, 51.33, 44.23, 43.71, 38.47, 35.84, 17.95, 16.81, 14.86. HRMS calculated 
for C25H25O8S: [M+Na]+: 522.1205 (found), 522.1199 (calc). Melting point: 186 °C (dec). 
 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl thiazole-5-carboxylate. 1H NMR (500 MHz, 
CDCl3) δ 9.05 (s, 1H), 8.63 (d, J = 4.73 Hz, 1H), 7.42 (m, 1H), 7.39 (t, J = 1.68 Hz, 1H), 
6.71 (d, J = 2.17 Hz, 1H), 6.39 (dd, J = 0.79, 1.79 Hz, 1H), 5.55 (dd, J = 5.43, 11.47 Hz, 
1H), 3.81 (s, 2H), 3.60 (d, J = 2.16 Hz, 1H), 3.05 (dd, J = 5.30, 13.61 Hz, 1H), 2.46 (s, 
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1H), 2.20 (m, 2H), 2.12 (m, 1H), 1.71 (m, 4H), 1.37 (s, 3H), 1.23 (s, 3H).13C NMR (126 
MHz, CDCl3) δ 190.55, 171.29, 170.56, 170.19, 159.33, 158.86, 150.53, 144.76, 143.71, 
139.38, 130.68, 125.39, 108.43, 72.01, 63.44, 56.40, 52.55, 51.30, 44.26, 43.79, 38.41, 
35.86, 17.92, 16.81, 14.84. HRMS calculated for C25H25O8S: [M+Na]+: 522.1181 (found), 
522.1199 (calc). Melting point: 211-212°C (dec). 
 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl oxazole-4-carboxylate. 1H NMR (500 MHz, 
CDCl3) δ 8.41 (d, J = 0.96 Hz, 1H), 8.00 (d, J = 0.96 Hz, 1H), 7.41 (dd, J = 0.83, 1.50 
Hz, 1H), 7.39 (t, J = 1.70 Hz, 1H), 6.69 (d, J = 2.17 Hz, 1H), 6.39 (dd, J = 0.77, 1.76 Hz, 
1H), 5.54 (dd, J = 5.18, 11.47 Hz, 1H), 3.79 (s, 3H), 3.59 (d, J = 2.16 Hz, 1H), 3.04 (dd, J 
= 5.35, 13.67 Hz, 1H), 2.48 (s, 1H), 2.19 (m, 2H), 2.12 (m, 1H), 1.70 (m, 3H), 1.37 (s, 
3H), 1.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.51, 171.35, 170.22, 158.42, 
151.75, 145.50, 144.66, 143.69, 139.35, 131.69, 130.52, 125.42, 108.44, 72.04, 63.32, 
56.40, 52.49, 51.27, 44.21, 43.66, 38.42, 35.82, 29.70, 17.93, 16.79, 14.84. HRMS 
calculated for C25H25O9: [M+Na]+: 506.1424 (found), 506.1427 (calc). Melting point: 
209-213 °C (dec.). 
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 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl oxazole-5-carboxylate. 1H NMR (500 MHz, 
CDCl3) δ 8.09 (s, 1H), 7.94 (s, 1H), 7.42 (dt, J = 0.82, 1.60 Hz, 1H), 7.40 (t, J = 1.71 Hz, 
1H), 6.72 (d, J = 2.17 Hz, 1H), 6.39 (dd, J = 0.81, 1.79 Hz, 1H), 5.55 (dd, J = 5.30, 11.50 
Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.17 Hz, 1H), 3.05 (dd, J = 5.35, 13.65 Hz, 1H), 2.46 
(s, 1H), 2.20 (m, 2H), 2.13 (m, 1H), 1.69 (m, 3H), 1.37 (s, 3H), 1.22 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 190.37, 171.24, 170.11, 154.90, 154.13, 144.35, 143.73, 141.26, 
139.36, 135.43, 130.85, 125.39, 108.41, 72.01, 63.47, 56.41, 52.57, 51.30, 44.28, 43.77, 
38.43, 35.86, 17.92, 16.80, 14.84. HRMS calculated for C25H25O9: [M+Na]+: 506.1426 
(found), 506.1427 (calc). Melting point: 213-215 °C (dec.). 
 (2S,4aR,6aR,7R,10aR,10bR)-2-(Furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl pyrimidine-5-carboxylate. 1H NMR (500 
MHz, CDCl3) δ 9.44 (s, 1H), 9.36 (s, 2H), 7.42 (dt, J = 0.84, 1.62 Hz, 1H), 7.40 (t, J = 
1.70 Hz, 1H), 6.74 (d, J = 2.16 Hz, 1H), 6.39 (dd, J = 0.79, 1.78 Hz, 1H), 5.56 (dd, J = 
5.33, 11.50 Hz, 1H), 3.82 (s, 3H), 3.61 (d, J = 2.16 Hz, 1H), 3.04 (dd, J = 5.35, 13.61 Hz, 
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1H), 2.48 (s, 1H), 2.21 (m, 2H), 2.14 (dd, J = 6.46, 9.54 Hz, 1H), 1.71 (m, 3H), 1.38 (s, 
3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.38, 171.20, 170.13, 162.10, 
161.60, 158.48, 144.85, 143.75, 139.39, 130.87, 125.38, 122.91, 108.41, 71.98, 63.53, 
56.43, 52.60, 51.31, 44.32, 43.83, 38.43, 35.90, 17.93, 16.83, 14.86. HRMS calculated 
for C26H26N2O8: [M+Na]+: 517.1587 (found), 517.1587 (calc). Melting point: 121-124 °C. 
 (2S,4aR,6aR,7R,10aR,10bR)-2-(furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-2,4,4a,5,6,6a,7,10,10a,10b-
decahydro-1H-benzo[f]isochromen-9-yl 6-methoxynicotinate. 1H NMR (500 MHz, 
CDCl3) δ 8.91 (dd, J = 0.64, 2.40 Hz, 1H), 8.19 (dd, J = 2.41, 8.74 Hz, 1H), 7.42 (dt, J = 
0.81, 1.58 Hz, 1H), 7.39 (t, J = 1.71 Hz, 1H), 6.80 (dd, J = 0.65, 8.74 Hz, 1H), 6.66 (d, J 
= 2.18 Hz, 1H), 6.39 (dd, J = 0.81, 1.80 Hz, 1H), 5.55 (dd, J = 5.25, 11.51 Hz, 1H), 4.02 
(s, 3H), 3.80 (s, 3H), 3.59 (d, J = 2.18 Hz, 1H), 3.06 (dd, J = 5.34, 13.66 Hz, 1H), 2.46 (s, 
1H), 2.20 (m, 2H), 2.12 (m, 1H), 1.68 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 190.91, 171.36, 170.36, 167.42, 163.42, 151.05, 145.26, 143.69, 139.93, 
139.38, 130.20, 125.43, 117.84, 110.99, 108.45, 72.04, 63.48, 56.49, 54.22, 52.49, 51.36, 
44.21, 43.82, 38.44, 35.86, 17.95, 16.83, 14.86. HRMS calculated for C28H29NO9: 
[M+Na]+: 546.1735 (found), 546.1740 (calc). Melting point: 192-195°C (dec.). 
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Experimentals for Chapter IV 
Specific rotations were recorded on an Autopol IV automatic polarimeter at λ=589 nm 
and corrected to 20 °C. Enantiomeric ratios were measured on an Agilent 1100 series 
HPLC system with diode array detection at 209.4 nm using a CHIRALCEL OD-H 
column (4.6 x 150 mm) eluting with an isocratic mixture of 2-propanol (IPA) and 
hexanes (2% IPA/hexanes for 51 and 5% IPA/hexanes for 1). Compounds 10,11 13,1214,12 
15,12 27,13 50,14 54,15 were prepared according to previous reports. 
General MOMO-ether Protection Procedure: To a solution of phenol (1.0 equiv) in 
CH2Cl2 under an atmosphere of argon at 0 °C, was added, sequentially, DIPEA (2.0 
equiv) and MOMCl (2.5 equiv). The reaction was allowed to warm to room temperature 
and stirred until complete by TLC. The reaction was quenched with the addition of 
saturated aqueous NH4Cl and the layers allowed to separate. The aqueous layer was 
further extracted with CH2Cl2 (3x) and the combined organic layers washed with brine 
then dried over Na2SO4. The organic layer was concentrated in vacuo and the resulting 
residue purified by FCC. 
General Wittig Olefination Procedure: To a suspension of [Ph3PCH3]+I- (1.5 equiv) in 
THF under an atmosphere of argon was added a solution of n-BuLi (1.4 equiv) at 0 °C. 
The resulting bright yellow solution was stirred for 1 h at this temperature. The 
benzaldehyde (1.0 equiv) was added as a solution in THF and the reaction stirred for an 
additional hour before being quenched with saturated aqueous NH4Cl until the color had 
faded from the reaction. The mixture was extracted with Et2O (3x) and the combined 
organic layers were washed with brine then dried over Na2SO4. The solvent was removed 
in vacuo and the resulting residue was purified by FCC. 
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General Saponification Procedure: A solution of the ester (2-3 g) dissolved in MeOH 
(40 mL) was treated with NaOH (3 M, 20 mL) and stirred at RT for 3 h. The MeOH was 
removed in vacuo and the resulting aqueous layer rinsed with CH2Cl2 (25 mL). The 
aqueous was layer was acidified to pH<4 with HCl (6 M) and extracted with CH2Cl2 
(3x30 mL). The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo. 
General Amidation Procedure 1: A solution of propionic acid (1.0 equiv) in THF was 
treated with CDMT (1.2 equiv) under argon at RT. NMM (3.0 equiv) was added to the 
reaction and allowed to stir for 1 h before the addition of N,O-
dimethylhydroxylamine·HCl (1.1 equiv). The reaction was allowed to stir overnight then 
quenched with H2O. The mixture was extracted with Et2O (3x). The combined organic 
layers were washed with saturated aqueous Na2CO3 (2x), HCl (2 M, 2x), and brine (1x). 
The organic layer was dried over Na2SO4 and concentrated in vacuo the residue purified 
by FCC. 
General Amidation Procedure 2: A solution of iPrMgCl (2 M, 3.0 equiv) was added 
dropwise to a heterogeneous mixture of ethyl ester (1.0 equiv) and N,O-
dimethylhydroxylamine·HCl (1.55 equiv) in THF at -20 °C under argon. After  the 
reaction was complete by TLC (~30 min) the reaction was quenched by the careful 
addition of HCl (2M) and mixture extracted with Et2O (3x). The combined organic layer 
was washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was 
purified by FCC. 
General Borylation Procedure: Dry, degassed Et3N (3.0 equiv) was added to a solution 
of aryl bromide (1.0 equiv), PdCl2(CH3CN) 2 (0.02 equiv), and SPhos (0.04 equiv) in 1,4-
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diox (1.6 M). After vigorous stirring for 10 min, HBPin (1.5 equiv) was added to the 
reaction resulting in vigorous bubbling. The reaction tube was sealed with a teflon screw 
cap and heated to 110 °C for 4.5 h. Th reaction was then cooled to RT, diluted with 
EtOAc and filtered through a pad of Celite. The solvent was removed in vacuo and the 
residue purified by FCC. 
General Intermolecular Suzuki-Miyaura Procedure: A reaction tube fitted with a 
septum was charged with Pd(OAc)2 (0.01 equiv), SPhos (0.02 equiv), and K3PO4 (2.0 
equiv). A solution of boronate ester (1.5 equiv) and arylboromide (1.0 equiv) dissolved in 
toluene (0.6 M based on aryl bromide) was added. Argon sparged H2O was added and the 
reaction vessel sealed with a teflon screwcap. The reaction was heated to 100 °C for 16 h 
then cooled to RT, diluted with EtOAc, and filtered through a thin pad of Celite. The 
filtrate was concentrated in vacuo and the resulting residue purified by FCC. 
General Grignard Reaction Procedure: A three-neck flask fitted with a septum, reflux 
condenser and slow addition funnel filled with a solution of 4-bromo-1-butene (3.5 M, 
3.5 equiv) was charged with magnesium (3.8 equiv) and a crystal of I2. Approximately 
one tenth of the 4-bromo-1-butene solution was added to the magnesium/I2 mixture and 
heated until the reaction changed from brown to clear. The remaining solution 4-bromo-
1-butene solution was added to the reaction at a rate to maintain a gentle reflux. Upon 
complete addition, the reaction was heated to reflux for an additional 20 min and cooled 
to RT. The Grignard solution was added slowly to a solution of Weinreb amide (1.0 
equiv) in THF at 0 °C. After the reaction was complete by TLC, it was quenched with 
saturated aqueous NH4Cl and extracted with Et2O (3x). The combined organic layers were 
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washed with HCl (2 M, 2x) and brine (1x) then dried over Na2SO4. The solvent was 
removed in vacuo and the residue purified by FCC. 
General RCM/Reduction Procedure: A solution of the diene (1.0 equiv) dissolved in 
CH2Cl2 (3 mM) was degassed by argon spargining for 15 min. G II (0.10 equiv) was 
added and the reaction heated to reflux for 24 h then cooled to RT and concentrated in 
vacuo. The residue was redissolved in THF and treated with 10% Pd/C and placed under 
an atmosphere of H2 by evacuating and backfilling with H2. The reaction was stirred 
vigorously overnight then filtered through Celite. The solvent was removed from the 
filtrate and the residue purified by FCC. 
General Cross-Metathesis Procedure. A mixture of the two olefins (1:1) was dissolved 
in anhydrous and degassed CH2Cl2 (0.1 M) and degassed by argon sparging for 15 min. 
Grubbs II catalyst (10 mol%) was added and the reaction heated to reflux for 24 h, cooled 
to RT, treated with DMSO (50 equiv), and stirred at RT for an additional 24 h. The 
reaction mixture was purified by adsorbing onto silica gel and chromatographed by FCC 
eluting with 6% EtOAc/Pent. for 51 and 12% EtOAc/Pent. for 58. 
General Intramolecular Suzuki-Miyaura Reaction Procedure. A vial was charged 
with PdCl2(dppf) (20 mol%) and base (10.0 equiv) under an atmosphere of argon and 
sealed with a teflon coated cap. A solution of 51 in the appropriate solvent was degassed 
by evacuating and back filling with argon (3x). The solution was transferred to the 
reaction vessel and degassed H2O (argon sparged) was added. The reaction was heated in 
an oil bath at 90 °C for the indicated time then cooled to RT. The reaction was diluted 
with EtOAc and filtered through Celite. The solvent was removed in vacuo and residue 
purified by FCC eluting with 5% EtOAc/Pent. 
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5-Bromo-2-hydroxy-3,4-dimethioxybenzaldehyde. Bromine (1.48 mL, 
28.8 mmol) was slowly added to a solution of 10 (5.00 g, 27.4 mmol) in glacial AcOH 
(50 mL) and stirred for 1.5 h at RT. The reaction was diluted with CH2Cl2 (75 mL) and 
washed with Na2S2O3 (30 mL), H2O (3 x 30 mL) and brine (30 mL). The organic  layer 
was dried over Na2SO4 and concentrated in vacuo. The resulting residue was purified by 
FCC eluting with 8% EtOAc/Pent. to yield 11 as a white solid (5.80 g, 81%). Melting 
point: 66-68 °C. 1H NMR (500 MHz, CDCl3) δ 11.20 (s, 1H), 9.75 (s, 1H), 7.51 (s, 1H), 
4.07 (s, 3H), 3.94 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 194.50, 156.67, 156.25, 141.30, 
131.50, 118.15, 106.84, 61.40, 61.13. HRMS calculated for C9H9BrO4: [M-H]—: 
258.9594 (found); 258.9606 (calc.). 
5-Bromo-3,4-dimethoxy-2-(methoxymethoxy)benzaldehyde. Prepared 
from 11 (1.500 g, 5.745 mmol) in CH2Cl2 (20 mL) according to general MOM-ether 
protection procedure and purified via FCC eluting with 10% EtOAc/Hex. to yield 12 as a 
clear oil (1.631 g, 93%).1H NMR (400 MHz, CDCl3) δ 10.30 (s, 1H), 7.84 (s, 1H), 5.29 
(s, 2H), 4.01 (s, 4H), 3.92 (s, 4H), 3.60 (s, 1H). 13C NMR (126 MHz, CDCl3)  187.98, 
156.57, 153.74, 146.79, 126.73, 126.69, 113.05, 99.99, 99.98, 99.94, 61.18, 58.02. 
HRMS calculated for C11H13BrO5: [M+Na]+: 326.9853 (found); 326.9844 (calc). 
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1-Bromo-2,3-dimethoxy-4-(methoxymethoxy)-5-vinylbenzene. Prepared 
from 12 (1.631 g, 5.346 mmol) according to general Wittig olefination procedure and 
purified via FCC eluting with 5% EtOAc/Hex. to yield a 8 as a clear oil (1.345 g, 83%). 1H 
NMR (500 MHz, CDCl3) δ 7.47 (s, 1H), 6.97 (dd, J = 11.06, 17.70 Hz, 1H), 5.69 (dd, J = 
0.92, 17.70 Hz, 1H), 5.32 (dd, J = 0.89, 11.05 Hz, 1H), 5.14 (s, 2H), 3.92 (s, 3H), 3.91 (s, 
3H), 3.59 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 150.71, 147.86, 147.21, 130.18, 129.19, 
124.01, 115.47, 112.38, 99.34, 61.05, 61.00, 57.75. HRMS calculated for C12H15BrO4: 
[M+Na]+: 325.0054 (found); 325.0051 (calc). 
3-(3-Bromo-4-(methoxymethoxy)phenyl)propanoic acid. 
Prepared from 1512 (2.41 g, 8.34 mmol) according to general saponification procedure to 
yield 15a as a white solid (2.14 g, 98%). 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.10 
(d, J = 2.83 Hz, 2H), 5.24 (s, 2H), 3.54 (s, 3H), 2.91 (t, J = 7.67 Hz, 2H), 2.68 (t, J = 7.67 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 178.06, 152.28, 135.20, 133.09, 128.30, 116.30, 
112.84, 95.16, 56.38, 35.39, 29.38. HRMS calculated for C11H13BrO4: [M-H]-:286.9937 
(found), 286.9924 (calc). 
  3-(3-Bromo-4-(methoxymethoxy)phenyl)-N-methoxy-N-
methylpropanamide. Prepared from 15a (2.136 g, 7.389 mmol) using general amidation 
procedure 1 or from 15 (1.016 g, 3.204 mmol) using general amidation procedure 2. 
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Purified by FCC eluting with 35% EtOAc/Hex. to yield 16 as a clear oil (90% and 91%, 
respectively). 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 1.84 Hz, 1H), 7.14 (dd, J = 1.91, 
8.37 Hz, 1H), 7.09 (d, J = 8.36 Hz, 1H), 5.24 (s, 2H), 3.66 (s, 3H), 3.54 (d, J = 0.82 Hz, 
3H), 3.21 (s, 3H), 2.91 (m, 2H), 2.73 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 173.34, 
152.04, 136.51, 133.13, 128.50, 116.32, 112.76, 95.22, 61.26, 56.36, 33.64, 32.20, 29.42. 
HRMS calculated for C13H18BrNO4: [M]+: 331.0416 (found); 331.0419 (calc). 
N-Methoxy-3-(4-(methoxymethoxy)-3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenyl)-N-methylpropanamide. Prepared from 16 (964.9 mg, 
2.905 mmol) according to general borylation procedure and purified via FCC eluting with 
30-35% EtOAc/Pent. to yield 9 as a clear yellow oil (1.095 g, 99%). 1H NMR (500 MHz, 
CDCl3) δ 7.54 (d, J = 2.36 Hz, 1H), 7.24 (dd, J = 2.44, 8.40 Hz, 1H), 6.96 (d, J = 8.40 
Hz, 1H), 5.16 (s, 2H), 3.62 (s, 3H), 3.51 (s, 3H), 3.18 (s, 3H), 2.90 (m, 2H), 2.71 (m, 2H), 
1.35 (s, 12H). 13C NMR (126 MHz, CDCl3) δ 173.80, 160.14, 136.40, 134.66, 132.36, 
116.11, 95.55, 83.49, 75.01, 61.24, 56.10, 34.06, 32.18, 29.84, 24.84. HRMS calculated 
for C19H30BNO6: [M]+: 379.2146 (found); 379.2166 (calc). 
3-(2',3'-Dimethoxy-4',6-bis(methoxymethoxy)-5'-vinyl-[1,1'-
biphenyl]-3-yl)-N-methoxy-N-methylpropanamide. Prepared from 8 (345 mg, 1.14 
mmol) and 9 (561 mg, 1.48 mmol) according to the general intermolecular Suzuki-
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Miyaura reaction conditions and purified by FCC eluting with 45% EtOAc/Hex. to yield 
17 as a clear yellow oil (526 mg, 97%). 1H NMR (500 MHz, CDCl3) δ 7.21 (dd, J = 2.23, 
8.41 Hz, 1H), 7.18 (s, 1H), 7.16 (d, J = 8.39 Hz, 1H), 7.13 (d, J = 2.16 Hz, 1H), 7.07 (dd, 
J = 11.11, 17.79 Hz, 1H), 5.67 (dd, J = 1.21, 17.73 Hz, 1H), 5.26 (dd, J = 1.20, 11.09 Hz, 
1H), 5.21 (s, 2H), 5.09 (s, 2H), 3.92 (s, 3H), 3.69 (s, 3H), 3.66 (s, 3H), 3.65 (s, 3H), 3.38 
(s, 3H), 3.21 (s, 3H), 2.97 (m, 2H), 2.77 (t, J = 7.52 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 173.78, 153.15, 151.61, 147.75, 145.77, 134.69, 131.23, 131.19, 128.73, 
128.70, 128.59, 127.02, 122.67, 115.65, 114.14, 99.44, 95.35, 61.26, 60.80, 60.76, 57.67, 
55.94, 33.88, 29.87, 24.87. HRMS calculated for C25H33NO8: [M]+: 475.2226 (found); 
475.2206 (calc). 
1-(2',3'-Dimethoxy-4',6-bis(methoxymethoxy)-5'-vinyl-[1,1'-
biphenyl]-3-yl)hept-6-en-3-one. Prepared from 17 (700 mg, 1.472 mmol) according to 
general Grignard reaction condition. Purified by FCC eluting with 15% EtOAc/Hex. to 
yield 7 as a clear oil (636 mg, 92%). 1H NMR (500 MHz, CDCl3) δ 7.14 (s, 1H), 7.12 (d, 
J = 1.30 Hz, 2H), 7.04 (m, 2H), 5.78 (ddt, J = 6.50, 10.20, 16.78 Hz, 1H), 5.64 (dd, J = 
1.28, 17.72 Hz, 1H), 5.24 (dd, J = 1.25, 11.09 Hz, 1H), 5.18 (s, 2H), 5.06 (s, 2H), 4.99 
(ddq, J = 1.47, 10.21, 19.36 Hz, 2H), 3.90 (s, 3H), 3.65 (s, 3H), 3.62 (s, 3H), 3.35 (s, 3H), 
2.88 (t, J = 7.64 Hz, 2H), 2.74 (t, J = 7.62 Hz, 2H), 2.50 (t, J = 7.38 Hz, 2H), 2.32 (ddd, J 
= 4.07, 7.36, 12.34 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 209.31, 153.13, 151.58, 
147.76, 145.78, 137.05, 134.34, 131.17, 131.11, 128.65, 128.60, 127.04, 122.63, 115.64, 
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115.26, 114.16, 99.43, 95.31, 60.79, 60.77, 57.66, 55.94, 44.46, 42.01, 28.89, 27.71. 
HRMS calculated for C27H34O7: [M+Na]+: 493.2221(found); 493.2202 (calc). 
1,12-Bis(5'-ethyl-2',3'-dimethoxy-4',6-
bis(methoxymethoxy)-[1,1'-biphenyl]-3-yl)dodecane-3,10-dione. Prepared from 7 
according to general RCM/reduction procedure and purified by FCC to yield 19 as a clear 
oil. 1H NMR (500 MHz, CDCl3) δ 7.10 (s, 4H), 7.05 (s, 2H), 6.81 (s, 2H), 5.17 (s, 4H), 
5.05 (s, 4H), 3.89 (s, 6H), 3.63 (s, 6H), 3.61 (s, 6H), 3.34 (s, 6H), 2.86 (t, J = 7.63 Hz, 
4H), 2.70 (m, 8H), 2.38 (td, J = 3.75, 7.39 Hz, 4H), 1.55 (dd, J = 5.77, 9.35 Hz, 4H), 1.24 
(dt, J = 5.48, 15.13 Hz, 10H). 13C NMR (126 MHz, CDCl3) δ 210.25, 153.08, 149.74, 
148.16, 145.50, 134.39, 132.49, 131.21, 128.91, 128.36, 128.18, 125.43, 115.78, 99.34, 
95.37, 60.73, 60.69, 57.36, 55.90, 44.44, 42.87, 42.66, 28.95, 23.40, 22.81, 14.71. HRMS 
calculated for C52H70O14: [M+Na]+: 941.4648 (found), 941.4663 (calc). 
2-(Benzyloxy)-5-bromo-3,4-dimethoxybenzaldehyde. A solution of 11 
(5.30 g, 20.30 mmol) in anhydrous DMF (50 mL) was treated sequentially with BnBr 
(2.53 mL, 21.32 mmol) and K2CO3 and stirred overnight at RT. The reaction was diluted 
with Et2O (150 mL) and H2O (100 mL). The organic layer was rinsed with additional 
H2O (2 x 100 mL) and brine (100 mL), dried over Na2SO4 and solvent removed in vacuo 
to yield 26 as a white solid (7.08 g, 99%).  Melting point: 48-50 °C. 1H NMR (500 MHz, 
CDCl3) δ 10.05 (s, 1H), 7.76 (s, 1H), 7.38 (m, 5H), 5.21 (s, 2H), 4.03 (s, 3H), 3.96 (s, 
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3H). 13C NMR (126 MHz, CDCl3) δ 187.81, 156.60, 155.33, 147.21, 135.81, 128.82, 
128.76, 128.65, 126.62, 126.41, 112.80, 61.37, 61.28. HRMS calculated for C16H15BrO4: 
[M+Na]+: 373.0034(found); 373.0051(calc.). 
 1-Bromo-2,3-dimethoxy-5-vinylbenzene. Prepared from 3-bromo-4,5-
dimethoxybenzaldehyde (526 mg, 2.15 mmol) using the general Wittig olefin procedure 
and purified by FCC eluting with 5% EtOAc/Hex. to yield 28 as colorless oil (402 mg, 
77%). 1H NMR (500 MHz, CDCl3) δ 7.19 (d, J = 1.89 Hz, 1H), 6.89 (d, J = 1.88 Hz, 1H), 
6.59 (dd, J = 10.84, 17.51 Hz, 1H), 5.67 (d, J = 17.50 Hz, 1H), 5.25 (d, J = 10.83 Hz, 
1H), 3.89 (s, 3H), 3.85 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 153.62, 146.14, 135.32, 
134.82, 122.77, 117.80, 114.46, 109.23, 60.67, 56.06. HRMS calculated for C10H11BrO2: 
[M+Na]+: 264.9825 (found); 264.9840 (calc.). 
2-(Benzyloxy)-5-bromo-3,4-dimethoxy-1-vinylbenzene. Prepared from 26 
(1.021 g, 2.906 mmol) using the general Wittig olefin procedure and purified by FCC 
eluting with 2% EtOAc/Hex to yield 29 as a colorless oil (786 mg, 77%). 1H NMR (500 
MHz, CDCl3) δ 7.45 (dd, J = 3.79, 10.51 Hz, 3H), 7.39 (m, 2H), 7.35 (m, 1H), 6.87 (dd, J 
= 11.10, 17.77 Hz, 1H), 5.65 (dd, J = 1.02, 17.70 Hz, 1H), 5.24 (dd, J = 1.01, 11.06 Hz, 
1H), 4.99 (s, 2H), 3.92 (s, 3H), 3.92 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 150.69, 
149.72, 147.71, 137.03, 129.97, 129.17, 128.51, 128.26, 128.21, 123.84, 115.34, 112.26, 
75.66, 61.26, 61.15. HRMS calculated for C17H17BrO3: [M+Na]+: 371.0257 (found); 
371.0259 (calc).    
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 4-Bromo-1-(methoxymethoxy)-2-vinylbenzene. Prepared from 27 (1.09 g, 
4.45 mmol) using the general Wittig olefin procedure and purified by FCC eluting with 
2% EtOAc/Hex. to yield 30 as a colorless oil (963 mg, 89%). 1H NMR (500 MHz, 
CDCl3) δ 7.59 (d, J = 2.48 Hz, 1H), 7.29 (dd, J = 2.50, 8.78 Hz, 1H), 6.98 (m, 2H), 5.73 
(dd, J = 1.15, 17.72 Hz, 1H), 5.31 (dd, J = 1.14, 11.12 Hz, 1H), 5.18 (s, 2H), 3.47 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 153.34, 131.33, 130.30, 129.55, 129.05, 116.50, 115.83, 
114.52, 94.74, 56.18. HRMS calculated for C10H11BrO2: [M+H]+: 243.0018 (found); 
243.0021 (calc). 
3-(4-(Benzyloxy)-3-bromophenyl)propanoic acid. Prepared from 54 
(3.01 g, 8.29 mmol) using general saponification procedure to yield 32 as a white solid 
(2.53 g, 91%) Melting point: 102-104 °C. 1H NMR (500 MHz, CDCl3) δ 7.47 (m, 2H), 
7.42 (d, J = 2.18 Hz, 1H), 7.38 (m, 2H), 7.32 (m, 1H), 7.06 (dd, J = 2.20, 8.37 Hz, 1H), 
6.85 (d, J = 8.40 Hz, 1H), 5.13 (s, 2H), 2.87 (t, J = 7.67 Hz, 2H), 2.64 (t, J = 7.69 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 178.20, 153.59, 136.56, 134.13, 133.17, 128.57, 
128.18, 127.92, 126.99, 113.93, 112.44, 70.89, 35.45, 29.34. HRMS calculated for 
C16H15BrO3: [M-H]- : 334.0124 (found), 333.0126 (calc). 
 3-(3-Bromophenyl)-N-methoxy-N-methylpropanamide. Prepared 
from 3-(3-bromophenyl)propionic acid (1.000 g, 4.365 mmol) according to general 
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amidation procedure 1 to yield 33 as an oil (1.180 g, 99%). 1H NMR (500 MHz, CDCl3) 
δ 7.38 (m, 1H), 7.33 (m, 1H), 7.16 (m, 2H), 3.63 (s, 3H), 3.18 (s, 3H), 2.93 (m, 2H), 2.73 
(t, J = 7.56 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 173.22, 143.71, 131.47, 130.02, 
129.24, 127.20, 122.45, 61.26, 33.41, 32.20, 30.22. HRMS calculated for C11H14BrNO2: 
[M+Na]+: 294.0113 (found), 294.0106 (calc). 
3-(4-(Benzyloxy)-3-bromophenyl)-N-methoxy-N-
methylpropanamide. Prepared from 32 (3.000 g, 8.952 mmol) according to general 
amidation procedure 1 to yield 34 as a clear oil (3.35 g, 99%). 1H NMR (400 MHz, 
CDCl3) δ 7.49 (d, J = 7.46 Hz, 2H), 7.45 (t, J = 2.40 Hz, 1H), 7.40 (t, J = 7.34 Hz, 2H), 
7.34 (d, J = 7.17 Hz, 1H), 7.10 (m, 1H), 6.87 (d, J = 8.38 Hz, 1H), 3.63 (s, 2H), 3.19 (s, 
2H), 2.90 (t, J = 7.75 Hz, 2H), 2.68 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 173.63, 
153.36, 136.64, 135.41, 133.21, 128.56, 128.40, 127.90, 127.00, 113.93, 112.35, 70.90, 
61.25, 33.66, 32.18, 29.42. HRMS calculated for C18H20BrNO3: [M+Na]+: 400.0536 
(found); 400.0524 (calc). 
N-Methoxy-N-methyl-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)phenyl)propanamide. Prepared from 33 (1.500 g, 5.511 mmol) according to 
general borylation procedure and purified by FCC eluting with 30% EtOAc/Hex. to yield 
35 as a yellow oil (1.202 g, 68%). 1H NMR (500 MHz, CDCl3) δ 7.66 (m, 2H), 7.33 (m, 
2H), 3.61 (s, 3H), 3.18 (s, 3H), 2.95 (m, 2H), 2.75 (m, 2H), 1.35 (s, 12H). 13C NMR (126 
BnO
N
O
Br
34 OMe
Me
N
O
B
35 OMe
Me
OO
! 218 
MHz, CDCl3) δ 173.74, 143.71, 140.64, 134.68, 132.60, 131.53, 131.47, 130.02, 129.24, 
127.92, 127.20, 122.45, 83.78, 61.24, 33.93, 33.41, 32.19, 24.87. HRMS calculated for 
C17H26BNO4: [M+Na]+: 3421865 (found); 342.1853 (calc). 
3-(4-(Benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenyl)-N-methoxy-N-methylpropanamide. Prepared from 34 (2.085 g, 5.512 
mmol) according to general borylation procedure and purified by FCC eluting with 33% 
EtOAc/Hex. to yield 36 as yellow oil (2.347 g, 100%). 1H NMR (500 MHz, CDCl3) δ 
7.62 (d, J = 7.51 Hz, 2H), 7.57 (d, J = 2.26 Hz, 1H), 7.39 (t, J = 7.57 Hz, 2H), 7.31 (t, J = 
6.36 Hz, 2H), 6.89 (d, J = 8.41 Hz, 1H), 5.12 (s, 2H), 3.63 (s, 3H), 3.20 (s, 3H), 2.93 (m, 
2H), 2.74 (m, 2H), 1.39 (s, 12H). 13C NMR (126 MHz, CDCl3) δ 171.21, 161.79, 137.73, 
136.49, 133.26, 132.52, 129.44, 128.13, 127.29, 126.79, 112.27, 83.48, 75.03, 70.12, 
34.09, 32.15, 29.83, 24.85. HRMS calculated for C24H32BNO5: [M+Na]+: 448.2245 
(found), 448.2271 (calc). 
3-(2',3'-Dimethoxy-5'-vinyl-[1,1'-biphenyl]-3-yl)-N-methoxy-N-
methylpropanamide. Synthesized according to general intermolecular Suzuki-Miyaura 
reaction procedure with 28 (143 mg, 0.588 mmol) and 35 (282 mg, 0.882 mmol) and 
purified by FCC eluting with 30-35% EtOAc/Hex. to yield 37 as a thick oil (178 mg, 
84%). 1H NMR (500 MHz, CDCl3) δ 7.39 (m, 2H), 7.34 (t, J = 7.52 Hz, 1H), 7.22 (dt, J = 
1.46, 7.39 Hz, 1H), 6.98 (s, 2H), 6.69 (dd, J = 10.84, 17.54 Hz, 1H), 5.69 (dd, J = 0.72, 
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17.54 Hz, 1H), 5.23 (dd, J = 0.66, 10.84 Hz, 1H), 3.93 (s, 3H), 3.62 (s, 3H), 3.59 (s, 3H), 
3.19 (s, 3H), 3.02 (m, 2H), 2.78 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 173.74, 153.08, 
146.39, 141.11, 138.30, 136.43, 135.78, 133.53, 129.22, 128.23, 127.39, 127.01, 121.08, 
113.33, 108.77, 61.24, 60.73, 55.95, 33.80, 32.19, 30.76. HRMS calculated for 
C21H25NO4: [M+Na]+: 355.1754 (found), 355.1784 (calc). 
3-(2',3'-Dimethoxy-6-(methoxymethoxy)-5'-vinyl-[1,1'-
biphenyl]-3-yl)-N-methoxy-N-methylpropanamide. Synthesized according to general 
intermolecular Suzuki-Miyaura reaction procedure with 28 (100 mg, 0.411 mmol) and 9 
(222 mg, 0.585 mmol) and purified by FCC eluting with 40% EtOAc/Hex to yield 38 as a 
clear oil (138 mg, 81%).  1H NMR (400 MHz, CDCl3) δ 7.18 (ddd, J = 2.11, 9.48, 18.89 
Hz, 3H), 7.01 (d, J = 2.00 Hz, 1H), 6.93 (d, J = 2.00 Hz, 1H), 6.69 (dd, J = 10.86, 17.55 
Hz, 1H), 5.68 (d, J = 17.52 Hz, 1H), 5.23 (d, J = 10.87 Hz, 1H), 5.09 (s, 2H), 3.95 (s, 
3H), 3.64 (s, 3H), 3.62 (s, 3H), 3.37 (s, 3H), 3.20 (s, 3H), 2.96 (m, 2H), 2.76 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 173.76, 153.10, 152.61, 146.91, 136.51, 134.52, 132.98, 
132.95, 131.12, 128.75, 128.63, 121.78, 115.59, 113.02, 108.95, 95.22, 61.25, 60.64, 
55.91, 55.86, 33.89, 32.18, 29.89. HRMS calculated for C23H29NO6: [M+Na]+: 415.1966 
(found), 415.1995 (calc). 
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3-(4',6-Bis(benzyloxy)-2',3'-dimethoxy-5'-vinyl-[1,1'-biphenyl]-
3-yl)-N-methoxy-N-methylpropanamide. Prepared from 29 (1.137 g, 3.256 mmol) and 
36 (2.077 g, 4.883 mmol) according to general intramolecular Suzuki-Miyaura reaction 
conditions and purified by FCC eluting with 33% EtOAc/Hex. to yield 41 as an oil (1.687 
g, 91%).1H NMR (500 MHz, CDCl3) δ 7.52 (dd, J = 0.92, 7.74 Hz, 2H), 7.41 (m, 2H), 
7.36 (m, 1H), 7.27 (m, 4H), 7.20 (m, 4H), 6.99 (dd, J = 11.21, 17.85 Hz, 1H), 6.95 (d, J = 
8.25 Hz, 1H), 5.63 (dd, J = 1.32, 17.73 Hz, 1H), 5.18 (dd, J = 1.29, 11.11 Hz, 1H), 5.06 
(s, 2H), 5.04 (s, 2H), 3.92 (s, 3H), 3.67 (s, 3H), 3.62 (s, 3H), 3.18 (s, 3H), 2.95 (m, 2H), 
2.75 (t, J = 7.37 Hz, 2H).13C NMR (126 MHz, CDCl3) δ 173.84, 154.50, 151.71, 149.69, 
146.26, 137.60, 137.46, 133.61, 131.33, 131.04, 128.57, 128.55, 128.48, 128.29, 128.23, 
128.19, 128.03, 127.49, 126.90, 126.87, 122.68, 113.94, 113.14, 75.66, 70.55, 61.26, 
61.04, 60.97, 33.92, 32.17, 29.90. HRMS calculated for C35H37NO6: [M+Na]+: 590.2557 
(found), 590.2519 (calc). 
1-(2',3'-Dimethoxy-5'-vinyl-[1,1'-biphenyl]-3-yl)hept-6-en-3-one. 
Prepared from 37 (178 mg, 0.473 mmol) according to general Grignard reaction 
procedure and purified by FCC eluting with 10% EtOAc/Hex. to yield 20 as a clear oil 
(134 mg, 76%). 1H NMR (500 MHz, CDCl3) δ 7.37 (m, 2H), 7.33 (t, J = 7.45 Hz, 1H), 
7.17 (dt, J = 1.42, 7.41 Hz, 1H), 6.97 (dd, J = 1.99, 7.89 Hz, 2H), 6.69 (dd, J = 10.85, 
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17.54 Hz, 1H), 5.78 (ddt, J = 6.50, 10.20, 16.79 Hz, 1H), 5.69 (dd, J = 0.71, 17.54 Hz, 
1H), 5.23 (dd, J = 0.66, 10.84 Hz, 1H), 4.98 (ddq, J = 1.47, 10.20, 19.24 Hz, 2H), 3.93 (s, 
3H), 3.58 (s, 3H), 2.95 (t, J = 7.68 Hz, 2H), 2.78 (t, J = 7.68 Hz, 2H), 2.50 (t, J = 7.38 
Hz, 2H), 2.33 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 209.27, 153.09, 146.37, 140.78, 
138.31, 137.04, 136.42, 135.74, 133.56, 129.12, 128.26, 127.27, 126.98, 121.03, 115.28, 
113.35, 108.79, 60.72, 55.96, 44.32, 42.03, 29.74, 27.72. HRMS calculated for C23H26O3: 
[M+Na]+: 373.1756 (found), 373.1780 (calc). 
1-(2',3'-Dimethoxy-6-(methoxymethoxy)-5'-vinyl-[1,1'-biphenyl]-3-
yl)hept-6-en-3-one. Prepared from 38 (131 mg, 0.316 mmol) according to general 
Grignard reaction procedure and purified by FCC eluting with 10% EtOAc/Hex. to yield 
21 as a clear oil (99 mg, 76%).  1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 2.02 Hz, 2H), 
7.06 (d, J = 1.14 Hz, 1H), 6.98 (d, J = 2.02 Hz, 1H), 6.89 (d, J = 1.97 Hz, 1H), 6.67 (dd, J 
= 10.85, 17.54 Hz, 1H), 5.78 (ddt, J = 6.50, 10.20, 16.78 Hz, 1H), 5.66 (dd, J = 0.75, 
17.53 Hz, 1H), 5.20 (dd, J = 0.69, 10.84 Hz, 1H), 5.06 (s, 2H), 4.98 (ddq, J = 1.47, 10.21, 
18.85 Hz, 2H), 3.93 (s, 3H), 3.58 (s, 3H), 3.35 (s, 3H), 2.87 (t, J = 7.63 Hz, 2H), 2.73 (t, J 
= 7.62 Hz, 2H), 2.49 (t, J = 7.38 Hz, 2H), 2.32 (tdd, J = 3.52, 4.60, 8.28 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 209.35, 153.08, 152.62, 146.88, 137.05, 136.76, 136.50, 
134.17, 133.00, 132.89, 131.01, 128.62, 121.73, 115.59, 115.25, 113.03, 108.95, 95.20, 
60.63, 55.91, 55.86, 44.46, 42.02, 28.91, 27.71. HRMS calculated for C25H30O5: 
[M+Na]+: 433.1986 (found); 433.1991 (calc). 
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1-(2',3'-Dimethoxy-4'-(methoxymethoxy)-5'-vinyl-[1,1'-biphenyl]-3-
yl)hept-6-en-3-one. Prepared from 39 (233 mg, 0.561 mmol) according to general 
Grignard reaction procedure and purified by FCC eluting with 10% EtOAc/Hex. to yield 
22 as a clear oil (190 mg, 83%). 1H NMR (500 MHz, CDCl3)  7.32 (m, 3H), 7.21 (s, 
1H), 7.16 (ddd, J = 2.09, 3.72, 5.12 Hz, 1H), 7.05 (dd, J = 11.18, 17.83 Hz, 1H), 5.79 
(ddt, J = 6.50, 10.20, 16.78 Hz, 1H), 5.70 (dd, J = 1.24, 17.74 Hz, 1H), 5.27 (dd, J = 1.21, 
11.09 Hz, 1H), 5.18 (s, 2H), 4.99 (ddq, J = 1.47, 10.21, 19.62 Hz, 2H), 3.92 (s, 3H), 3.65 
(s, 3H), 3.61 (s, 3H), 2.96 (t, J = 7.66 Hz, 2H), 2.78 (t, J = 7.68 Hz, 2H), 2.51 (t, J = 7.38 
Hz, 2H), 2.33 (m, 2H).13C NMR (126 MHz, CDCl3)  209.22, 151.08, 147.72, 146.24, 
140.89, 138.23, 137.04, 131.72, 131.13, 129.09, 128.32, 127.65, 127.13, 126.93, 122.00, 
115.28, 114.54, 99.41, 60.97, 60.89, 57.72, 44.37, 42.02, 29.74, 27.72. HRMS calculated 
for C25H30O5: [M+Na]+: 433.1976 (found); 433.1991 (calc). 
1-(4'-(Methoxymethoxy)-3'-vinyl-[1,1'-biphenyl]-3-yl)hept-6-en-3-one. 
Prepared from 40 (168 mg, 0.473 mmol) according to general Grignard reaction 
procedure and purified by FCC eluting with 5% EtOAc/Hex. to yield 23 as a clear oil 
(110 mg, 66%). 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 2.34 Hz, 1H), 7.40 (m, 3H), 
7.34 (t, J = 7.58 Hz, 1H), 7.15 (t, J = 8.01 Hz, 2H), 7.11 (dd, J = 11.09, 17.71 Hz, 1H), 
5.80 (m, 2H), 5.33 (dd, J = 1.36, 11.14 Hz, 1H), 5.25 (s, 2H), 4.99 (ddq, J = 1.46, 10.21, 
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19.51 Hz, 2H), 3.52 (s, 3H), 2.96 (t, J = 7.67 Hz, 2H), 2.79 (t, J = 7.68 Hz, 2H), 2.51 (t, J 
= 7.37 Hz, 2H), 2.33 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 209.23, 153.88, 141.56, 
141.55, 141.05, 137.03, 134.95, 131.52, 128.90, 127.72, 127.55, 126.93, 126.90, 125.21, 
124.75, 115.30, 115.01, 94.72, 56.20, 44.42, 42.02, 29.78, 27.72. HRMS calculated for 
C23H26O3: [M+Na]+: 373.1768 (found); 373.1780 (calc). 
1-(4',6-Bis(benzyloxy)-2',3'-dimethoxy-5'-vinyl-[1,1'-biphenyl]-3-
yl)hept-6-en-3-one. Prepared from 41 (316 mg, 0.556 mmol) according to general 
Grignard reaction procedure and purified by FCC eluting with 7.5% EtOAc/Hex. to yield 
24 as a clear oil (261 mg, 83%). 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 6.92 Hz, 2H), 
7.41 (t, J = 7.26 Hz, 2H), 7.36 (d, J = 7.26 Hz, 1H), 7.27 (d, J = 3.57 Hz, 5H), 7.19 (s, 
1H), 7.11 (d, J = 7.18 Hz, 2H), 6.99 (dd, J = 11.16, 17.81 Hz, 1H), 6.93 (dd, J = 1.56, 
7.32 Hz, 1H), 5.78 (ddt, J = 6.50, 10.20, 16.80 Hz, 1H), 5.63 (dd, J = 1.28, 17.73 Hz, 
1H), 5.18 (dd, J = 1.26, 11.12 Hz, 1H), 5.06 (s, 2H), 5.04 (s, 2H), 4.98 (dddd, J = 1.47, 
3.13, 10.21, 19.40 Hz, 2H), 3.92 (s, 3H), 3.65 (s, 3H), 2.88 (dd, J = 5.44, 9.77 Hz, 2H), 
2.75 (t, J = 7.57 Hz, 2H), 2.50 (t, J = 7.39 Hz, 2H), 2.32 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 209.43, 154.47, 151.68, 149.68, 146.26, 137.58, 137.41, 137.05, 133.26, 
131.19, 131.00, 128.48, 128.44, 128.29, 128.22, 128.18, 128.03, 127.49, 126.88, 122.63, 
115.26, 113.95, 113.13, 75.65, 70.53, 61.05, 60.96, 44.52, 42.03, 28.89, 27.71. 
HRMS calculated for C35H34O3: [M+Na]+: 585.2599 (found); 585.2617 (calc). 
OBn
MeO
MeO
BnO
O24
! 224 
Prepared from 20 (133 mg, 0.380 mmol) according to 
general RCM/reduction procedure to yield 20a as a white solid (38 mg, 31%). 1H NMR 
(500 MHz, CDCl3) δ 7.41 (m, 2H), 7.29 (d, J = 7.62 Hz, 2H), 7.25 (d, J = 1.50 Hz, 2H), 
7.14 (d, J = 7.66 Hz, 2H), 6.76 (d, J = 2.00 Hz, 2H), 6.71 (d, J = 2.02 Hz, 2H), 3.90 (s, 
6H), 3.56 (s, 6H), 2.93 (m, 8H), 2.76 (t, J = 7.44 Hz, 4H), 2.33 (t, J = 7.28 Hz, 4H), 1.52 
(dd, J = 4.64, 9.49 Hz, 4H), 1.18 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 210.52, 152.84, 
144.71, 140.99, 138.49, 137.42, 137.32, 135.46, 128.83, 128.04, 127.25, 122.76, 111.72, 
60.67, 55.97, 44.27, 42.86, 38.15, 29.91, 28.40, 23.43. HRMS calculated for C42H48O6: 
[M+Na]+: 671.3322 (found), 671.3349 (calc). 
 Prepared from 21 (98.1 mg, 0.239 mmol) according 
to general RCM/reduction procedure to yield 21a as a white solid (31 mg, 34%). 1H 
NMR (500 MHz, CDCl3) δ 7.11 (m, 4H), 6.99 (s, 2H), 6.75 (m, 2H), 6.60 (m, 2H), 5.01 
(s, 4H), 3.89 (s, 6H), 3.57 (s, 6H), 3.33 (s, 6H), 2.91 (s, 4H), 2.85 (t, J = 7.22 Hz, 4H), 
2.72 (t, J = 7.26 Hz, 4H), 2.30 (t, J = 7.36 Hz, 4H), 1.51 (m, 4H), 1.18 (m, 4H). 13C NMR 
(126 MHz, CDCl3) δ 210.63, 153.25, 152.22, 145.22, 136.99, 134.41, 132.94, 130.88, 
129.13, 128.70, 123.20, 115.66, 111.90, 95.35, 60.58, 55.89, 55.83, 44.27, 43.05, 38.10, 
29.01, 28.57, 23.49. HRMS calculated for C46H56O10: [M+Na]+: 791.3802 (found), 
791.3771 (calc). 
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Prepared from 24 (120 mg, 0.213 mmol) according to 
general RCM/reduction procedure to yield 24a as a white solid (16 mg, 21%). 1H NMR 
(500 MHz, CDCl3) δ 7.08 (dt, J = 2.85, 5.46 Hz, 4H), 6.95 (d, J = 8.83 Hz, 2H), 6.83 (s, 
2H), 6.68 (s, 2H), 5.88 (s, 2H), 4.00 (s, 6H), 3.66 (s, 6H), 2.87 (t, J = 7.61 Hz, 4H), 2.73 
(dd, J = 5.55, 9.67 Hz, 4H), 2.67 (m, 4H), 2.38 (t, J = 7.39 Hz, 4H), 1.54 (m, 4H), 1.23 (t, 
J = 7.55 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 210.44, 151.64, 147.10, 146.71, 139.24, 
133.46, 130.72, 128.76, 127.50, 126.25, 125.84, 122.91, 117.81, 61.56, 61.39, 44.55, 
42.95, 29.07, 28.98, 23.54, 22.94, 14.09. HRMS calculated for C42H48O10: [M+Na]+: 
735.3112 (found), 735.3145 (calc). 
1-(2-(Benzyloxy)-5-bromo-3,4-dimethoxyphenyl)but-3-en-1-ol. 26 
(7.08 g, 20.16 mmol) was dissolved in a mixture of THF (56 mL) and saturated aqueous 
NH4Cl (112 mL). To the reaction was added allyl bromide (3.5 mL, 40.32 mmol) and Zn 
dust (2.637 g, 40.32 mmol). The biphasic reaction was stirred vigorously for 6 h over 
which time the solid Zn was consumed. The two layers were separated and the aqueous 
layer extracted with Et2O (3 x 50 mL). The combined organic layers were washed with 
H2O (100 mL) and brine (100 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by FCC eluting with 8% EtOAc/Pent. to 
yield 44 as a clear oil (7.33 g, 92%). 1H NMR (500 MHz, CDCl3) δ 7.37 (m, 6H), 5.74 
(dddd, J = 6.55, 7.62, 10.76, 16.98 Hz, 1H), 5.11 (m, 4H), 4.85 (dt, J = 4.26, 8.38 Hz, 
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1H), 3.94 (s, 3H), 3.92 (s, 3H), 2.40 (m, 2H), 1.98 (d, J = 4.00 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 150.45, 148.93, 147.23, 137.04, 134.47, 134.39, 128.62, 128.36, 128.24, 
124.70, 118.37, 111.93, 75.38, 67.80, 61.15, 61.06, 42.45. HRMS calculated for 
C19H21BrO4: [M+Na]+: 415.0521(found); 415.0533 (calc.). 
 2-(Benzyloxy)-5-bromo-1-(but-3-en-1-yl)-3,4-dimethoxybenzene. A 
solution of 44 (3.50 g, 8.90 mmol) in MeNO2 (50 mL) under an atmosphere of argon was 
treated with Et3SiH (3.13 mL, 19.6 mmol) followed by FeCl3 (144 mg, 0.890 mmol). 
After 4 h, the solvent was removed in vacuo and residue purified by FCC eluting with 2% 
EtOAc/Pent.) to yield 42 as a clear oil (2.93 g, 87%). 1H NMR (500 MHz, CDCl3) δ 7.45 
(dd, J = 1.02, 7.77 Hz, 2H), 7.39 (dd, J = 6.43, 8.00 Hz, 2H), 7.35 (dt, J = 4.32, 9.74 Hz, 
1H), 7.09 (s, 1H), 5.80 (ddt, J = 6.60, 10.21, 16.88 Hz, 1H), 5.03 (s, 2H), 4.98 (m, 2H), 
3.93 (s, 3H), 3.91 (s, 3H), 2.59 (dd, J = 6.79, 9.05 Hz, 2H), 2.26 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 150.20, 149.40, 147.61, 137.86, 137.45, 132.72, 128.50, 128.09, 128.03, 
127.38, 115.05, 111.31, 75.15, 61.12, 61.06, 34.43, 29.25. HRMS calculated for 
C19H21BrO3: [M+Na]+: 399.0579 (found); 399.0572 (calc.) 
 Ethyl 3-(4-(benzyloxy)phenyl)propanoate. A solution of 13 (1.93 g, 
9.94 mmol) in DMF (5 mL) was treated with BnBr (1.3 mL, 1.1 equiv) and K2CO3 (4.12 
g, 29.8 mmol). The reaction was stirred overnight at RT then quenched with H2O (70 
mL). The mixture was extracted with Et2O (3x50 mL). The combined organic layers were 
washed with HCl (2 M, 1x) and brine (1x) then dried over Na2SO4 and concentrated in 
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vacuo. The residue was purified by FCC  eluting with 5% EtOAc/Pent. to yield 45 as a 
clear oil (2.288 g, 81%) that matched the literature values.16  
3-(4-(Benzyloxy)phenyl)-N-methoxy-N-methylpropanamide. 
Prepared from 45 (643 mg, 2.26 mmol) according to general amidation procedure 2 to 
provide 46 as a clear oil (582 mg, 86%). 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 7.07 
Hz, 2H), 7.38 (t, J = 7.40 Hz, 2H), 7.32 (t, J = 7.21 Hz, 1H), 7.15 (d, J = 8.57 Hz, 2H), 
6.91 (m, 2H), 5.04 (s, 2H), 3.60 (s, 3H), 3.17 (s, 3H), 2.90 (m, 2H), 2.71 (t, J = 7.32 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 157.18, 137.14, 133.71, 129.40, 129.26, 128.56, 
127.91, 127.46, 114.83, 70.02, 61.21, 36.20, 34.00, 32.16. HRMS calculated for 
C18H21NO3: [M+Na]+: 322.1419 (found); 322.1404 (calc).  
3-(4-(Benzyloxy)phenyl)propanal. A solution of 46 (584 mg, 1.95 
mmol) in THF (15 mL) was cooled to -78 °C and treated with LiAlH4 (148 mg, 3.90 
mmol) in two portions. The reaction was stirred at this temperature for 3 h and quenched 
by pouring into ice. The mixture was filtered through Celite and the filterate extracted 
with CH2Cl2 (3x25 mL). The combined organic layers were washed with brine (1x) and 
dried over Na2SO4. The solvent was removed in vacuo and the resulting residue purified 
by FCC eluting with 10% EtOAc/Pent. to yield 47 that solidified upon standing (355 mg, 
76%).  
Alternate method: A solution of DIBAlH (1 M, 4.0 mL) was added dropwise to a solution 
of 45 (1071 mg, 3.765 mmol) in PhMe (20 mL) cooled to -78 °C. After stirring at this 
temperature for 2 h, the reaction was quenched with ~1mL MeOH and warmed to RT. 
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After 20 min, 20 mL of concentrated Rochelle salt solution was added and the mixture 
stirred vigorously for 30 min. The two layers were separated and the aqueous layer 
extracted with EtOAc (3x). The combined organic layers were washed with brine, dried 
over Na2SO4, and concentrated in vacuo. The residue was purified by FCC eluting with 
10% EtOAc/Pent. to yield a white solid (859 mg, 95%). 
Material prepared by either method was spectroscopically identical to literature values.17 
5-(4-(Benzyloxy)phenyl)pent-1-en-3-ol. A solution of 47 (277 mg, 
1.156 mmol) cooled to 0 °C was treated with a solution of vinyl magnesium bromide (1 
M, 2.3 mL). The reaction was allowed to warm to RT over 5 h then quenched with HCl 
(2 M). The reaction mixture was extracted with Et2O (3x) and the combined organic 
layers were washed with brine and dried over Na2SO4. The solvent was removed in vacuo 
and the residue purified by FCC eluting with 10% EtOAc/Pent. to yield 43 as a clear oil 
(292 mg, 94%). 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 6.93 Hz, 2H), 7.37 (t, J = 7.41 
Hz, 2H), 7.31 (ddd, J = 1.33, 4.48, 8.58 Hz, 1H), 7.11 (d, J = 8.67 Hz, 2H), 6.90 (d, J = 
8.66 Hz, 2H), 5.89 (ddd, J = 6.17, 10.41, 17.11 Hz, 1H), 5.23 (dt, J = 1.40, 17.21 Hz, 
1H), 5.12 (dt, J = 1.31, 10.41 Hz, 1H), 5.03 (s, 2H), 4.11 (dd, J = 6.14, 12.82 Hz, 1H), 
2.65 (m, 2H), 1.81 (m, 2H), 1.62 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 157.00, 141.01, 
137.14, 134.16, 129.34, 128.54, 127.88, 127.46, 114.86, 114.74, 72.41, 70.00, 38.67, 
30.70. HRMS calculated for C18H20O2: [M+Na]+: 291.1366 (found); 291.1361 (calc). 
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7-(2-(Benzyloxy)-5-bromo-3,4-dimethoxyphenyl)-1-(4-
(benzyloxy)phenyl)heptan-3-one. Synthesized from 42 (150 mg, 0.397 mmol) and 43 
(107 mg, 0.397 mmol) by general cross-metathesis procedure and purified by FCC 
eluting with 5% EtOAc/Hex. to yield 5 as a clear oil (56 mg, 23%) 1H NMR (500 MHz, 
CDCl3) δ 7.42 (m, 4H), 7.37 (t, J = 7.47 Hz, 4H), 7.32 (tdd, J = 1.40, 3.15, 6.15 Hz, 2H), 
7.07 (m, 3H), 6.89 (m, 2H), 5.03 (s, 2H), 5.00 (s, 2H), 3.91 (s, 3H), 3.90 (s, 3H), 2.80 (t, J 
= 7.65 Hz, 2H), 2.63 (t, J = 7.55 Hz, 2H), 2.47 (m, 2H), 2.32 (t, J = 7.25 Hz, 2H), 1.53 
(dd, J = 7.50, 14.64 Hz, 2H), 1.46 (m, 2H).13C NMR (126 MHz, CDCl3) δ 210.17, 
157.13, 150.14, 149.31, 147.56, 137.44, 137.08, 133.41, 133.07, 129.25, 128.56, 128.50, 
128.10, 128.07, 127.91, 127.45, 127.26, 114.83, 114.81, 111.36, 69.99, 61.11, 61.05, 
44.48, 42.68, 29.95, 29.42, 28.89, 23.40. HRMS calculated for C35H37O5: [M+Na]+: 
639.1753 (found); 639.1722 (calc). 
 3-(4-(Benzyloxy)-3-bromophenyl)propanal. A solution of 54 (9.84 g, 
27.0 mmol) in toluene (150 mL) was cooled in a dry-ice/acetone bath under an 
atmosphere of argon. A solution of DIBAlH (1.0 M in hex., 28 mL, 28 mmol) was added 
dropwise to the quickly stirring solution. After 2 h, the reaction was quenched with 
MeOH (1 mL) and warmed to RT. A concentrated solution of Rochelle’s salt was added 
and the reaction was stirred vigorously for 1 hr. The organic layer was separated and the 
aqueous layer extracted with EtOAc (2 x 50 mL). The combined organic layers were 
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washed with H2O (3 x 50 mL) and brine (2 x 50 mL), then dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by FCC (12-17.5%) EtOAc to yield 55 
(7.46 g, 87%) as a clear oil that was spectroscopically identical to that prepared by Mori 
et al.18 
5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-ol. A solution of 55 
(7.46 g, 23.4 mmol) dissolved in THF was cooled to 0 °C and treated with a solution of 
vinyl magnesium bromide (1.0 M in THF, 35.1 mL, 35.1 mmol). The reaction was slowly 
warmed to RT over 3 h and then quenched with aqueous HCl (6M, 10 mL). Th reaction 
was extracted with Et2O (4 x 60 mL) and the combined ethereal layers were washed with 
brine (2 x 100 mL), dried over Na2SO4, and concentrated in vacuo. The residue was 
purified by FCC eluting with!12% EtOAc/Pent.) to yield 16 as a clear oil (6.90 g, 85%).  
Enzymatic kinetic resolution.  A solution of (±)-56 (4.42 g, 12.7 mmol) dissolved in 
diisopropyl ether (65 mL) with ~100 mg 4 Å molecular sieves was treated with vinyl 
acetate (1.76 mL, 19.1 mmol) and amano lipase from Pseudomonas fluorescens (50 
w/w%). The reaction was stirred until half complete as observed by 1H-NMR (~24 hr). 
Reaction was filtered through celite and concentrated in vacuo. Residue purified by FCC 
(15%-20% EtOAc/Pent.) to yield 57 (2.186 g, 44%) as a clear oil and (R)-56 (1.998 g, 
45%) as a white solid. 
 (R)-5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-ol. Melting point: 
42-45 °C. 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 0.96, 7.93 Hz, 2H), 7.41 (d, J = 
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2.14 Hz, 1H), 7.39 (t, J = 7.47 Hz, 2H), 7.32 (t, J = 7.33 Hz, 1H), 7.05 (dd, J = 2.16, 8.34 
Hz, 1H), 6.85 (d, J = 8.36 Hz, 1H), 5.89 (ddd, J = 6.18, 10.41, 17.12 Hz, 1H), 5.24 (dt, J 
= 1.37, 17.20 Hz, 1H), 5.14 (td, J = 1.36, 2.80 Hz, 1H), 5.13 (s, 2H), 4.11 (m, 1H), 2.64 
(m, 2H), 1.80 (m, 2H), 1.48 (d, J = 4.22 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 153.21, 
140.87, 136.68, 135.93, 133.27, 128.56, 128.26, 127.89, 127.01, 115.07, 113.93, 112.35, 
72.27, 70.94, 38.41, 30.39. HRMS calculated for C18H19BrO2: [M+Na]+: 346.0588 
(found); 346.0568 (calc.). []20D=+4.4 (c 1.00, CHCl3). Chiral HPLC: tr = 25.195 min, 
e.r. = 95:5. 
 (S)-5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-yl acetate. 1H 
NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 0.59, 7.56 Hz, 2H), 7.39 (t, J = 7.45 Hz, 3H), 
7.32 (t, J = 7.33 Hz, 1H), 7.02 (dd, J = 2.17, 8.34 Hz, 1H), 6.85 (d, J = 8.37 Hz, 1H), 5.79 
(m, 1H), 5.23 (m, 3H), 5.13 (s, 2H), 2.57 (dt, J = 6.21, 9.25 Hz, 2H), 2.06 (s, 3H), 1.90 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.31, 153.29, 136.64, 136.11, 135.37, 133.15, 
128.56, 128.16, 127.90, 127.01, 117.09, 113.93, 112.39, 74.13, 70.92, 35.74, 30.23, 
21.21. HRMS calculated for C20H21BrO3: [M+Na]+: 441.0576 (found); 441.0572 (calc.). 
[α]20D=+2.1 (c 1.00, CHCl3). 
 (S)-5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-ol. A solution of 57 
(1.060 g, 2.723 mmol) in MeOH (30 mL) was cooled to 0 °C was treated with K2CO3 
(1.129 g, 8.168 mmol) and stirred for 3 h. The reaction was diluted with CH2Cl2 (30 mL) 
and H2O (30 mL). The aqueous layer was extracted with additional CH2Cl2 (4 x 30 mL) 
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and the combined organic layers were dried over Na2SO4 and concentrated. The residue 
was purified by FCC eluting with 25% EtOAc/Pent. to yield (S)-56 (0.946 g, 100%).1H 
NMR (500 MHz, CDCl3)  7.47 (m, 2H), 7.39 (m, 3H), 7.32 (m, 1H), 7.05 (dd, J = 2.17, 
8.34 Hz, 1H), 6.85 (d, J = 8.36 Hz, 1H), 5.89 (ddd, J = 6.19, 10.41, 17.13 Hz, 1H), 5.20 
(m, 2H), 5.13 (s, 2H), 4.11 (m, 1H), 2.64 (m, 2H), 1.80 (m, 2H), 1.49 (d, J = 4.22 Hz, 
1H). 13C NMR (126 MHz, CDCl3)  153.21, 140.87, 136.68, 135.93, 133.27, 128.56, 
128.26, 127.89, 127.01, 115.07, 113.93, 112.35, 72.27, 70.94, 38.41, 30.39. HRMS 
calculated for C18H19BrO2: [M+Na]+: 369.0472 (found); 369.0466 (calc). []20D= -4.5 (c 
1.00, CHCl3). Chiral HPLC: tr = 22.424 min, e.r. = 96:4. 
Mitsunobu procedures 
A solution of (R)-56 (150 mg, 0.432 mmol) in THF was treated with AcOH (0.03 mL, 
0.518 mmol) and PPh3 (135.9 mg, 0.518 mmol). DIAD (0.10 mL, 0.518 mmol) was 
slowly added and reaction stirred overnight at RT.  Reaction diluted with EtOAc (30 mL) 
and rinsed with aqueous HCl (2 M, 20 mL), sat. NaHCO3 (20 mL), and brine (20 mL). 
Organic layer dried over Na2SO4 and concentrated in vacuo. The residue was purified by 
FCC eluting with 6-8% EtOAc/Pent. 57 as a clear oil (104.8 mg, 62%). [α]20D= +2.1 (c 
1.00, CHCl3). 
 (R)-5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-yl 4-
nitrobenzoate. A solution of (S)-56 (149 mg, 0.429 mmol) in THF was treated with 4-
nitrobenzoic acid (85.9 mg, 0.514 mmol) and PPh3 (134.9 mg, 0.514 mmol). DIAD (0.11 
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mL, 0.53 mmol) was slowly added and the reaction stirred overnight at RT.  The reaction 
was diluted with EtOAc (30 mL) and rinsed with aqueous HCl (2 M, 20 mL), sat. 
NaHCO3 (20 mL), and brine (20 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by FCC eluting with 7.5% EtOAc/Pent. 
to yield the title compound as a faint yellow oil (195 mg, 92%). 1H NMR (500 MHz, 
CDCl3) δ 8.29 (d, J = 8.98 Hz, 2H), 8.17 (d, J = 9.01 Hz, 2H), 7.45 (d, J = 6.97 Hz, 2H), 
7.39 (m, 3H), 7.32 (t, J = 7.30 Hz, 1H), 7.02 (dd, J = 2.17, 8.35 Hz, 1H), 6.82 (d, J = 8.38 
Hz, 1H), 5.91 (ddd, J = 6.50, 10.52, 17.13 Hz, 1H), 5.53 (dd, J = 6.50, 12.89 Hz, 1H), 
5.33 (ddt, J = 1.11, 10.52, 31.82 Hz, 2H), 5.09 (m, 2H), 2.66 (t, J = 7.83 Hz, 2H), 2.08 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 163.85, 153.39, 150.54, 136.53, 135.65, 135.46, 
134.97, 133.14, 130.68, 128.58, 128.16, 127.93, 126.97, 123.53, 118.01, 113.88, 112.48, 
75.98, 70.89, 35.61, 30.32. HRMS calculated for C25H22BrNO5: [M+Na]+: 518.0567 
(found); 518.0579 (calc.) [α]20D = +0.7 (c 1.00, CHCl3). 
(R)-5-(4-(benzyloxy)-3-bromophenyl)pent-1-en-3-yl 4-nitrobenzoate (86.5 mg, 0.174 
mmol) was dissolved in a combination of MeOH (5 mL) and THF (0.5 mL). K2CO3 (72.1 
mg, 0.522 mmol) was added and the reaction was stirred at RT for 1 h. The solvent was 
removed in vacuo and the residue redissolved in CH2Cl2 (10 mL) and H2O (10 mL). The 
aqueous layer was extracted with additional CH2Cl2 (2 x 20 mL). The combined organic 
layers were washed with aqueous HCl (2 M, 10 mL) and brine (10 mL) then dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by FCC eluting with 20 % 
EtOAc/Pent. to yield (R)-56 (51.9 mg, 86%). 
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 (R)-((5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-yl)oxy)(tert-
butyl)dimethylsilane (7). A solution of (R)-56 (1.596 g, 4.597 mmol) in CH2Cl2 (30 mL) 
was cooled in a dry-ice/acetone bath and treated sequentially with anhydrous Et3N (1.0 
mL, 7.2 mmol) and TBSOTf (1.1 mL, 4.8 mmol). After 1 h, the reaction was warmed to 
RT and quenched with sat. NaHCO3 (15 mL). The aqueous layer was separated and 
extracted with additional CH2Cl2 (3 x 25 mL). The combined organic layers were washed 
with NaHCO3 and dried over Na2SO4. The solvent was removed in vacuo and the residue 
purified by FCC eluting with 5% EtOAc/Pent. to yield (R)-52 as a clear oil (2.015 g, 
95%). 1H NMR (500 MHz, CDCl3) δ 7.47 (m, 2H), 7.38 (t, J = 7.48 Hz, 3H), 7.31 (m, 
1H), 7.02 (dd, J = 2.13, 8.34 Hz, 1H), 6.84 (d, J = 8.36 Hz, 1H), 5.82 (ddd, J = 6.09, 
10.37, 16.99 Hz, 1H), 5.16 (m, 1H), 5.13 (s, 2H), 5.06 (m, 1H), 4.13 (q, J = 6.21 Hz, 1H), 
2.57 (m, 2H), 1.75 (m, 2H), 0.91 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 153.05, 141.32, 136.72, 136.60, 133.19, 128.54, 128.14, 127.86, 127.01, 
114.10, 113.95, 112.29, 73.17, 70.96, 39.72, 30.23, 25.89, 18.26, -4.30, -4.83. HRMS 
calculated for C24H33BrO2Si: [M+Na]+: 346.0558 (found); 346.0568 (calc.) [α]20D = -7.8 (c 
1.00, CHCl3). 
 (S)-((5-(4-(Benzyloxy)-3-bromophenyl)pent-1-en-3-yl)oxy)(tert-
butyl)dimethylsilane ((S)-52). Prepared from (S)-56 (876 mg, 2.52 mmol) in 95% yield 
using the same procedure described for (R)-52. 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J 
= 6.97 Hz, 2H), 7.41 (d, J = 2.14 Hz, 1H), 7.39 (t, J = 7.47 Hz, 2H), 7.32 (t, J = 7.33 Hz, 
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1H), 7.05 (dd, J = 2.17, 8.34 Hz, 1H), 6.85 (d, J = 8.36 Hz, 1H), 5.89 (ddd, J = 6.19, 
10.41, 17.13 Hz, 1H), 5.20 (m, 2H), 5.13 (s, 2H), 4.11 (m, 1H), 2.64 (m, 2H), 1.80 (m, 
2H), 1.49 (d, J = 4.22 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 153.21, 140.87, 136.68, 
135.93, 133.27, 128.56, 128.26, 127.89, 127.01, 115.07, 113.93, 112.35, 72.27, 70.94, 
38.41, 30.39. HRMS calculated for C24H33BrO2Si: [M+Na]+: 369.0472 (found); 369.0466 
(calc). [α]20D = +7.8 (c 1.00, CHCl3).!
 2-(4-(Benzyloxy)-5-(but-3-en-1-yl)-2,3-dimethoxyphenyl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane. In a glove box, Pd(dba)2 (68.6 mg, 0.119 mmol) and 
PCy3 (80.2 mg, 0.286 mmol) were combined in a Schlenk flask. The reaction vessel was 
removed from the glove box and 1,4-dioxane (24 mL) was added. The reaction was 
stirred at RT for 30 min before being treated with KOAc (585.3 mg, 5.964 mmol), B2Pin2 
(1.211 g, 4.771 mmol), and 42 (1.500 g, 3.976 mmol). The reaction was heated to 80 °C 
for 24 h. The reaction was cooled to RT and treated with CuCl (15 mg, 0.15 mmol) to 
remove excess PCy3 and stirred for 20 min before diluted with EtOAc (30 mL) and H2O 
(25 mL). The aqueous layer was extracted with additional EtOAc (3 x 30 mL). The 
combined organic layers were washed with brine (40 mL) and dried over Na2SO4. The 
solvent was removed in vacuo and the residue purified by FCC eluting with 5% 
EtOAc/Pent. to yield 53 as a faint yellow oil (1.110 g, 66%) 1H NMR (500 MHz, CDCl3) 
δ 7.46 (d, J = 7.23 Hz, 2H), 7.38 (t, J = 7.29 Hz, 2H), 7.33 (t, J = 7.27 Hz, 1H), 7.25 (s, 
1H), 5.83 (ddt, J = 6.60, 10.20, 16.87 Hz, 1H), 5.09 (s, 2H), 4.97 (m, 2H), 3.91 (s, 3H), 
3.87 (s, 3H), 2.62 (dd, J = 6.76, 9.47 Hz, 2H), 2.28 (dd, J = 6.73, 16.08 Hz, 2H), 1.36 (s, 
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12H). 13C NMR (126 MHz, CDCl3) δ 157.89, 153.51, 146.17, 138.53, 137.84, 131.36, 
131.27, 128.43, 128.41, 127.96, 127.91, 114.52, 83.43, 75.02, 62.03, 61.02, 34.90, 29.71, 
24.82. HRMS calculated for C25H33BO5: [M+Na]+: 447.2325(found); 447.2319 (calc.). 
 (R)-((7-(2-(Benzyloxy)-3,4-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)-1-(4-(benzyloxy)-3-bromophenyl)hept-4-en-3-yl)oxy)(tert-
butyl)dimethylsilane. Synthesized according to General Cross-Metathesis Procedure 
using 53 (364 mg, 0.858 mmol) and (R)-52 (396 mg, 0.858 mmol) to yield  (R)-51 as a 
clear oil (644 mg, 88%). 1H NMR (500 MHz, CDCl3) δ 7.47 (m, 4H), 7.37 (m, 5H), 7.31 
(m, 2H), 7.24 (s, 1H), 7.00 (dd, J = 2.14, 8.37 Hz, 1H), 6.83 (d, J = 8.39 Hz, 1H), 5.55 
(dt, J = 8.73, 13.51 Hz, 1H), 5.41 (m, 1H), 5.13 (s, 2H), 5.09 (s, 2H), 4.03 (m, 1H), 3.90 
(s, 3H), 3.86 (s, 3H), 2.54 (m, 4H), 2.25 (dd, J = 7.57, 15.10 Hz, 2H), 1.69 (m, 2H), 1.34 
(s, 12H), 0.88 (s, 9H), 0.02 (s, 3H), -0.02 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.94, 
153.50, 153.00, 146.18, 137.80, 136.75, 134.44, 133.50, 133.21, 131.36, 131.17, 130.28, 
128.54, 128.45, 128.18, 128.02, 127.98, 127.95, 127.85, 127.02, 113.95, 112.26, 83.42, 
75.03, 73.00, 70.97, 62.03, 61.02, 40.09, 33.15, 30.46, 30.04, 25.95, 24.82, 18.25, -3.99, -
4.74. HRMS calculated for C47H62BBrO7Si: [M+Na]+: 879.3440 (found); 879.3439 (calc.) 
[α]20D = +2.7 (c 1.0, CHCl3). 
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 (S)-((7-(2-(Benzyloxy)-3,4-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)-1-(4-(benzyloxy)-3-bromophenyl)hept-4-en-3-yl)oxy)(tert-
butyl)dimethylsilane. Prepared from 53 (142 mg, 0.336 mmol) and (S)-52 (155 mg, 
0.336 mmol) in 79% yield using the same procedure described for (R)-51. 1H NMR (400 
MHz, CDCl3) δ 7.46 (m, 4H), 7.34 (m, 7H), 7.24 (s, 1H), 6.99 (t, J = 8.86 Hz, 1H), 6.82 
(t, J = 8.49 Hz, 1H), 5.56 (m, 1H), 5.40 (m, 1H), 5.13 (s, 2H), 5.09 (s, 2H), 4.02 (m, 1H), 
3.90 (s, 3H), 3.86 (s, 3H), 2.54 (ddd, J = 5.24, 9.46, 22.56 Hz, 4H), 2.25 (dd, J = 7.25, 
15.43 Hz, 2H), 1.71 (m, 2H), 1.34 (s, 12H), 0.89 (s, 9H), 0.02 (s, 3H), -0.01 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 157.94, 153.50, 152.99, 146.18, 137.80, 136.74, 134.44, 
133.50, 133.20, 131.36, 131.17, 130.28, 128.54, 128.45, 128.18, 128.02, 127.98, 127.95, 
127.85, 127.02, 113.94, 112.25, 83.41, 75.03, 72.99, 70.96, 62.03, 61.01, 40.09, 33.15, 
30.46, 30.04, 25.95, 24.82, 18.25, -3.99, -4.74. HRMS calculated for C47H62BBrO7Si: 
[M+Na]+: 879.3440 (found); 879.3439 (calc.) [α]20D = -2.7 (c 1.0, CHCl3). 
(S)-7-(2-(Benzyloxy)-3,4-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)phenyl)-1-(4-(benzyloxy)-3-bromophenyl)hept-4-en-3-yl acetate. 
Synthesized according to General Cross-Methathesis Procedure using 53 (236 mg, 0.557 
mmol) and 57 (217 mg, 0.557 mmol) to yield 58 as a tan oil (217 mg, 50%). 1H NMR 
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(500 MHz, CDCl3) δ 7.46 (ddd, J = 3.67, 7.90, 13.87 Hz, 4H), 7.37 (m, 5H), 7.32 (ddd, J 
= 1.97, 4.48, 7.79 Hz, 2H), 7.22 (s, 1H), 6.98 (dd, J = 2.14, 8.36 Hz, 1H), 6.83 (d, J = 
8.38 Hz, 1H), 5.72 (m, 1H), 5.38 (m, 1H), 5.18 (dd, J = 6.94, 13.88 Hz, 1H), 5.13 (s, 2H), 
5.08 (s, 2H), 3.90 (s, 3H), 3.86 (s, 3H), 2.60 (m, 2H), 2.49 (ddd, J = 2.44, 6.46, 8.93 Hz, 
2H), 2.27 (m, 2H), 2.02 (s, 3H), 1.88 (m, 1H), 1.77 (m, 1H), 1.34 (s, 12H). 13C NMR (126 
MHz, CDCl3) δ 170.30, 157.97, 153.50, 153.22, 146.15, 137.82, 136.68, 135.55, 134.17, 
133.15, 131.38, 130.89, 128.56, 128.45, 128.19, 128.16, 127.98, 127.95, 127.92, 127.88, 
127.01, 113.92, 112.35, 83.44, 75.03, 74.19, 70.93, 62.03, 61.02, 36.05, 33.32, 30.34, 
29.75, 24.81, 21.34. HRMS calculated for C43H50BBrO8: [M+Na]+: 807.2704 (found); 
807.2680 (calc.) [α]20D = -1.1 (c 1.0, CHCl3). 
Synthesized according to general intramolecular Suzuki-Miyaura reaction 
procedure with (R)-51 (415 mg, 0.483 mmol), K3PO4, and 1,4-dioxane/H2O (30:1, 24.2 
mL) to yield (R)-59 as a clear oil (88.0 mg, 26%). 1H NMR (500 MHz, CDCl3) δ 7.49 (m, 
4H), 7.41 (m, 3H), 7.34 (m, 4H), 7.03 (d, J = 7.36 Hz, 2H), 6.85 (m, 1H), 5.56 (t, J = 
10.56 Hz, 2H), 5.17 (s, 2H), 5.06 (s, 2H), 4.22 (m, 1H), 3.95 (s, 3H), 3.79 (s, 3H), 2.98 (s, 
2H), 2.79 (dd, J = 12.18, 16.32 Hz, 2H), 2.53 (s, 2H), 2.19 (d, J = 15.88 Hz, 1H), 2.07 
(dd, J = 10.89, 16.92 Hz, 1H), 0.87 (s, 9H), 0.07 (s, 3H), 0.03 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 153.43, 149.71, 145.99, 140.47, 137.93, 137.70, 131.96, 128.87, 128.49, 
128.46, 128.40, 128.31, 128.26, 128.14, 128.11, 127.99, 127.80, 127.64, 127.48, 127.37, 
127.16, 112.66, 75.51, 74.78, 70.48, 60.87, 60.49, 37.92, 37.82, 29.71, 26.14, 25.90, 
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18.17, -4.03, -4.39. HRMS calculated for C41H50O5Si: [M+Na]+: 673.3342 (found); 
673.3325 (calc.) [α]20D=-2.0 (c 1.0, CHCl3). 
 Prepared from (S)-51 (175 mg) in 25% yield using the same procedure 
described for (R)-1.1H NMR (500 MHz, CDCl3) δ 7.50 (dd, J = 0.86, 7.75 Hz, 2H), 7.47 
(m, 2H), 7.40 (m, 3H), 7.33 (m, 4H), 7.03 (m, 2H), 6.85 (d, J = 8.46 Hz, 1H), 5.54 (m, 
2H), 5.17 (s, 2H), 5.06 (s, 2H), 4.22 (m, 1H), 3.95 (s, 3H), 3.79 (s, 3H), 2.98 (m, 2H), 
2.79 (dd, J = 12.14, 16.24 Hz, 2H), 2.53 (d, J = 6.16 Hz, 2H), 2.21 (d, J = 8.34 Hz, 1H), 
2.06 (m, 1H), 0.87 (s, 9H), 0.07 (s, 3H), 0.03 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
153.42, 149.71, 145.98, 140.46, 137.93, 137.69, 136.73, 135.79, 134.44, 131.95, 128.86, 
128.48, 128.45, 128.39, 128.31, 128.25, 127.98, 127.80, 127.48, 127.36, 127.15, 112.66, 
75.48, 74.77, 70.47, 60.86, 60.48, 37.85, 33.49, 30.37, 26.13, 25.90, 18.16, -4.03, -4.39. 
HRMS calculated for C41H50O5Si: [M+Na]+: 673.3351 (found); 673.3325 (calc.) 
[α]20D=+2.0 (c 1.0, CHCl3). 
A solution of (R)-59 (82.9 mg, 0.127 mmol) dissolved in EtOAc (25 mM) 
was treated with 10% Pd/C (20 w/w%) and placed under and atmosphere of H2 by 
evacuating and backfilling with H2 (3x). The reaction was stirred for 48 h then filtered 
through Celite. The filtrate was concentrated in vacuo and purified by FCC eluting with 
10% EtOAc/Pent. to yield (S)-60 as a white solid (47.2 mg, 78%). Melting point: 159-
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162 °C. 1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H), 7.19 (d, J = 1.93 Hz, 1H), 7.06 (dd, J 
= 2.27, 8.27 Hz, 1H), 6.94 (s, 1H), 6.90 (d, J = 8.20 Hz, 1H), 5.84 (s, 1H), 4.01 (m, 1H), 
4.00 (s, 3H), 3.89 (s, 3H), 2.83 (m, 3H), 2.54 (ddd, J = 3.09, 11.58, 17.76 Hz, 1H), 2.25 
(m, 1H), 1.91 (m, 3H), 1.73 (m, 1H), 1.65 (t, J = 12.48 Hz, 1H), 1.53 (m, 2H), 0.86 (s, 
9H), -0.10 (s, 3H), -0.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.28, 147.64, 145.80, 
138.66, 133.27, 130.98, 130.05, 129.39, 124.65, 123.59, 122.73, 116.74, 68.99, 61.46, 
61.43, 39.38, 35.13, 27.00, 25.89, 25.85, 25.45, 23.25, 17.98, -4.33, -4.59. HRMS 
calculated for C27H40O5Si: [M+Na]+: 495.2996 (found); 495.2989 (calc.) [α]20D= +26 (c 
0.69, CHCl3). 
!Prepared from (S)-59 (30.5 mg, 0.0469 mmol) in 71% yield using the 
same procedure described for (S)-60. Melting point: 159-162 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.63 (s, 1H), 7.19 (s, 1H), 7.06 (d, J = 8.09 Hz, 1H), 6.91 (m, 2H), 5.84 (s, 1H), 
4.03 (m, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 2.83 (m, 3H), 2.53 (ddd, J = 3.26, 11.54, 17.75 
Hz, 1H), 2.25 (m, 1H), 1.90 (m, 3H), 1.71 (m, 2H), 1.53 (m, 2H), 0.86 (s, 9H), -0.10 (s, 
3H), -0.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 151.28, 147.65, 145.80, 138.67, 
133.27, 130.98, 130.05, 129.39, 124.65, 123.59, 122.74, 116.74, 68.99, 61.46, 61.43, 
39.38, 35.13, 27.01, 25.89, 25.85, 25.45, 23.25, 17.98, -4.33, -4.59. HRMS calculated for 
C27H40O5Si: [M-H]-: 471.2557 (found); 471.2567 (calc.) [α]20D= -26 (c 0.69, CHCl3). 
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 (+)-Myricanol. A solution of (S)-60 (18.7 mg) in EtOH (5 mL) was 
acidified with conc. HCl (90 μL) and stirred at room temperature for 30 min. The 
reaction mixture was neutralized with aqueous NaHCO3 and extracted with CH2Cl2 (4×20 
mL). The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated in vacuo. The resulting residue was purified by FCC eluting with 33% 
EtOAc/Pent to yield a (+)-1 as a white solid (11.3 mg, 80%). Melting point 100-103°C. 
1H NMR (400 MHz, CDCl3) δ 7.67 (s, 1H), 7.17 (s, 1H), 7.09 (dd, J = 2.26, 8.20 Hz, 
1H), 6.90 (m, 2H), 5.86 (s, 1H), 4.09 (t, J = 9.76 Hz, 1H), 4.00 (s, 3H), 3.88 (s, 3H), 2.91 
(m, 2H), 2.80 (dt, J = 3.31, 18.14 Hz, 1H), 2.54 (m, 1H), 2.34 (m, 1H), 1.92 (m, 3H), 
1.70 (m, 2H), 1.57 (dd, J = 10.54, 14.25 Hz, 2H), 1.50 (s, 1H). 13C NMR (126 MHz, 
CDCl3) δ 151.40, 147.71, 145.85, 138.63, 133.10, 130.64, 129.91, 129.37, 124.67, 
123.42, 122.61, 116.86, 68.57, 61.43, 61.40, 39.44, 34.72, 26.89, 25.75, 25.41, 22.90. 
HRMS calculated for C21H26O5: [M-H]-: 357.1702 (found); 357.1702 (calc). [α]20D=+51 (c 
0.10, CHCl3). Chiral HPLC: tr=17.586 min, e.r. = 96:4. 
 (-)-Myricanol. Prepared from (R)-17 (9.7 mg) in 80% using the same 
procedure described for (+)-1. Melting point 100-103°C 1H NMR (500 MHz, CDCl3) δ 
7.66 (s, 1H), 7.17 (d, J = 1.85 Hz, 1H), 7.09 (dd, J = 2.33, 8.22 Hz, 1H), 6.90 (m, 2H), 
5.83 (s, 1H), 4.09 (t, J = 9.83 Hz, 1H), 3.99 (s, 3H), 3.87 (s, 3H), 2.91 (m, 2H), 2.80 (dt, J 
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= 3.16, 18.07 Hz, 1H), 2.54 (m, 1H), 2.33 (m, 1H), 1.93 (m, 3H), 1.69 (m, 2H), 1.55 (m, 
2H), 1.43 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 151.43, 147.71, 145.85, 138.63, 
133.11, 130.62, 129.92, 129.38, 124.68, 123.44, 122.61, 116.87, 68.60, 61.43, 61.41, 
39.44, 34.74, 26.90, 25.77, 25.41, 22.91. HRMS calculated for C21H26O5: [M-H]-: 
357.1699 (found); 357.1702 (calc). [α]20D=-51 (c 0.1, CHCl3). Chiral HPLC: tr=22.164 
min, e.r. = 97:3. 
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